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A depiction of Escherichia coli in the mammalian gut environment, in which it has to 
co-exist and compete with several microbial species. Credits go to Joana Carvalho 
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Antibiotic resistance is one of the major contemporary threats to global health. 
Studies on evolutionary biology, molecular biology and genetics have revealed that 
many phenomena contribute for the subsistence of resistant bacteria. The 
environment has been shown to be a key factor, capable of altering fitness costs and 
the epistasis patterns between resistance determinants. Still, few studies have 
ventured to assess the costs of antibiotic resistance in natural environments, and 
such studies are centered on pathogens. It is now known that commensal bacteria 
can act as reservoirs of resistance, and that resistant commensals can evolve to 
express pathogenicity and share resistance genes with pathogens. Here, we explore 
how selection acts on resistant, commensal E. coli in the mouse gut. 
We observe that the fitness effects of resistance mutations in the gut are not 
predictable by experiments in standard laboratory media, and that after an antibiotic 
perturbation, the presence of microbiota affects the outcome of competitions with the 
sensitive strain. The costs become host-specific and lead to situations in which the 
resistant strain bears no cost, suggesting a role of the microbiota in the maintenance 
of resistance.  We then report that when resistant bacteria are evolving in this system, 
they acquire a multitude of mutations that do not correspond to classic compensatory 
mutations, and that the latter appear at a different pace in mice carrying different 
microbiota. For the studied mutants, adapting to the gut environment seems to prevail 
over compensation. We also present a study in which we look for frequency-
dependent selection in two environments with different complexity. We find an 
association between frequency-dependent selection and secretome-related 
functions in a minimal medium environment, and we observe Darwinian selection in 
the mouse gut, with a single mutant dominating the competition against the wild-type 
and other mutants in genes related to the secretome. 
The research presented on this thesis highlights the gut microbial community 
as a factor that influences the survival of resistant and multi-resistant bacteria, and 
as a whole, stresses the importance of studying bacteria in environments that reflect 
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their place in nature. Following studies taking into account the biotic environment in 
























A resistência a antibióticos é uma das maiores ameaças contemporâneas à 
saúde a nível global. Estudos de biologia evolutiva, biologia molecular e genética 
revelaram vários fenómenos que contribuem para a subsistência das bactérias 
resistentes. O ambiente é um factor-chave, capaz de alterar os custos de fitness e 
os padrões de epistasia entre determinantes de resistência. Ainda assim, os estudos 
focados no custo da resistência em ambientes naturais são escassos e centrados 
em agentes patogénicos. Hoje, as bactérias comensais são reconhecidas como 
reservatórios de resistência, e sabe-se que comensais resistentes podem evoluir no 
sentido de expressar patogenicidade e partilhar genes de resistência com bactérias 
patogénicas. Aqui, exploramos como é que a seleção actua sobre E. coli comensais 
resistentes, no intestino de ratinho. 
Reportamos que no intestino, os efeitos no fitness das mutações de 
resistência, não correspondem ao previsto através de meios de laboratório 
convencionais, e que após uma perturbação através de um antibiótico, a presença 
da microbiota afecta o desenlace de competições com a estirpe sensível. Os custos 
tornam-se específicos consoante o hospedeiro, levando a situações nas quais as 
estirpes resistentes não têm custo, o que sugere um papel da microbiota na 
manutenção da resistência. Reportamos de seguida que quando bactérias 
resistentes evoluem neste sistema, adquirem uma variedade de mutações que não 
correspondem a mutações compensatórias clássicas. Estas aparecem a um ritmo 
diferente em ratinhos com microbiotas diferentes. Para os mutantes estudados, a 
adaptação ao ambiente do intestino parece prevalecer em relação à compensação. 
Por último, apresentamos um estudo no qual procuramos por selecção dependente 
da frequência em dois ambientes de complexidade distinta. Encontramos uma 
associação entre selecção dependente da frequência e funções relacionadas ao 
secretoma num ambiente de meio mínimo, mas observamos selecção Darwiniana 
no intestino, no qual um mutante domina a competição contra o wild-type e contra 
outros mutantes para genes ligados ao secretoma. 
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O trabalho de investigação presente nesta tese realça a comunidade 
microbiana do intestino como um factor capaz de influenciar a sobrevivência de 
bactérias resistentes e multirresistentes e dá ênfase à importância de estudar as 
bactérias em ambientes que reflictam o seu lugar na natureza. Estudos 
subsequentes que tenham em consideração o ambiente biótico que rodeia as 
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When a bacterium acquires a mutation, its survivability will depend on the 
fitness effect of the genetic modification. The fitness effect can vary across 
environments, reflecting different selective pressures, which may stem from the 
activity of other microbes. 
This study was designed to evaluate the contribution of microbiota to the fitness 
effect of chromosomal mutations in a natural environment – the mouse gut - focusing 
on how the gut microbiota changes the fitness effect of mutations conferring antibiotic 
resistance, how it conditions the evolution of antibiotic resistant strains, and to assess 
the occurrence of stable polymorphisms for public traits in simple and complex 
environments. 
Chapter I presents a general introduction on antibiotic resistance, going 
through the cell targets of the main classes of antibiotics, how resistance is acquired, 
and the mechanisms of resistance. Afterwards, the chapter addresses the fitness 
cost of resistance and the known mechanisms by which bacteria reduce or 
circumvent this cost. The role of commensal strains as a reservoir and as a source 
of resistance determinants is then addressed. The major aims of this thesis are stated 
at the end of this chapter. 
In Chapter II the fitness of resistant Escherichia coli strains was measured 
through in vivo competitions, showing that the cost of chromosomal resistance 
mutations is affected by the presence of microbiota, in a host-specific manner. 
Chapter III follows the evolution of resistant E. coli in the gut environment, 
identifying mutations through sequencing and revealing a prominent role of 





Chapter IV is a stand-alone chapter, which looks at frequency-dependent 
fitness effects on single gene deletion polymorphisms in E. coli, finding frequency-
dependence for secretome genes in a simple environment, and strong, positive 
selection in the mouse gut. 
Chapter V highlights the main findings of this study, briefly contextualizes them 

























































The incorporation of antibiotics into medical practice was one of the major 
landmarks in the history of medicine. Their utilization enhanced the combat against 
diseases of bacterial origin, many of which fatal by the time of their discovery 1, and 
allowed the prevention of opportunistic infections in delicate medical practices 2, 
resulting in an effective reduction in human morbidity and mortality caused by 
bacterial infections 3. However, over time, the intensive use of antibiotics has led to 
the dissemination of resistant bacteria, making the treatments ineffective 1. 
The prospect got worse with the early reports of multi-resistance 4,5, which 
allows pathogenic bacteria to accumulate means of survival to treatments 6. These 
worrisome news led to a response of the pharmaceutical industry, with the design of 
synthetic antibiotics, some of which directed to new cell targets. However, resistance 
to these new agents was developed 7, indicating that bacteria can evolve and acquire 
resistance to synthetic compounds as well. As a consequence of the unrestrained, 
extensive and excessive use of multiple antibiotics for decades 8, antibiotic resistance 
has turned into one of the major public health problems 1,2, and might lead to the 
failure of quimioterapy based treatments 9 due to the spread at epidemic levels of 
infections carried out by resistant bacteria 10. A post-antibiotic era, in which common 
infections can once again kill, is indeed a real possibility 11. 
 
Main targets of antibiotics 
Antibiotics are grouped in several classes based on their composition, target 
and mechanism of action. Antibiotics target fundamental processes of the cell, such 
as cell wall biosynthesis, nucleic acid synthesis, both at the level of folate synthesis, 
DNA replication and transcription into RNA, and at the level of protein synthesis by 
targeting subunits of the ribosome 12. Following is a brief description of the 
mechanism of action of the most commonly used antibiotics, grouped by the targeted 




Cell wall biosynthesis 
Bacterial cell walls are made of peptidoglycans, long sugar polymers. The 
peptidoglycan undergoes cross-linking of glycan strands through cross links between 
peptides. In this process, penicillin binding proteins (PBP) are essential for the cross 
linking of the D-alanyl-alanine portion of the peptide chains by glycine residues. There 
are two main classes of antibiotics targeting cell wall synthesis, β-lactams, including 
extended spectrum β-lactams and large spectrum carbapenems, and glycopeptides. 
β-lactams compete with alanine for PBP by binding to it, preventing transpeptidation 
and leading to synthesis disruption 13. Glycopeptides such as vancomycin also act 
on the transpeptidation step by binding to the D-alanyl D-alanine portion of the 
peptides, also preventing the action of PBP on these residues 14. The prevention of 
the synthesis of peptidoglycan leads to lysis of the bacterial cell 13. 
 
Replication 
Within the bacterial cell cycle, the chromosomal DNA is replicated in order to 
pass genetic information to both daughter cells. Topoisomerases, such as DNA 
gyrase and topoisomerase IV are essential in this process, as they control and 
maintain the topological state of DNA molecules 15. Gyrase acts while DNA is 
unwinded by helicase during replication and during the elongation by RNA 
polymerase in transcription by nicking double-stranded DNA, introducing negative 
supercoils and resealing the nicked ends. The functional gyrase is a topoisomerase 
made by joining two A subunits, responsible by the nicking and sealing, and two B 
subunits, that introduce negative supercoils. In Gram-negative bacteria, quinolones 
such as nalidixic acid and fluoroquinolones such as ciprofloxacin target DNA 
replication by binding to the gyrase A subunit with high affinity and blocking its strand 
cut and reseal ability, although certain analogues such as norafloxacin seem to inhibit 
gyrase activity while binding directly to DNA 16. In Gram-positive bacteria, quinolones 
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primary target is topoisomerase IV 17, which nicks and separates DNA strands after 
replication without introducing negative supercoils 18. As with gyrase binding in Gram-
negative bacteria, quinolone action leads to the impairment of DNA replication. In 
both gram positive and gram-negative bacteria, topoisomerase inhibitors lead to the 
generation of single and double strand breaks and culminate in apoptosis of 
proliferating cells 19.  While quinolones are typically bactericidal, nalidixic acid was 
shown to turn bacteriostatic in very high drug concentrations, a paradox that may be 
related with a secondary effect of the drug blockading RNA synthesis 20. 
 
RNA and protein synthesis 
Through the action of the DNA-dependent RNA polymerase, the information 
coded in DNA molecules is used to synthesize messenger RNA or functional non-
coding RNA 21, in a process known as transcription. 
RNA polymerase is a complex enzyme composed by five subunits, two α, one 
β, one β’ and an ω subunit 22. Rifamycins, including rifampicin, inhibit DNA-dependent 
RNA synthesis by strongly binding in a pocket of the β subunit of the RNA 
polymerase, deep within the DNA/RNA channel. The binding does not occur in the 
RNA polymerase active site but sterically blocks the extension of the nascent RNA 
chain after the RNA transcript becomes 2 or 3 nucleotides in length 23, effectively 






Figure 1 - Mechanism of action of rifampicin. A) Using a DNA strand as a template, RNA 
polymerase forms an elongated mRNA molecule that corresponds to the coded gene. B) By 
binding to the β-subunit of the DNA-dependent RNA polymerase, rifampicin, also known as 
rifampin, blocks the elongation of messenger RNA and impairs transcription. Adapted from  
24. 
 
The messenger RNA sequence is then processed by the multimeric structure 
known as ribosome to generate peptides and proteins, with each RNA triplet, named 
as codon, corresponding to a specific amino-acid residue. This process is called 
translation. The bacterial ribosome is composed of two subunits, 30S and 50S, made 
by RNA enveloped by proteins. 30S is composed of 16S rRNA and 21 proteins (S1–
S21) whereas 50S is composed of 5S and 23S rRNAs and 36 proteins (L1–L36) 25. 
As the two units work together to perform translation, different antibiotics affect 
protein biosynthesis by targeting either one or the other subunit. 
Aminoglycoside antibiotics, such as streptomycin, kanamycin, gentamicin and 
kanamycin are positively charged molecules, and their uptake depends on their 
interaction with the negatively charged components of the outer membrane which 
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lead to an increase in permeability. This process allows the entrance to the cytoplasm 
through energy-dependent, electro-transport-mediated process 26. Once in the 
cytoplasm, aminoglycosides interact with the 16S rRNA of the 30S ribosome subunit 
through hydrogen bonds in the first ribosome binding site for tRNA, the aminoacyl 
binding site (A site). Some aminoglycosides, including streptomycin, cause 
mistranslation of proteins and premature termination of translation 27,28. The 
mistranslated proteins can cause damage to the cytoplasmic membrane and facilitate 
aminoglycoside entry, leading to an increased inhibition of protein synthesis and 
mistranslation, culminating in cell death 29. Other aminoglycosides, such as 
kasugamycin, act by blocking peptide chain initiation 27. (Figure 2). Tetracyclines 
also interfere with the binding of the t-RNA to the ribosomal A site by acting upon the 
conserved sequences of 16S rRNA, inhibiting the elongation phase of protein 
synthesis with a bacteriostatic effect 30,31.  
Commonly used drugs such as chloramphenicol, macrolides and 
oxazolidinones act on the 50S subunit of the ribosome. Chloramphenicol interacts 
with the peptidyl transferase cavity of the 23S rRNA, also preventing the binding of 
the tRNA to the A site. Macrolides affect translocation in the early stage of protein 
synthesis, by targeting the peptidyl transferase center of the 23S rRNA, leading to 
the premature detachment of incomplete peptide chains. 12. Oxazolidinones, 
including the synthetic linezolid, bind to the peptidyl tRNA binding site of the ribosome 
(P site). Besides affecting the initiation of protein synthesis by inhibiting the formation 




two subunits to initiate protein synthesis), and the translocation of the peptide chain 
if the two ribosomal subunits are already performing translation 32.  
 
 
Figure 2 – Mechanisms of action of aminoglycoside antibiotics. All 
aminoglycosides bind to the 30S subunit of the ribosome. Depending on their structure, they 
may act by blocking the initiation of protein synthesis or by causing mRNA misreading, which 
can lead to the the block of ongoing translation and cause translation errors. Streptomycin in 
particular causes mRNA misreading,  promoting mistranslation and translation termination. 
Adapted and modified from 33. 
 
Metabolism 
Some antibiotics have as targets central metabolic pathways of the cell. For 
instance, sulfonamides and trimethoprim target the essential folic acid pathway. 
Folate is a critical precursor for the synthesis of glycine, methionine, thymidine 
triphosphate and purines 34. Sulfonamides inhibit dihydropteroate synthase through 
competition with the natural substrate, while trimethoprim acts at a later stage, 
inhibiting dihydrofolate reductase. Both drugs are bacteriostatic. However, their 
combination has a synergistic effect, killing the cell and leading to a reduced 
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probability of evolving resistance 35. Besides allowing for the expansion of the 
spectrum of targets of current antibiotics, the development of these drugs is a 
promising approach to eliminate persistent bacteria - subpopulations of sensitive 
bacteria that are slow-growing but metabolically active, surviving exposure to 
antibiotics that act on the dividing clones 36. 
Despite the use of a multitude of diverse compounds with the purpose of 
leading to their death or inhibition, bacteria tend to gain resistance recurrently. To 
understand how bacteria become able to respond to these harmful agents, it is 
essential to consider the biologic processes by which resistance is obtained. 
 
The acquisition of resistance 
Antibiotic resistance occurs in nature and is found in non-agricultural, non-
clinical environments 37. Furthermore, relatively recent studies indicate that antibiotic 
resistance is ancient, with targeted metagenomic studies showing the presence of 
diverse antibiotic resistance determinants in thousands-of-years-old permafrost 
samples 38,39, and with multi-resistance being reported in environments that were 
isolated for millions of years 40. 
As many antimicrobial compounds are produced by living organisms, bacteria 
in constant contact with them have evolved to survive in their presence. These 
bacteria are considered to be intrinsically resistant to one or more antibiotics 41,42. 
However, the public health threat of antibiotic resistance does not only come from 
the expansion of intrinsically resistant bacteria, but also from the acquisition of 
resistance by previously susceptible strains, including life-threatening pathogens in 
clinical settings.  Resistance can be acquired by spontaneous chromosomal 
mutations or through the acquisition of genes carrying resistance determinants, 





Resistance through horizontal gene transfer 
Horizontal gene transfer (HGT) of antibiotic resistance genes has been shown 
to occur through 3 main mechanisms: transformation 43,44, which involves the 
incorporation of external DNA 45; conjugation 46, a contact-dependent exchange of 
genetic material 47 through the transfer of conjugative plasmids 48 or transposons 49; 
transduction 50,51, in which the foreign DNA is transferred through bacteria viruses 
called phages 52 (Figure 3). 
HGT is now considered to be a key player in the evolution of bacteria 53. While 
it typically ensues between different strains and species, the transfer of homologous 
regions can also occur between higher taxa 54,55. As an example, bacteria can acquire 
antibiotic resistance by transformation with genes of plant origin 56, evidentiating how 
“promiscuous” bacteria can be. Horizontal gene transfer can occur in various natural 
habitats. Gene transfer through conjugative plasmids alone has been observed in 
distinct environments such as soil and rhizosphere 57,58, plant surfaces 59, water 60 
and in the mammalian gut 61,62. Furthermore, environmental conditions can boost the 
occurrence of HGT. As an example in the context of the mammalian gut, HGT 
















Figure 3 – Horizontal gene transfer between bacteria. A) Transformation occurs when 
naked DNA is released on lysis of an organism and is taken up by another organism. The 
antibiotic-resistance gene can be integrated into the chromosome or plasmid of the recipient 
cell. B) In transduction, antibiotic resistance genes are transferred from one bacterium to 
another by means of bacteriophages and can be integrated into the chromosome of the 
recipient cell. C) Conjugation occurs by direct contact between two bacteria: plasmids form a 
mating bridge across the bacteria and DNA is exchanged, which can result in acquisition of 
antibiotic-resistance genes by the recipient cell. Transposons are sequences of DNA that 
carry their own recombination enzymes that allow for transposition from one location to 
another. As other mobile genetic elements, transposons can carry antibiotic-resistance 








Additionally, horizontal gene transfer processes can lead to a very fast spread of new 
genes in nature. For instance, resident E. coli in the mouse gut can transfer prophage 
genes at an epidemic level to an invading strain in a matter of days, a process that 
precedes the occurrence of adaptive point mutations 66. 
Antibiotic resistance genes coded on mobile genetic elements are frequently 
acquired in integrons 67. These DNA elements can be found in conjugative plasmids, 
phages and transposons, and act as assembly platforms that incorporate exogenous 
open reading frames through site-specific recombination and convert them to 
functional genes by securing their expression 68. Integrons typically encode an 
integrase, a primary recombination site and an outward-orientated promoter, 
providing all of the tools for the transcription of the captured gene. Multiple genes can 
be sequentially integrated as gene cassettes, allowing for the accumulation of 
functional resistance determinants 67. In fact, integron-bearing mobile genetic 
elements are thought to have been major agents in the fast spread of multi-resistance 
in Gram-negative bacteria through horizontal gene transfer 69. Very large, integron-
like structures can also be found in the chromosome – the super-integrons. Although 
not mobile, these sequences can contain hundreds of accessory genes, including 
cassettes related to antibiotic resistance 70, and are present in many bacterial 
species, being considered to have an important role in genome evolution 68. 
 
Resistance acquisition through mutations 
Despite the important role of HGT in its spread, antibiotic resistance can 
originate de novo in sensitive strains. Some bacteria, such as the intracellular 
parasite Mycobacterium tuberculosis, are mostly clonal, and typically acquire 
resistance in this way 71. Antibiotic resistance through de novo mutation often occurs 
through single nucleotide substitutions that modify the drug target, but resistance can 
also be acquired through other classes of spontaneous mutations. For instance, 
insertions and deletions generate frameshifts and premature stop codons in genes 
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involved in antibiotic susceptibility 72, while gene duplication can lead to an increased 
dosage of antibiotic hydrolytic enzymes and efflux gene pumps 73. While gene 
duplications are often unstable, they can facilitate the development of a stable 
resistance phenotype, by allowing survival and population expansion until the 
occurrence of point mutations conferring higher levels of resistance 74. Point 
mutations can confer resistance without modification of the primary antibiotic target. 
One such example regards point mutations in regulatory regions of porin coding 
genes that reduce porin expression 75, decreasing susceptibility. Point mutations and 
deletions on such genes can lead to porin impermeability 76,77 culminating in an 
increased resistance to carbapanems in Enterobacteraceae. Another example 
regards multi-drug (MDR) efflux pumps. Point mutations on gene repressors of MDR 
efflux pump genes, or in the gene regulator to which they bind can lead to 
overexpression of the efflux pump. On the other hand, mutations of the coding region 
may change the substrate binding, both at the range and affinity level 41, resulting in 
an elevated level of resistance. 
Mutation rates and effects 
Mutations can occur through errors in DNA replication or through DNA damage. 
As cell division ensues, mutations with fitness effects spanning from fitness benefits 
to lethality can occur. In haploid microbes, the mean genome mutation rate is 
estimated to be of 0.003 mutations per DNA replication 78. In E. coli, the mutation rate 
is estimated to be close to this value 78, and mutation accumulation studies in this 
species estimate that roughly 1 in every 15 mutations is deleterious (rate of 0.0002; 
79), while 1 in every 150 newly arising mutations is beneficial (rate of 2 x 10-5, 80), in 
line with theoretical and molecular evolution studies suggesting that most mutations 
are neutral 81,82 or nearly neutral 83–85. Across haploid species, the variation in 
mutation rate per base pair is high (≈16000-fold). However, the variation in mutation 
rate per genome is quite low (≈2.5-fold), suggesting a selective pressure towards a 
balance between deleterious effects of mutations and the maintenance of a minimal 
mutation rate in haploid organisms 78. This hypothesis is supported by data on 




crenarchaeon Sulfolobus acidocaldarius and the bacterium Thermus thermophilus, 
which have evolved in extreme heat conditions, is about 5 times lower than in their 
mesophile counterparts, possibly reflecting an adjustment of the mutation rate to 
strong purifying selection 86.In bacteria, mutation frequencies are generally found to 
be between 10-10 and 10-9 per replicated base pair 87. While this mutation rate per 
nucleotide reflects a low probability of a specific mutation to occur, bacterial 
populations in nature can reach high population size. Furthermore, mutations 
conferring resistance can occur in multiple positions in the same target gene. As an 
example, a classical study mapped 17 mutational distinct alterations able to confer 
rifampicin resistance 88. The disposal of multiple mutational options also promotes 
the recurrent appearance of resistance mutations in natural populations. Additionally, 
the rate of emergence of antibiotic resistance mutants is affected by cell physiology, 
genetics, and by aspects of the environment, such as temperature 89 and physical 
structure 90. 
Environmental effects on mutation rate 
The mutation rate towards resistance can also change with the presence and 
dose of antibiotics themselves. In fact, sublethal concentrations of antibiotics can 
increase the rate and frequency of HGT, recombination and mutagenesis 91, while 
the nature of the selected resistance mutations can vary with the dose of antibiotic 
92. Furthermore, drug exposition can increase the mutation rate towards resistance 
to the antibiotic - as an example, the exposition to ciprofloxacin can increase 10000-
fold the rate at which ciprofloxacin resistance mutations occur 93,94, through DNA 
damage and the activation of the SOS response 94. A mutagenic effect has also been 
described for other fluoroquinolones 95 and for streptomycin 96. 
Successive selective pressures, such as the use of different antibiotics can lead 
to the emergence of “mutator” bacteria. These strains originate through certain 
mutations in core genes related with DNA repair, which vastly increase genome 
mutation rate, sometimes up to 1000-fold 97. In vitro studies indicate that resistance 
to ampicillin, streptomycin and ofloxacin 98, as well as low level resistance to 
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rifampicin and ciprofloxacin 99 emerge more frequently in mutator lines of E. coli. 
Mutator phenotypes were reported to occur in natural populations of pathogenic 100–
102 and commensal bacteria 103,104 and allow for greater resistance levels than non-
mutator populations, particularly when full resistance requires more than one 
mutational step 99,105. Furthermore, some mutations conferring mutator phenotype 
also increase the recombination rate and are under frequent horizontal gene transfer 
themselves 104, promoting the sharing of potentially beneficial traits such as virulence 
factors and antibiotic resistance determinants. 
Resistance through chromosomal mutations can be easily produced in a 
laboratory with culturable bacteria through a fluctuation test, by letting bacteria grow 
into very high population size while accumulating mutations, followed by a strong 
selection with an antibiotic - a test adapted from classic studies on the origin of 
resistance phenotypes to phages 106 and to antibiotics themselves 107,108. This test is 
often used to estimate the mutation rate of bacteria in a given environment 109. Due 
to the ease of production and the immediate acquisition of a selective phenotype, 
chromosomal resistance is one of the most studied types of genetic alteration. As 
many spontaneous resistance mutations occur in essential genes, the study of the 
different types of resistance has led to important findings in molecular and cell biology 
of bacteria, often coupling molecular and evolutionary mechanisms together. 
 
Mechanisms of resistance 
There are several mechanisms by which bacteria can avoid antibiotic mediated 
killing or inhibition (Figure 4). These fall in 3 main categories: mechanisms that 
decrease target access and minimize the intracellular concentration of the antibiotic; 
mechanisms that modify the antibiotic target by genetic mutation or post-translational 
modification; and mechanisms that lead to the inactivation of the antibiotic through 




 Decreased target access 
One way through which bacteria limit the access of the antibiotic target is by 
reducing permeability. As the outer membrane of Gram-negative bacteria forms a 
permeability barrier 110,111, hydrophilic antibiotics have to enter the cell through outer 
membrane porin proteins, which are thought to function as non-specific channels in 
Proteobacteria 111. Through the down-regulation of porin expression 112, and through 
the replacement of porins with selective channels 113, bacteria can block the entry of 
hydrophilic antibiotics inside the cell. 
Bacteria can also limit the access to intra-cellular targets through the 
expression or overexpression of efflux pumps. Bacterial pumps are a means of active 
transport and are a major contributor for the intrinsic resistance of Gram-negative 
bacteria 110. Some pumps have a narrow substrate specificity [e. g. tetracycline 
pumps) 114], but many are able to transport a wide range of structurally dissimilar 
compounds. Such transporters can confer resistance to a multitude of antibiotics, and 
hence are known as multidrug resistance (MDR) efflux pumps.  While efflux pumps 
are ubiquitous in the chromosome of bacteria, some are also coded in mobile genetic 
elements  115–117 and can be shared through horizontal gene transfer. 
Another important mechanism of reduction of target access has to do with 
population level phenotypes such as biofilm formation. Bacteria can encase 
themselves in a self-produced polymer matrix made of polysaccharide and protein 
and DNA. These structures can harbor a single or more bacterial species living in a 
socio-microbiological way 118, and frequently confer increased tolerance to antibiotics 
and disinfectant chemicals 119, by physically reducing the exposition to the antibiotic 
through slow penetration 120. Additionally, biofilms typically generate a gradient of 
nutrients and oxygen that lead to concentration driven changes in division rate and 
metabolic activity, with some cells developing a level of tolerance by fine tuning of 
the expression of genes involved in the additional resistance mechanisms such as 
efflux pumps and degrading enzymes, leading to further reduced target access 119. 




Figure 4 – Main mechanisms of resistance in gram-negative bacteria. a) 
Impermeable barriers. Some bacteria are intrinsically resistant to certain antibiotics (blue 
squares) due to membrane impermeability, while others can limit drug entry through changes 
in gene expression that reduce drug permeability. b) Efflux pumps. Bacteria can also limit 
target access through the activity of these pumps, which secrete antibiotics to the outside of 
the cell. c) Resistance mutations. These mutations modify the target protein, and reduce 
target affinity, for example, by disabling the antibiotic-binding site but leaving the cellular 
functionality of the protein intact. d) Inactivation of the antibiotic. Inactivation can occur by 
modification covalent modification of the antibiotic, such as that catalyzed by acetylases 
(purple) acting on aminoglycosides, or by degradation of the antibiotic, such as that catalyzed 




growing in a biofilm when compared to planktonic growth [e. g. 105-fold increase in 
mutability for Pseudomonas aeruginosa PA01, 121], and horizontal gene transfer is 
also known to be increased in biofilms 122, which in turn can increase the chance of 
acquiring antibiotic resistance mutations. 
 
Reduced target affinity and target protection 
Most antibiotics bind specifically to their targets with high affinity and impair the 
target’s function. However, certain naturally occurring mutations and gene 
recombination in the target structure can prevent antibiotic binding while still allowing 
for the target to carry its function, even if not optimally. Such alteration in the target 
site is a common, ubiquitous mechanism of resistance, as examples of clinical strains 
with this type of resistance can be found for every single class of antibiotic, regardless 
of the mechanism of action 123.  
Perhaps the most classic examples of resistance through reduced target affinity 
refer to beta-lactams. The acquisition of spontaneous mutations in penicillin binding 
proteins conferring resistance has been reported for several genera of bacteria, 
including Haemophilus influenzae, Helicobacter pylori, Proteus mirabilis, 
Acinetobacter baumanii, Pseudomonas aeruginosa, Streptococcus pyogenes and 
Listeria monocytogenes 123. Strikingly, these altered targets with reduced affinity can 
be shared by horizontal gene transfer. One the best examples refer to β-lactam 
resistance derived in bacteria such as Streptococcus pneumoniae 124 and pathogens 
such as Neisseria gonorrhoeae 125 and Neisseria meningitidis 126 through the 
formation of “mosaic” penicillin binding proteins. These proteins are generated 
through transformation and recombination with acquired DNA coding beta-lactam 
insensitive variants of the proteins, usually originated from closely related species, 
including bacteria of commensal nature 126. Another reported situation refers to the 
acquisition of the mecA gene by methicillin resistant Staphylococcus aureus. The 
gene encodes an alternative penicillin-binding protein 2 (PBP2a), and is carried on a 
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large genetic element, the staphylococcal cassette chromosome mec, which is 
presumed to have been acquired by horizontal gene transfer from other 
Staphylococcus species 127. 
Mutations conferring resistance to rifampicin and streptomycin are also classic 
examples of reduced target affinity. Rifampicin is a relevant drug in the treatment of 
pathogenic bacteria, being particularly important to treat tuberculosis 128. Resistance 
to rifampicin typically occurs through chromosomal mutations in the rpoB gene, which 
codes for the target of rifampicin, the β subunit of the DNA-dependent RNA 
polymerase. The genome alterations include point mutations, with certain single 
nucleotide modifications being sufficient to grant high levels of resistance, but can 
also occur through small insertions and deletions 129,130, most of which occurring in a 
81 base pair restricted region of the rpoB gene called cluster I 129.  Additional 
resistance mutations can occur in other rpoB regions, such as cluster N, cluster II 
and cluster III 131, but only a fraction of the resistance mutation spectrum is 
responsible for the majority of clinical rifampicin resistance in Mycobacterium 
tuberculosis 129. Most resistance mutations map directly in a fork domain of the RNA 
polymerase, proximal to the catalytic site, or in adjacent regions 88,132. Amino-acid 
substitutions in these sites are expected to affect the conformation of the binding 
pocket and lower its affinity for rifampicin 132, not allowing the drug to bind and block 
transcription elongation. 
Mutations in the ribosomal protein S12, coded by the rpsL gene 133 and in the 
16S rRNA 530 loop, coded by the rrn operons 134,135 can confer high levels of 
streptomycin resistance. The ribosome 30S subunit contains a conformational switch 
that is important for the optimization of translation. The H27 switches from an error-
prone, ribosomal ambiguity form (ram), and an alternative hyperaccurate, “restrictive” 
form 136. Streptomycin in particular acts by stabilizing the error prone state and 
increasing the binding of non-cognate tRNA. Most S12 resistance mutations and 16S 
mutations in the 530 loop lead to changes in ribosome accuracy. In the respective 
mutants, the ram state is very destabilized, and the stabilization induced by 




balancing equilibrium between ribosomal states, in a fraction of these mutants, 
streptomycin presence can even become essential 137,138. 
 
Target protection by modification 
The antibiotic target can be protected by modifications that do not require 
mutational change. Protection of targets has been found to be a clinically relevant 
mechanism of resistance to several antibiotics. One example is the action of 
erythromycin ribosome methylase on the 16S rRNA, protecting the target from being 
bound by macrolides and lincosamines 139. Another example is the chloramphenicol-
florfenicol resistance methyltransferase. This enzyme methylates the position A2503 
of the 23SrRNA, conferring resistance to a wide range of drugs with nearby targets, 
such as phenicols, pleuromutilins, streptogramins, lincosamides and oxazolidonones 
140. Resistance to aminoglycosides can also be granted through 16S rRNA 
methylation 141,142. Protective agents can also associate with the antibiotic target. 
Such examples are the quinolone resistance qnr genes, which encode pentapeptide 
repeat proteins. These agents bind to DNA gyrase and topoisomerase IV and protect 
the enzymes of inhibition by quinolones. While the mechanism of action of these 
resistance determinants is not fully understood, a model of the mechanism of action 
based on structural data of QnrN1 suggests that these agents might interact with 
topoisomerase-quinolone complexes, effectively rescuing the enzyme and allowing 
it to re-ligate DNA, thus preventing the formation of double-strand DNA breaks that 
typically occur with the antibiotic action 143. Some of the antibiotic resistance genes 
conferring target protection can be encoded by cryptic genes, and a recent study in 
Salmonella enterica shows that such genes can be activated and confer resistance 
through mutations that affect their expression – a chromosomal mutation induced the 
expression of an aminoglycoside adenyl transferase in stringent conditions, leading 
to resistance to streptomycin and spectinomycin 144. On a similar note, mutations 
inactivating the 16S rRNA methyltransferase gidB were shown to confer low-levels 
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of streptomycin resistance in Mycobacterium tuberculosis, Staphylococcus aureus 
and Escherichia coli through methylation of the 16S rRNA 530 loop 145, effectively 
protecting the target from the antibiotic action. 
 
Antibiotic inactivation 
Antibiotic inactivation is a major mechanism of antibiotic resistance. Naturally 
occurring antibiotic resistance through antibiotic modification was first reported in 
1940, with the discovery of penicillinase 146, roughly a decade after the discovery of 
penicillium 147. Since then, thousands of enzymes degrading or modifying antibiotics 
of different classes have been identified, including β-lactams, aminoglycosides, 
phenicols and macrolides 41. Some of these enzymes are able to degrade different 
antibiotics of the same class 148, inclusively to modified β-lactams that were designed 
to be effective against strains producing natural β-lactamases 149,150. The carriage of 
these extended-spectrum β-lactamases and carbapenemases has led to a fast, 
world-wide spread of strains that are resistant to clinically used β-lactam antibiotics 
151–153. 
Many antibiotics have hydrolytically susceptible chemical bonds which are 
essential to their biological activity. β-lactamases, conferring resistance to β-lactams, 
esterases, conferring macrolide resistance and fosfomycin resistance epoxidases 
cleave these vulnerable bonds, destroying antibiotic activity. As hydrolytic enzymes 
require only water as a co-substrate, they can be excreted by bacteria and intercept 
antibiotics before they reach the cell 154. 
Another common type of antibiotic modification is group transfer, which is 
carried out by the large and diverse family of group transferases. These enzymes 
modify antibiotics covalently, resulting in the prevention of target binding by steric 
hindrance. Various chemical groups can be transferred, including acyl, thiol, 
phosphate, nucleotidyl and ribitoyl groups 41,154. These strategies require molecular 




with the antibiotic, and hence are active only in the cytosol 154. Aminoglycoside 
antibiotics are particularly susceptible to modification, since these large molecules 
can be deactivated by the action of different classes of enzymes 41. Group transfer 
mediated antibiotic inactivation is also known to act on other antibiotics such as 
chloramphenicol 155 and streptogramin 156 through acetyltransferases, and rifamycins 
through a phosphotransferase enzyme 157. A bioinformatic analysis of GenBank 
sequences coupled with heterologous expression experiments suggests that cryptic 
orthologues of the latter are present across environmental and pathogenic Gram-
positive bacteria 157, further supporting that cryptic embedded genes may be a 
significant fraction of the antibiotic resistome 158. Besides hydrolysis and group 
transfer, antibiotics can also be inactivated by oxidation 159,160, and by the action of 
lyases 161, although these routes seem to be much less common in nature 154. 
 
The fitness effects of antibiotic resistance 
A critical aspect for the maintenance of an antibiotic resistant bacteria lies in its 
ability to compete with antibiotic sensitive ones. In order to predict which strains are 
maintained in a population, evolutionary biologists estimate and compare their fitness 
— a quantitative measure of a genotype’s competitive ability. Fitness is derived from 
all phenotypes affecting the ability to survive and reproduce in a given environment. 
In the absence of strong random genetic drift, fitness will determine the frequency 
change of a population’s genotypes over time 162.  
Fitness can be measured in one of two ways: as absolute fitness and as relative 
fitness. Absolute fitness refers to the variation in absolute numbers of a genotype, 
while relative fitness refers to the frequency change of the genotype in the population 
163. As every environment has a limit to the number of individuals that it can carry — 
a carrying capacity — relative fitness is commonly used to predict the fate of a given 
genotype — maintenance, fixation or extinction. In bacteria, relative fitness is typically 
measured through a direct competitive fitness assay, in which competing strains are 
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co-cultured in the same set of growth conditions, or estimated by measuring and 
comparing quantifiable growth traits, such as maximum growth rate, in single culture 
growth 164. When a change in the genetic information affecting one or more 
phenotypes occurs, it will have a fitness effect in the individuals carrying it. This 
fitness effect can lead to a higher fitness by rendering a fitness benefit or lead to a 
lower fitness by imposing a fitness cost. 
 
The cost of antibiotic resistance 
As previously discussed, antibiotic targets are often core components of the 
cell. These components are typically involved in essential cellular functions, such as 
replication 165, transcription 166, translation 167, and cell wall biogenesis 168. Mutations 
conferring resistance by target gene modification can structurally change these 
elements into a suboptimal state 169 and lead to pleiotropic effects 170–172. On the other 
hand, genes obtained by horizontal gene transfer, as well as genes with an amplified 
expression imply a metabolic cost to the cell due to increased transcription and 
translation of genes conferring antibiotic resistance 173. Furthermore, the acquisition 
of mobile genetic elements can alter the transcription of profile of chromosomal genes 
174 and cause chromosomal perturbations if integrated into the host’s genome 175. As 
a consequence, the acquisition of antibiotic resistance is expected to inflict a fitness 
cost in the absence of antibiotics 164,176,177. Several laboratory studies have shown 
that resistance is effectively associated with deleterious effects, and the fitness cost 
of resistance has become a well-established concept 178–180. 
 
Selection favoring the maintenance of resistance 
As resistant bacteria tend to be inferior competitors than their sensitive 
counterparts, an intuitive strategy for containing the spread of antibiotic resistance is 




frequency 176. This strategy has been adopted by different countries and for different 
antibiotics, but its effectiveness has been inconsistent 164,181. In some cases, 
resistance has decreased as predicted 182–186. However, in other situations, resistant 
determinants were not eliminated 185,187,188, and there is evidence of spread of 
resistance after antibiotic reduction campaigns 189, indicating that in nature, bacteria 
have ways to persist despite the expected cost of acquiring resistance. 
Over time, several biological phenomena allowing the reduction or 
circumvention of a fitness cost of resistance were reported. These include resistance 
mutations with no detectable cost, selection for resistance at residual antibiotic 
concentrations, co-selection, environment influence on the fitness effects, 
compensatory mutations and epistasis. 
Costless mutations 
Some resistance mutations have been reported to confer high levels of 
resistance while imposing reduced costs or even no cost at all 9. This absence of cost 
is thought to be related with the nature of the mutations. For instance, certain 
streptomycin resistance mutations leading to an amino acid change from a lysine to 
an arginine have an insignificant effect on fitness in Salmonella enterica 190,191 and E. 
coli 192, and in the latter study, some nalidixic acid resistance mutations seem to have 
no cost as well in standard laboratory conditions 192. The costless mutations in 
streptomycin happen to match with non-restrictive resistance phenotypes, which are 
similar to the wild-type’s regarding translation speed and fidelity 193. Furthermore, in 
Salmonella enterica these mutations do not impair virulence 190, suggesting that the 
corresponding mutants may be able to compete with the wild-type in clinical settings 




Selection and mutagenesis at residual antibiotic concentrations 
The minimum inhibitory concentration (MIC) is the lowest concentration of a 
compound that prevents visible growth of a bacterium 194. Resistant strains have a 
higher MIC than their sensitive counterparts. MIC measurements allows the detection 
of resistant strains and the determination of the level of resistance. 
It should be noted that the level of resistance can vary extensively depending 
on the resistance mechanism. Certain mechanisms confer such low-level resistance 
that it can only be detected by time-kill experiments 195, while others may provide 
extremely high resistance levels, which may even surpass the solubility limit of the 
antibiotic 196,197.  Mechanisms involved in drug efflux tend to confer a lower level of 
resistance than those that modify the antibiotic target or inactivate the drug 198. 
Furthermore, bacterial growth may be unaffected by increasing antibiotic 
concentration until the MIC is reached, such as for amdinocillin resistant mutants in 
E. coli 199, or monotonically decrease with the increasing levels of antibiotic 200,201. 
Thus, the fitness of resistant bacteria might be constant or vary extensively as a 
function of antibiotic concentration 198. 
Selection for resistance is classically thought to be driven by high, supra-MIC 
concentrations of antibiotics used in therapy, animal husbandry and agriculture. 
However, nowadays, antibiotics are widespread throughout the environment in low 
concentrations due to contamination from human activities 202, with many interactions 
between antibiotics and microbial populations occurring in such conditions. It has 
thus been hypothesized that these low concentrations have a relevant role in the 
development of resistance 203 and it has been experimentally demonstrated that 
concentrations below the wild-type’s MIC can affect selection and favor resistance 91. 
A fitness advantage of resistant strains at sub-MIC concentrations of tetracycline and 
ciprofloxacin was shown for E. coli mutants 204, while in S. enterica, such advantage 
was shown for the same antibiotics and streptomycin 201. The latter study further 
shows that resistant mutants occur under a sub-MIC regime, sustaining the idea that 




A recent work focused in S. enterica’s evolution at sub-MIC levels of 
streptomycin shows that the acquired resistance mutations can have a different 
nature than the ones obtained in high drug concentration regimes. Low antibiotic 
levels are shown to lead to high levels of resistance through the accumulation of 
different small-effect resistance mutations that either alter the ribosome target, 
reduce the aminoglycoside uptake or induce a cryptic aminoglycoside modifying 
enzyme 205. These observations indicate that low levels of antibiotics foster a greater 
mutational space for the selection of resistant phenotypes and provide additional 
evolutionary paths towards high-level resistance. Unlike supra-MIC concentrations of 
antibiotics, which typically kill non-resistant bacteria, below MIC concentrations still 
affect and act as a stress to sensitive bacteria. The stress leads to a physiological 
response of the cell, often leading to the activation of conserved stress response 
systems and leading to an increase in the rate and frequency of genetic processes 
that promote resistance acquisition, such as horizontal gene transfer 206–208, 
recombination 209–211 and mutagenesis 212–214.  
One of the main stress responses to sub-MIC concentrations of antibiotics is 
the SOS response – a systemic reaction to DNA damage in which cell growth is 
arrested and DNA repair is promoted. This response implies the recruitment of RecA, 
which is involved in recombination, and of translesion DNA polymerases, which 
introduce base substitutions at a high frequency 215, increasing mutagenesis. Another 
major stress response activated by antibiotic stress is the general stress response, 
mediated by RpoS induction 216. As with other sigma factors, RpoS it interacts with 
the core RNA polymerase and controls the expression of a large, yet specific 
collection of genes 217. Within such a set, RpoS positively regulates the expression 
of sdsR, a small RNA molecule that represses the messenger RNA of MutS. The 
latter is a protein involved in the DNA mismatch repair, being pivotal in mending 
replication errors. Furthermore, the error prone DNA polymerase IV is also a part of 
the RpoS regulon. Together with the depletion of MutS, the action of DNA polymerase 
IV leads to a RpoS-mediated induction of mutagenesis in the presence of beta-lactam 
antibiotics 216, which in turn can generate mutations conferring resistance. 
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Co-selection and cross resistance 
When adapting to a specific environment, bacteria can acquire mutations or 
genetic elements that are beneficial in other environmental settings. Such 
acquisitions, which prepare bacteria for environments to which they are not exposed, 
are broadly called as co-selection. Antibiotic resistance is frequently co-selected with 
multiple resistance phenotypes, such as resistance to a different antibiotic, to heavy 
metals or other biocide agents 218,219. 
Resistance to an antibiotic can be acquired after exposure to another agent if 
the two attack the same target, initiate a common pathway to cell death or share a 
common route of access to their targets, through the evolution or activation of a 
shared resistance mechanism. This type of co-selection is called cross-resistance, 
and allows the development of resistance to multiple antibacterial agents through a 
single selective pressure 220. Cross-resistance is commonly associated to multidrug 
resistance elements, especially those involved in efflux mechanisms 221. Multidrug 
pumps in particular have often a wide substrate specificity and can lead to elevated 
levels of resistance to multiple agents 222. In addition to antibiotics, multidrug pumps 
can simultaneously confer resistance to metals223–225, and to the natural substances 
produced by the bacteria’s host such as bile salts, hormones and defense molecules 
226. There is accumulated evidence that multidrug pumps can be involved in bacterial 
pathogenicity, indicating that in certain situations, the use of an antibiotic may help to 
select for increased virulence 226. 
Co-selection can be driven by co-resistance, which occurs when a resistance 
determinant is coded in the same genetic element as another, such as plasmids, 
transposons or integrons 220. Antibiotic and toxic metal resistance genes are 
frequently linked in plasmids 227–230. A key example of co-resistance regards Tn21-
like transposons, in which a mercury resistance and multiple antibiotic resistance 
genes are contained 231–233. Tn21 is thought to have accumulated multiple antibiotic 




resulting in Tn21 dissemination at a time when clinical, agricultural and industrial 
practices provided both types of selective agents 233. 
There is evidence that permafrost-derived Pseudomonas contains transposons 
that are closely related with ones found in present-day bacteria, but do not carry 
resistant determinants 234. Furthermore, the characterization of ancestral R-plasmids 
from pre-antibiotic era culture collections of Enterobacteriaceae indicate that while a 
significant fraction of pre-existing R-plasmids had the ability to be transferred, they 
did not yet carry transferable antibiotic resistance determinants 235. These studies 
suggest that co-resistance may have been selected and amplified by the 
anthropogenic use of antibiotics. 
Co-selection can also occur due to a mechanism of co-regulation. Resistance 
genes can have a linked transcriptional and translation response with other stress 
response genes. For instance, in E. coli MG1655, excess zinc has been shown to 
cause the upregulation of the mdtABC operon 236, which codes for an efflux system 
that confers resistance to antimicrobial agents such as novobiocin and deoxycholate 
237. Zinc exposition was also shown to induce and select for resistance to the 
carbapenem antibiotic imipenem in Pseudomonas aeruginosa. The heavy metal 
efflux pump CzcCBA, involved in zinc resistance, was shown to have increased 
expression, while the expression of the OprD porin, involved in carbapenem 
transport, was reduced. This was due to a single amino-acid substitution in the CzcS 
sensor protein, shown to be involved in their regulation 238. Such co-regulated stress 
responses can lead to the expression of antibiotic resistance determinants prior to 
the exposition to the antibiotic and render it ineffective. Unless co-regulation is lost, 
selection favoring one of the phenotypes can drive the maintenance of the other. 
Compensation 
Although antibiotic resistance determinants are often deleterious, resistant 
bacteria can lower their cost through the acquisition of compensatory mutations. 
These mutations confer a genetic background-specific fitness benefit by 
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counteracting the phenotype of deleterious mutations, partially or sometimes fully 
restoring the strain’s competitive ability 169. As such, they are extremely important to 
secure the competitive ability of resistant strains against sensitive bacteria. 
Compensation for single resistance mutations has been widely described in 
laboratory conditions 239–241, including through in vivo studies involving pathogens 
190,191,242, and compensatory mutations are often found in clinic isolates 241,243,244. 
Bacteria can overcome the deleterious effect of resistance through an 
extensive array of compensatory mutations 169, including mutations in different gene 
targets 190,196,240,245,246, making compensation through the acquisition of mutations far 
more common than genotypic reversion 191,239,240,247,248. The latter is a specific case 
of compensation in which the mutant loses the original resistance mutation, fully 
recovering fitness and antibiotic sensitivity. In this work, I will refer to genotypic 
reversions in separate from the remaining compensatory mutations. 
Compensation can occur via several mechanisms. One of the most common is 
the restoration of the structure and function of the protein or RNA molecule 
responsible for the altered phenotype, by the acquisition of additional intragenic 
mutations 169. Intragenic compensation has been shown to occur for a wide array of 
antibiotics, such as fusidic acid 242,247, streptomycin 190,191,240,249, beta lactams 250–252, 
rifampicin 190,239,245, sulfonamids 253, coumarins 254 and mupirocins 255. 
Regarding streptomycin resistance, a fraction of the mutations in the rpsL gene 
increase translation accuracy and decrease the protein elongation rate, a restrictive 
phenotype that results in an impaired bacterial growth 240,256. In Salmonella enterica, 
the fitness cost of one such restrictive mutation (rpsL K42N) could be compensated 
by an intragenic mutation (rpsL H93R) which restored the translation accuracy and 
elongation rate by destabilizing the mutant ribosome’s restrictive conformation 240.  
A similar situation occurs when considering rifampicin resistance mutations. 
Resistance mutations in the rpoB gene have often been reported to impose a cost 
177,190,239. The rpoB R529C mutation in particular was shown to be defective in the 




aborted transcription initiation 257. For other rpoB resistance mutations, the increased 
cost was correlated with a lower transcription efficiency 239. In the latter study, during 
the evolution of a resistant strain in the absence of antibiotic, intragenic 
compensatory mutations were acquired in roughly half (11/20) of the evolved lines. 
While the compensatory mutations improved growth rate without altering the level of 
resistance, in 5 out of 7 tested lines, the transcription efficiency was rescued. 
Compensatory mutations also occur frequently in other genes besides the one 
conferring resistance. These targets are intimately related with the resistance gene, 
with compensation allowing the restoration of the structure and function of multi-
subunit complex proteins or organelles, such as the RNA polymerase and the 
ribosome 169. 
In E. coli and S. enterica, the aforementioned restrictive phenotype of 
streptomycin resistance mutations, which leads to ribosomal hyper accuracy, could 
be counter balanced by mutations in other ribosome proteins that decrease the 
accuracy of the translational process. In most mutants, fitness was partially restored, 
but in some cases, the compensated strains could grow at a pace similar to the 
sensitive wild-type’s 190,240,249. As with intragenic compensation, these mutations are 
thought to destabilize the restrictive conformation of the ribosome, counteracting the 
phenotype of the restrictive antibiotic resistance mutations 169. 
For rifampicin resistance mutations, extragenic rpoA and rpoC mutations are 
commonly found in compensation experiments 196,245,258,259. Furthermore, in a study 
comparing the genomes of clinical rifampicin resistant and rifampicin susceptible M. 
tuberculosis isolates, mutations in these genes were associated with resistance, with 
27.1% of resistant strains carrying non-synonymous mutations in one of the two 
genes 243. In a study in S. enterica, involving genetic reconstructions through phage 
transduction, single compensatory mutations in rpoA and rpoC (and also in rpoB) that 
occurred during the evolution of a resistant strain were shown to be necessary and 
sufficient for growth compensation 258, effectively proving that that these genes are 
compensatory targets. In a subsequent, similar study, mutations in the same targets 
were shown to compensate for the clinically relevant rpoB S531L mutation 245. 
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Compensation can also occur by a bypass mechanism, through which the 
resistant bacteria evolves to reduce the need of an altered function or by exploring 
an alternative protein or metabolic pathway to the ones affected by the antibiotic. One 
such example is compensation of isoniazid resistance in Mycobacterium 
tuberculosis. Resistance mutations impairing KatG catalase peroxidase activity 
confer resistance but are extremely costly. Such cost can be compensated by 
mutations increasing the expression of the AhpC alkyl hydroperoxidase, bypassing 
the need of KatG for protection against organic peroxidases 260. Another exquisite 
example of compensation regards resistance to actinonin in Salmonella enterica. 
Resistant mutants have an impaired formylation of methionyl initiator tRNA, and a 
fraction of the mutants compensated this defect by amplifying the tRNAi encoding 
genes metZ and metW. The high tRNAi levels allowed translation initiation to proceed 
without formylation, effectively heightening fitness by allowing the bypass of the 
reaction 261. 
Compensation studies are usually performed in the absence of antibiotics. Still, 
some studies have compared the evolution of resistant strains in the presence and 
in the absence of the drug 239,255. Both studies suggest that the two regimes imply 
different loci in the compensation process. Curiously, for mupirocin-resistant mutants, 
compensatory mutations acquired in the absence of the drug do not confer fitness 
rescue in its presence 255. 
The appearance and spread of compensatory mutations is conditioned by 
various factors, such as population size, bottlenecks 240 and mutation rate 262, as well 
as the fitness effect of compensatory mutations, which depend on the genetic 
background in which they occur 196,259. Compensation (and adaptation in general) 
tends to be faster in backgrounds with a higher fitness cost (Couce & Tenaillon, 
2015). A study involving antibiotic resistant E. coli strains with different costs shows 
that mutants with a higher cost can compensate rapidly and compete with mutants 
with a lower initial cost, leading to the subsistence of both compensated strains for 




compensation can be in the rescue of low fitness resistant mutants from their 
predicted extinction. 
Importantly, certain compensatory mutations acquired in the absence of 
antibiotics were found to decline resistance. While in most situations the 
compensated strains still had a higher level of resistance that the sensitive strain, 
there are reports of full recovery of sensitivity through second site mutations, a 
process of phenotypic reversion 196,263–265. In a recent study with 23 strains carrying 
at least 2 mutations conferring multiple antibiotic resistance, phenotypic reversion 
was found to be common, with the extent of reversions depending on the considered 
antibiotic 265. These observations suggest that the varying success of banishment 
policies in reducing resistance is related with the antibiotic nature. Further studies on 
the likelihood of phenotypic reversions could help identify the most suitable antibiotics 
for the application of banishment policies. Also recently, three studies have focused 
on the induction of phenotypic reversions. One of the studies applies the treatment 
of resistant bacteria with a short antisense oligomer that inhibits the expression of 
acrA, a gene involved in efflux system AcrAB-TolC, one of the major intrinsic 
resistance determinants in E. coli 266. In the second study, the authors developed 
drug-like molecules that activate a cryptic bioactivation pathway of the prodrug 
ethionamide in Mycobacterium tuberculosis, bypassing the classic pathway in which 
resistance mutations occur 267. One such molecule named SMARt-420 (Small 
Molecule Aborting Resistance) was shown to fully reverse resistance, to clear an 
ethionamide-resistant infection in mice and to increase basal sensitivity of bacteria to 
ethionamide. In the third study, the authors perturb the assembly of functional 
membrane microdomains (FMM) in methicillin-resistant Staphylococcus aureus 
(MRSA). MRSA’s β-lactam resistance determinant PBP2a typically accumulates in 
these domains. Through the use of the staphyloxanthin biosynthesis inhibitor 
zaragozic acid, the authors were able to disrupt FMM and inhibit resistance in vitro 
and in vivo 268. 
It should be noted that both resistance and compensatory mutations can have 
pleiotropic effects in bacteria, affecting multiple relevant phenotypes. In Salmonella 
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enterica, nalidixic acid, rifampicin and streptomycin resistance mutations were shown 
to impair virulence in mice. While evolving through successive mouse infections, the 
mutants acquired compensatory mutations that not only heightened their relative 
fitness, but also and restored virulence 190, with compensation leading to 
simultaneously fit, resistant and virulent genotypes. 
Environment dependence of fitness effects 
Different organisms are more or less adapted to specific environments. A 
change in environment can lead to a shift in selective pressures and favor a 
previously unfavored genotype. Antibiotic resistance mutations, in particular those 
which are pleiotropic, can confer environment-specific fitness effects. Many 
examples of unexpected benefits have been reported. For instance, rifampicin 
resistance mutations we able to spread into high frequencies in populations under 
regimes of resource limitation 89,269. In another study, transposon insertions in the 
oprD gene leading to the loss of the coded carbapenem entry channel, also instigate 
transcriptional changes in numerous genes and confer a fitness advantage to 
Pseudomonas aeruginosa, both during colonization of the mouse gut and in the 
dissemination to the spleen 270.  
Various studies have addressed the environmental contribution to the growth 
and fitness effects of resistance mutations by comparing them in multiple 
environments with the same resistant genotypes 271–274. In one of these studies, both 
the fitness of E. coli double mutants resistant to rifampicin and streptomycin and the 
epistasis between resistance mutations were shown to drastically vary between two 
of the most commonly used laboratory media, LB and M9 minimal medium with 
glucose 274. Particularly important are studies comparing the fitness effects on 
laboratory media compared to bacteria’s natural environments 191,242. In one such 
study, Bjorkman et al. have shown that in Salmonella enterica, mutations conferring 
resistance to fusidic acid and to streptomycin have a different fitness in LB and mice. 
The authors proceeded to the evolution of the strains through mice intra-peritoneal 




compensatory mutations occurring in the two regimes. Importantly, the compensated 
mutants also had different fitness in the two environments 191, implying a strong 
environmental effect in the fitness cost of compensated strains as well. 
Epistasis 
Epistasis is a phenomenon of genetic interaction, in which the phenotype of an 
allele in a particular locus is affected by the presence of other alleles on different loci  
275. In other words, the effect of a mutation depends on the genetic background in 
which it occurs 276. This type of interaction can involve phenotypes that contribute to 
fitness and influence evolution. 
Considering two mutations under epistasis, mutations with a shared beneficial 
or detrimental effect on fitness can either act synergistically, amplifying their effect, 
or antagonistically, with a lower combined effect of the two. When considering 
deleterious mutations, a synergistic interaction leads to a combined cost that is higher 
than expected, and consequently, to a lower fitness. This genetic interaction is 
classified as negative epistasis.  Alternatively, epistasis is considered positive if the 
two deleterious mutations have an antagonistic effect, leading to a lower cost, and a 
higher fitness than the expected for independent mutations 277,278. 
According to its effects, different classes of epistasis can be considered. 
Epistasis can act maintaining the beneficial or deleterious effects of the mutations, 
being classified as magnitude epistasis. Alternatively, the effect of a mutation might 
vary in sign with the genetic background, being beneficial or deleterious depending 
on the presence or absence of the other mutation. Such scenario is classified as sign 
epistasis 279. Considering two deleterious mutations, sign epistasis can be partial, in 
with the double mutant being fitter than one of the single mutant genotypes, or 
reciprocal, through which the double mutant is fitter than both single mutants 280. For 
this particular class of epistasis, both paths towards the fitness optimum involve a 




In the particular case of antibiotic resistance, genetic interactions between 
different antibiotic resistance determinants can occur. Positive epistasis between 
resistance mutations has been reported to occur in bacteria such as E.coli 192,274, 
Mycobacterium tuberculosis 281 and Pseudomonas aeruginosa 282,283, with multi-
resistance being less costly than expected. These studies indicate that epistasis 
between resistance mutations may promote the maintenance of multi-resistant 
strains by mitigating their fitness costs. It should also be noted that positive epistasis 
can occur between a costly and a costless mutation as well 274. Furthermore, positive 
epistasis is also observed between plasmids carrying resistance 284, and between 
conjugative plasmids and chromosomal mutations 285. 
In a study demonstrating positive epistasis between chromosomal single 
nucleotide polymorphisms (SNPs) conferring resistance to nalidixic acid, rifampicin 
and streptomycin, some double mutants manifested partial sign epistasis 192. Sign 
epistasis between mutations conferring resistance to the clinically relevant antibiotics 
rifampicin and ofloxacin was also described in Mycobacterium smegmatis 281. 
Furthermore, sign epistasis was shown to occur between chromosomal mutations 
and conjugative plasmids carrying antibiotic resistance determinants, including a 
case of reciprocal sign epistasis 285. These observations are particularly troubling 
because they imply that for certain combinations of resistance determinants, the 
multi-resistant strain may be more fit than its single counterparts. In this 
circumstance, evolution through natural selection will not promote the loss of 
resistance. In fact, it may select against reversions in the multi-resistant strain. 
It has been observed that the beneficial effect of a mutation tends to be smaller 
as the overall fitness increases 286–288, a phenomenon called diminishing returns of 
beneficial mutations. A study with rifampicin resistant Pseudomonas aeruginosa 
evolving in a constant environment in the presence of the drug corroborates these 
classic observations and further discloses that the same mutation can have a 
different fitness effect across genetic backgrounds, effectively showing that epistasis 
is driving these diminishing returns in fitness 289. Two key studies evaluating the 




such diminishing returns epistasis 290,291, further evidentiating the fundamental role of 
the genetic background in the fitness effect of a mutation. 
Fortunately, resistance determinants can lead to an increased susceptibility to 
a different drug 292,293. This phenomenon of negative cross-resistance, also known as 
collateral sensitivity, can be particularly useful to determine which drugs to use 
sequentially in chemotherapy 294. 
As epistasis affects fitness, it is expectable that the occurrence of 
compensatory mutations in multi-resistant bacteria can also be affected by these 
genetic interactions. In the presence of positive epistasis, compensatory effects are 
expected to be weaker. In the particular case of sign epistasis, in which the double 
mutant has an advantage over single resistant clones, compensatory targets are 
expected to be less due to genetic constraints. In the case of negative epistasis 
however, a stronger compensatory effect is expectable, as mutations compensating 
specifically for the deleterious genetic interaction can occur. In a recent study 196, an 
E. coli double mutant for rifampicin and streptomycin resistance bearing negative 
epistasis between the two chromosomal resistance mutations, as well as the 
respective single mutants were evolved in the absence of antibiotics. By comparing 
the genome sequences of the evolved lines, the authors discovered mutations 
occurring exclusively in the double mutant background. Through genetic 
reconstruction and fitness assays, the authors proved that a specific amino-acid 
change in the RNA polymerase subunit β’, RpoC, and a mutation causing increased 
expression of the ribosome-RNA polymerase coupling protein, NusG, were 
advantageous in the double resistant background, but neutral or deleterious in the 
respective singles. Furthermore, the authors showed that the compensatory effects 
were present no more in an environment in which the two mutations did not have 
negative epistasis, effectively showing that these mutations were specifically 
compensating for the deleterious genetic interaction 196. The discovery of 
compensatory targets for epistasis allows the identification of new genes involved in 
multiple key cellular mechanisms. As such, the corresponding proteins are potential 




Gut commensal bacteria 
Host-bacteria interactions can be classified as symbiosis, commensalism and 
pathogenesis. Symbiosis occurs when at least one of the two species has a clear 
benefit of the association, without harming the other, and typically involves the 
exploitation of a nutritional niche that would not be available without such association. 
Commensalism typically refers to when bacteria coexist with their host, without 
detriment but also no obvious benefit for any of the partners. Pathogenicity implies 
damage to the host 296. 
Although it is generally believed that the composition of the gut flora is 
associated with health and disease, the specific roles and potential benefits of most 
non-pathogenic gut bacteria are still undisclosed. Having this into account, 
throughout this work, I will be using the term commensal to broadly describe non-
pathogenic bacteria. 
 
Commensal bacteria as a reservoir of resistance 
Pathogens are agents that directly cause disease, and resistant pathogens are 
an immediate threat to humans. As such, it is understandable that many of the early 
resistance and epidemiological studies were focused on them. However, pathogens 
are only a tiny fraction of the microbes interacting with humans 297. The realization 
that commensal bacteria could act as a reservoir for resistance has gradually shifted 
the focus of resistance studies to natural bacterial communities. 
Antibiotic resistance in commensal bacteria is currently recognized as a threat. 
The recurrent use of antibiotics in the clinics to treat disease and perform prophylaxis, 
in crops and in animal husbandry selects for resistance not only in disease causing 




Consecutive rounds of selection lead to the enrichment in resistant bacteria that are 
not the primary target of antibiotic use 299. These bacteria can then transfer antibiotic 
resistance determinants between themselves and potential pathogens, providing an 
alternative route to generate resistant disease-causing agents 300. 
Transfer of multiple drug resistance from commensal to pathogenic 
enterobacteria was described over half a century ago, depicting the transference of 
resistance from commensal E. coli to pathogen enterobacteria such as Shigella sp. 
301 and Salmonella enterica serovar Typhimurium 302. Meanwhile, several studies 
have further contributed to the notion, such as the report of recent dissemination of 
streptomycin and sulfonamide resistance genes among commensal and pathogenic 
bacteria 303 and the dissemination of tetracycline resistance gene tetQ and of the 
erythromycin resistance genes ermF and ermG in Bacteroides species 304. This last 
report is particularly impressive, as tetQ has spread its representation from 30% to 
more than 80% of Bacteroides strains in just 3 decades, while the erm genes rose 
from below 2% to 23% frequency in the isolates. The carriage of resistance was as 
high in isolates from people without recent history of antibiotic use as in isolates from 
patients with Bacteroides infections, indicating that resistance transfer is occurring 
outside the clinic environment 304. 
Additional studies support the origin of resistance determinants in 
environmental bacteria. One example relates to the β-lactamase resistance blaCTX-M 
genes, which have spread worldwide 305. Through homology inferences of the genes 
and their flanking regions, the origin of these genes was pinpointed to the 
chromosomal DNA from environmental Kluyvera species, from where the genes have 
spread to other bacterial species 306. Another example relates to quinolone resistance 
qnrA genes, which have disseminated globally in enterobacteria 307. Shewanella 
algae, a marine and fresh water bacteria, was found to be a reservoir and the likely 
origin of these resistance determinants 308. Evidence supporting horizontal gene 
transfer from commensal to pathogen bacteria extends to Gram-positive bacteria as 
well. Studies focused on sequence diversity of several commensal and pathogenic 
streptococci strains have found extensive sequence variation in transpeptidase 
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genes, conferring β -lactam resistance in both groups, with homologous variants 
found in between the two 309–312. These observations strongly suggest that β-lactam 
resistant variants of Streptococcus pneumoniae originated in horizontal gene transfer 
events from commensal related species 309,310, such as Streptococcus mitis and 
Streptococcus oralis 311,312. 
Armed with the knowledge that bacteria often exchange genes laterally 53 and 
evidence of horizontal gene transfer of antibiotic resistance determinants, 
researchers have focused on studying the whole resistance repertoire of bacterial 
communities. This repertoire, called resistome 158 refers to all antibiotic resistance 
determinants and precursors in a given environment or group of environments 313,314. 
Many studies have sampled the resistome of environments such as the soil 313, 
wastewater 315 and human 316 and animal microbiota 317, and confirmed the 
widespread of antibiotic known resistance determinants, including clinically relevant 
resistance genes 318. The application of metagenomic approaches in particular 
allowed the direct recovery of DNA from all micro-organisms in a sample, avoiding 
culturability limitations and selective biases 319,320. Mining of metagenomic data can 
lead to the discovery of antibiotic resistance genes, inclusively in databases that were 
not designed to study resistance 321. 
On their own, sequence-based studies are limited to the identification of genes 
that are already known and to the prediction of novel functions of genes with high 
sequence homology of novel gene functions. Researchers have addressed this 
limitation by coupling the discovery of candidate genes with phenotypic tests of their 
function in surrogate hosts 322,323. Through functional metagenomics, numerous 
studies have revealed several unknown and unnoticed antibiotic resistance 
determinants in soil 39,313,324,325, wastewater treatment facilities 326–328, in the 
microbiota of farm animals 166,329 and of humans 330–332. Thus, resistomes are more 
extensive than initially thought, with commensal bacteria indeed acting as large 




It should be noted that under certain conditions, bacteria that are typically 
commensal can evolve to cause disease. Often, pathogenic bacteria are members 
of a genus in which non-pathogenic or marginally pathogenic bacteria are the norm.  
In fact, many pathogenic bacteria inhabit the same primary habitat as their 
commensal relatives, causing disease only after spreading into other areas of the 
body – their “virulence niche” 333. Some of these lineages are carried by humans as 
permanent or transient commensals, with high virulence resulting from the acquisition 
and expression of traits that promote adaptation to secondary or novel niches. These 
traits consist in mechanisms that allow adhesion and/or damage to the host tissues, 
consumption of the secondary niche’s nutrients and the ability to evade or overcome 
antibacterial defenses 333.  
Nonpathogenic bacteria can acquire virulence traits through the horizontal 
gene transfer of virulence factors of foreign nature into the “commensal” genome, 
through the acquisition of plasmids, phages and pathogenicity islands 334. The latter 
are a particular class of genomic island that is present on the genomes of pathogenic 
strains but absent in nonpathogenic members of the same species and typically 
encode multiple virulence factors, including adhesins, secretion systems, toxins, 
invasins, modulins, effectors, superantigens and iron uptake systems, besides 
carrying other virulence associated genes 335. 
Alternatively, commensals can become more pathogenic through the 
acquisition of patho-adaptive mutations - adaptive mutations that lead to loss or 
modification of function of pre-existing genes, benefitting bacteria in the virulence 
niche 333. These pathoadaptive mutations can confer phenotypes such as increased 
evasion of phagocytosis 336,337, resistance to phagocytosis 338 increase in resistance 
to host clearance 339,340, increased capsule production 341, prolonged intracellular 
persistence 337,342, endotoxin activity 343, increased hemolysin production 344 and 
increased tropism to uroepithelium 345. 
Pathoadaptive changes can act by affecting the host’s ability to recognize 
bacteria. As an example, E. coli evolving in the presence of macrophages was shown 
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to recurrently acquire transposable element insertions that induce altered gene 
expression profiles both in the bacteria and in the macrophage, resulting in a delay 
on phagosome maturation by the latter 337. 
As with other genetic changes, pathoadaptive mutations can imply trade-offs in 
fitness and generate a cost in nonpathological habitats. One such example regards 
mutations in genes encoding the fimH adhesin can change the tissue tropism of 
commensal E. coli and confer a urovirulent phenotype 345. The pathoadapted variants 
gained a selective advantage in the colonization of the urinary tract, but at the price 
of a lowered ability to bind to buccal cells in the presence of the mannose-containing 
inhibitors bathing mucosal surfaces. 
Importantly, pathoadaptive traits, such as growth rate and survival inside 
macrophages, can be enhanced directly by antibiotic resistance mutations 346,347. 
Furthermore, pathoadaptation can impact antibiotic resistance on its own, by 
increasing or decreasing antibiotic sensitivity. As an example, a recent study shows 
that besides having a fitness advantage in the colonization of the mouse gut, 
pathoadapted E. coli small colony variants have increased resistance to kanamycin 
and increased sensitivity to tetracycline, featuring collateral sensitivity in vitro and in 
vivo 348. 
 
The gut microbiota 
The gut microbiota is one of the most densely populated microbial ecosystems 
on earth 316. Recent reports estimate that the number of bacterial cells in the human 
body is in the same order of magnitude of human cells, with the vast majority (≈99%) 
present in the colon 349. A landmark study catalogued the human gut microbial genes 
by performing metagenomic sequencing from fecal samples of 124 European 
individuals. A total of 3.3 million non-redundant microbial genes was found, a gene 




size and an enormous genetic repertoire that has been co-evolving with its hosts’ 351–
353, the gut microbiota is a core element of our body. 
Mammals have become dependent on the microbiota in a wide array of 
functions354,355. These range from metabolization of complex nutrients and production 
of metabolites, such as fatty acids, bile acids, choline and vitamins, that are essential 
for host health 356, to organ development and morphogenesis 355 and the maturation 
and regulation of the immune system 354,357,358. Microbiota also plays a role in the 
protection against pathogens by confering colonization resistance to the host 359, 
either through competitive exclusion or by maintenance of immune homeostasis 360. 
Strong microbiota perturbations, such as the ones imposed by antibiotic 
treatments and diet changes can lead to a reduction of microbiota diversity and affect 
its functions.  This imbalance, known as dysbiosis, is associated health problems 
such as obesity 361,362, inflammatory bowel disease 363,364 and gastrointestinal cancer 
365, functional bowel disorders 366, and allergies 367. 
Due to the intimate host-microbe interactions and the critical role in the contact 
with the external environment, some authors conceptualize the gut microbiota as an 
effective organ 368,369. However, the gut microbiota is much less characterized than 
the host organs - we don’t know with precision its composition (it is not fixed), and its 
roles are still far from being fully explored 370.  
As mentioned, recent studies have addressed the resistome of the gut 
communities  and shown that the gut microbiome is indeed a large reservoir for 
antibiotic resistance genes 330–332. However, given the expected cost of carrying 
antibiotic resistance determinants, it is still not clear how this antibiotic resistance 
repertoire is maintained. Studying how selection acts on resistant commensal 





Escherichia coli as a model and as a gut commensal 
E. coli is a gram-negative, asporogenous, facultative anaerobe and a common 
member of the normal gut microbiota community in warm-blooded animals and 
reptiles 371,372. Despite being vastly outnumbered by obligate anaerobes in the large 
intestine of adult individuals 354, E. coli is the predominant aerobic organism in the 
gastrointestinal tract of humans 373. In the gut, E. coli typically resides in the caecum 
and the colon, namely in the mucus layer covering the epithelial cells and is shed into 
the intestinal lumen, being excreted in the feces 374. E. coli has adapted to acquire 
nutrients from mucus, and the ability to harvest mucus-derived sugars has a 
prominent role in the initiation and maintenance of E. coli’s gut colonization 375. While 
having the gut as a primary habitat, E. coli is able to subsist in secondary habitats 
such as soil, water and sediments 376. These nutritionally poor environments act 
mainly as a transitive habitat until a new host is found 376. 
E. coli is one of the first bacteria to colonize the intestine, reaching high cell 
density shortly after its host’s birth 377. E. coli is considered pivotal in the ecological 
succession of the gut microbiota by modifying the habitat into a reduced state, 
allowing the gut colonization by strictly anaerobic bacteria such as Bacteroides, 
Bifidobacterium and Clostridium 378,379. After the expansion of anaerobes, E. coli cell 
density stabilizes at around 108 cfu per gram of feces 373, although its numbers may 
rise in aged humans 380. 
Most E. coli strains act as commensals, benefiting from their hosts while 
causing no harm. E. coli is granted access to a limited supply of nutrients for which it 
competes 381, a relatively stable environment and protection against stresses, as well 
as transport and dissemination 373. On the other hand, commensal E. coli can 
contribute to the host’s health by producing vitamins 382, by activating the immune 
system 383,384 and by providing colonization resistance against antibiotic resistant 
Gram negative bacteria 385 and pathogens such as Shigella flexneri 386, Salmonella 





E. coli was first identified by the physician Theodor Escherich at the end of the 
19th century 389. The K-12 strain in particular was originally isolated by Blair in 1922 
from the stool of a convalescent diphtheria patient 390. Later on, the K-12 strain was 
selected as a model organism by Edward Tatum for his studies due to its 
prototrophism, ease of cultivation, short generation time and for permitting the study 
of very large populations, allowing the detection of rare events, such as mutations. 
Through these early studies, K-12 allowed for the isolation of auxotrophic mutants 391 
that were instrumental on the discovery of recombination 47,392. Since then, hundreds 
of strains were derived from the original K-12 either by spontaneous mutations or by 
treatment with mutation inducing agents such as X rays and UV irradiation 390. These 
derivative strains have been key in the advancement of genetics, molecular biology, 
physiology and biochemistry 373. 
With the dawn of sequencing technologies, E. coli K-12 MG1655 was the first 
E. coli having its whole genome sequenced. This K-12 sub-strain was chosen due to 
its minimal genetic manipulation, having only been cured of the lambda phage by 
means of UV light and of the F plasmid through the use of acridine orange 393. While 
other E. coli strains were classically used for landmark studies, the proximity of 
MG1655 with the original, basal E. coli K-12 strain and the availability of its 
sequenced genome promoted the use of MG1655 as a main model for genome and 
genetic engineering studies and turned this strain into one of the best-studied 
organisms in biology. The accumulated knowledge on MG1655, its commensal 
nature and the ability to sequence, detect and identify mutations led to its adoption 
for evolution studies on the genetic basis of adaptation to the mammalian gut 66,394–







This work had as a main objective to study the fitness and evolution of gut 
commensal antibiotic resistant bacteria in their natural environment. 
Specifically, we aimed to: 
1) Estimate the cost of chromosomal mutations conferring antibiotic 
resistance in commensal E. coli, in its natural environment, the mammalian 
gut.  
2) Assess the presence of epistasis and compare fitness costs and the 
epistasis pattern with the ones observed in competitions in standard 
laboratory environments.  
3) Determine the genetic basis of the compensatory evolution of resistant 
strains within the mouse gut. 
4) Study the commonality of frequency-dependent selection in single gene 
polymorphisms, in simple and complex environments. 
Our predictions regarding a strain’s survival depends on the conditions in which 
fitness is inferred, and in the way we measure fitness. Studying commensal resistant 
bacteria in their natural environments will help us comprehend how they subsist in 












Chapter II – Personalized fitness cost of antibiotic 





Personalized fitness costs of antibiotic 
resistance in the mouse gut 
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Antibiotic resistance mutations typically decrease the competitive ability of 
bacteria in the absence of antibiotics. This has justified a public strategy of 
suspending antibiotic use to lower levels of resistance. However, this strategy has 
met mixed results and the reasons for these different outcomes are still unclear. It 
has been shown that fitness costs can vary with the environment, but they have been 
mostly studied in vitro. Thus, it became relevant to study the cost of resistance in 
environments closer to natural conditions. Here we show that following an antibiotic 
treatment, the cost of resistance for Escherichia coli in the mouse gut is highly host-
specific. Using mice co-colonized with sensitive and resistant E. coli, but lacking 
microbiota, we find a measurable cost of single and double resistance. In mice with 
microbiota, the same resistance mutations exhibit a varying fitness effect, being 
deleterious in some of the hosts, while having no cost or even being beneficial in 
others. Through competitions in co-housed mice, with normalized microbiota, we 
observe a reduction of the variance of the fitness effects.  Our results suggest that 
microbiota imbalances following antibiotic treatment can generate ecological 
conditions where resistance can be neutral or beneficial even in the absence of 













The discovery and usage of antibiotics was a major medical event in the 20th 
century, greatly reducing human mortality following bacterial infections 1. Antibiotics 
are nowadays central in modern medicine, both to treat and prevent disease 2, but 
their effectiveness is threatened by antibiotic resistance. Resistance occurs in nature 
and is present in different ecological settings 38,40,314. However, the extensive use of 
antibiotics has led to the spread of resistance, reducing the effectiveness of 
antibiotics in clinical settings over time 1,8, being a contemporary threat to the effective 
prevention and treatment of infections 11. 
Resistance can be acquired through spontaneous chromosomal mutations 
affecting core metabolic pathways and physiological processes of the cell, such as 
transcription 399, translation 167, replication 165 and cell wall biogenesis 168. As a 
consequence, it often implies a functional or energetic fitness cost 9, which turns into 
a lowered ability to survive and reproduce in the absence of the antibiotic 164,176,177. 
The existence of a cost predicts that the susceptible strain should out-compete 
the resistant over time, through natural selection. Having this into account, a 
commonly adapted procedure is to banish the use of antibiotics that have lost their 
effectiveness until resistance recedes. However, campaigns promoting the reduction 
or banishment of antibiotics do not always lead to a decrease in resistance 181. In 
some cases, resistance decreased as expected 182–186. Still, in others it was 
maintained 185,188,400, and there is even evidence for the spread of resistance after 
antibiotic reduction campaigns 189. As the efficacy of this strategy ought to depend on 
the cost of antibiotic resistance, these observations suggest that in nature, resistant 
strains may not always pay a fitness cost, even in the absence of the antibiotic that 
allowed it to rise. 
In vitro studies have shown that the fitness effects of resistance are under a 
strong influence of environmental factors, such as temperature 272 nutrition 272,274 and 
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the presence of immune cells 346,347. Additionally, epistasis between resistance 
mutations in functionally related genes appears to be pervasive 192 and itself 
environment-dependent 274.  
Since resistance mutations can be highly pleiotropic 172, and their fitness effect 
depends on the environment, a relevant question is whether the fitness measured in 
standard laboratory settings can be extrapolated to natural systems. Some studies 
on pathogens have tackled this issue and found fitness costs in vivo during the 
infection of mice hosts 190,191,401 which were different when measured in laboratory 
media 191,401, reinforcing the need to measure fitness costs in more natural settings. 
It is known that commensal bacteria can be a reservoir of antimicrobial 
resistance genes 297,330,402. However, the fitness costs of resistance in commensal 
bacteria in their natural environments is difficult to measure. Furthermore, the role of 
complex microbial communities such as the gut microbiota in the maintenance of 
resistance is still poorly explored. To address this gap in knowledge, we have 
performed in vivo competitions to measure the fitness costs of antibiotic resistance 
when commensal E. coli colonize the mouse gut, in the presence and absence of 














Escherichia coli and mice strains 
For our experiments, we used fluorescence-labeled, E. coli K-12 MG1655-
derived strains, with different antibiotic resistances, bearing either a point mutation 
conferring streptomycin resistance, a point mutation conferring rifampicin resistance, 
both mutations, or none of the two. We also used a natural streptomycin resistant 
strain from the mouse gut, and a double resistant strain, derived from the latter. 
The point mutations conferring resistance in our K-12 strains, rpsL K43T and 
rpoB H526Y, were generated by Trindade et al. in a K-12 MG1655 genetic 
background, and confer streptomycin and rifampicin resistance, respectively 192. 
These mutations were moved into isogenic, YFP and CFP fluorescent-labeled strains 
by Moura de Sousa et al. 196. Since the gat operon was found to be a mutation hotspot 
under strong selection in the mouse gut for K-12 MG1655 derived strains 395,398, we 
modified our strains to a galactitol negative phenotype via a knock-out of the gatZ 
gene. P1 transductions 403 were performed to substitute the whole gatZ gene from 
our strains with a kanamycin resistance cassete, using E. coli JW2082-1 from the 
KEIO collection 404 as a donor for the transduction. The new strains, RB929 and LC88 
(ΔlacIZYA::scar galK::cat-YFP/CFP ∆gatZ::FRT-aph-FRT), were used as wild-type 
strains for the competitions. P1 transductions were also used to insert the point 
mutation rpoB H526Y in the wild-type background and to pass the gatZ deletion from 
the wild-type strains to the isogenic antibiotic resistant strains which carried either 
the point mutation rpsL K43T or both rpsL K43T and rpoB H526Y mutations (StrRRifR). 
The resulting streptomycin resistant (StrR) strains LC81 and LC82 (YFP/CFP, 
respectively), the rifampicin resistant (RifR) strains RB933 and LC84b (YFP/CFP, 
respectively), and the double resistant (StrRRifR) strains LC85, LC86 (YFP/CFP, 
respectively) were used to colonize mice in competitions with the sensitive strain. All 
of these strains possess a chloramphenicol resistance cassete associated with their 
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fluorescent protein, as well as the kanamycin resistance cassete. As this study is 
focused on streptomycin and rifampicin resistance, I will be designating our rpsL rpoB 
wild-type strains as sensitive, and the resistant strains as single or double mutants. 
For the streptomycin detection test, the strain JB77 (ΔlacIZYA::scar gatZ::IS1 
galK::cat-YFP rpsL K43R), was used to perform the competitions. For the 
competitions with resident E. coli, we used two streptomycin resistant strains, NF1 
and PJD5. The strain NF1 is an E. coli strain isolated from the mouse gut, and carries 
the streptomycin resistance mutation rpsL K88R, which emerged when the mice 
received streptomycin treatment.  The strain PJD5 was generated by growing NF1 in 
Luria-Bertani liquid medium and plating in LB agar medium supplemented with 100 
µg/ml of rifampicin. Through Sanger sequencing directed to the rpoB gene, PJD5 
was found to carry the resistance-conferring rpoB H526Y point mutation – the same 
as in our K-12 isolates. 
6-to-13 week-old female C57BL/6J germ-free (GF) mice were used as hosts 
for the in vivo competitions in the absence of microbiota, while 6-to-8 week-old female 
C57BL/6J specific pathogen free (SPF) mice were used for the in vivo competitions 
in the presence of microbiota. GF mice were bred and raised at the IGC gnotobiology 
facility in dedicated axenic isolators (La Calhene/ORM). Young adults were 
transferred into sterile ISOcages (Tecniplast) before the competition experiments. 
 
In vitro competitions 
To measure fitness effects in two nutritionally distinct environments in vitro, the 
strains were streaked from the frozen stocks in LB agar with antibiotics corresponding 
to their resistances and incubated at 37°C for 24 hours, followed by acclimatization 
for 24h in 150 µl of LB and in minimal medium with glucose [M9 salts, MgSO4 1 mM, 
CaCl2 0.1 mM, glucose 0.4% (w/v)], in 96-well plates, at 37°C, with shaking (700 




and competitions were performed for 24h in the same conditions as the 
acclimatization. To determine the initial and final ratios of resistant and susceptible 
strains in the competition assays, bacteria numbers were quantified with an LSR 
Fortessa flow cytometer using a 96-well plate autosampler. Samples were always 
run in the presence of SPHERO (AccuCount 2.0-µm blank particles) in order to 
accurately quantify bacterial numbers in the cultures. Briefly, flow cytometry samples 
consisted of 180 µl of PBS, 10 µl of SPHERO beads, and 10 µl of a 100-fold dilution 
of the bacterial culture in PBS. The bacterial concentration was calculated based on 
the known number of beads added. Cyan fluorescent protein (CFP) was excited with 
a 442-nm laser and measured with a 470/20-nm pass filter. Yellow fluorescent protein 
(YFP) was excited using a 488-nm laser and measured using a 530/30-nm pass filter. 
 
In vivo competitions 
To measure the fitness effects of each resistant strain in SPF mice, we used 
an antibiotic treatment in order to break the colonization resistance and allow 
colonization405. Mice were transferred into individual cages and given autoclaved 
drinking water containing streptomycin sulfate (5g/L) for seven days, and then were 
given regular autoclaved drinking water for 2 days, in order to wash out the antibiotic 
from the gut. Within experimental treatments, each mouse was bred in a unique litter. 
After 4 hours of starvation for food and water, the mice were gavaged with 100 µl of 
a ≈109 cells/ml suspension with a 1:1 ratio of the two competing strains. 
To make the suspension, the strains were streaked from frozen stocks in LB 
agar plates supplemented with the corresponding antibiotics (concentrations of 
100µg/ml) two days before gavage and incubated for 24 hours. Afterwards, an 
overnight culture of a single colony for each biological replicate in BHI (brain heart 
infusion) medium with the corresponding antibiotics was grown. The cultures were 
then diluted 100-fold and grown in BHI medium until an OD600nm ≈ 2. For the K12 
derived strains, fluorescence-associated flow cytometry was used to assess the 
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number of cells per growth and further adjust the initial number of cells while 
preparing a suspension in PBS for the gavage. Mice fecal pellets were collected 4 
hours and every 24 after gavage, for 5 days, suspended and homogenized, diluted 
in PBS and plated in LB agar plates. For the K-12 strains, the stool samples plates 
were diluted in PBS and plated in LB agar plates supplemented with chloramphenicol 
(30µg/ml). The plates were incubated overnight and the frequencies of CFP and YFP-
labeled bacteria were assessed by counting the fluorescent colony forming units 
(CFU) with the help of a fluorescent stereoscope (SteREO Lumar, Carl Zeiss). For 
the resident bacteria, the stool samples were diluted in PBS and plated in LB agar 
plates supplemented with streptomycin (100µg/ml) and with both streptomycin and 
rifampicin (100µg/ml), to count the total number of E. coli CFU and the fraction of 
double mutants. The samples were also stored in 15% glycerol at -80°C for future 
experiments. Apart from the streptomycin treatment, the same protocol was used in 
the competitions with GF mice. In the co-housing experiments, for each of the 
competing pair, five to six mice originated from 2 different litters were co-housed in 
the same cage 2 weeks prior to antibiotic treatment, and kept together until 
colonization with the competing strains (co-housed for a total period of 23 days, 
including the treatment and the period of antibiotic washout). Apart from the co-
housing, the protocol was identical to the one used for individually caged mice. 
 
Selection coefficient and epistasis calculations 
In the in vivo competitions, the selection coefficient per day (Sday) of each 
mutant strain was estimated through the slope of the linear regression of the 
logarithm of the ratio of the resistant strain to the reference strain, from day 1 to day 





 In the in vitro competitions, the selection coefficient (S) was estimated as the 














In this equation, Nm(0) corresponds to the initial number of mutant cells in the 
competition, Nm(t) to the final number of mutant cells, Nwt(0) to the initial number of 
wild-type cells and Nwt(t) to the final number of wild-type cells. 
Epistasis was calculated using the selection coefficients of the single and 
double mutants: 
𝜀 = 𝑆𝑆𝑡𝑟𝑅𝑅𝑖𝑓𝑅 − (𝑆𝑆𝑡𝑟𝑅 + 𝑆𝑅𝑖𝑓𝑅) 
 
The epistasis error was then estimated through the error propagation method: 





Epistasis was considered positive if its value was superior to the error, and 
negative if it was inferior. Epistasis was considered absent otherwise. 
 
Microbiota analysis 
To assess the effect of streptomycin in the gut microbiota composition, we 
extracted DNA from fecal samples obtained from a subset of individually caged SPF 
mice belonging to independent litters, and to all mice involved in the co-housing 
experiments, right before antibiotic treatment and 24 hours after gavage — 
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simultaneously with the first samples used for selection coefficient calculation. For 
the analysis of the microbiota regarding the cost in individually caged mice, we 
divided the samples extracted at 24 hours after gavage in two categories: A) a group 
where a fitness cost of resistance was estimated when competing against a 
susceptible strain and B) a group where no fitness cost could be detected when 
competing against a susceptible strain. With this design, we aimed to test if a specific 
microbiota composition was associated with the presence or absence of fitness costs 
independently of the resistance genotype. 
Fecal DNA was extracted with a QIAamp DNA Stool MiniKit (Qiagen), 
according to the manufacturer’s instructions and with an additional step of 
mechanical disruption 406. 16S rRNA gene amplification and sequencing was carried 
out at the Gene Expression Unit from Instituto Gulbenkian de Ciência, following the 
service protocol. For each sample, the V4 region of the 16 S rRNA gene was 
amplified in triplicate, using the primer pair F515/R806, under the following PCR 
cycling conditions: 94 ºC for 3 min, 35 cycles of 94 ºC for 60 s, 50 ºC for 60 s, and 72 
ºC for 105 s, with an extension step of 72 ºC for 10 min 407. Samples were then pair-
end sequenced on an Illumina MiSeq Benchtop Sequencer, following Illumina 
recommendations. 
QIIME2 408 was used to analyze the 16S rRNA sequences by following the 
authors’ online tutorial (https://docs.qiime2.org/2018.11/tutorials/moving-pictures/). 
Briefly, the demultiplexed sequences were filtered using the “denoise-single” 
command of DADA2 409, and forward and reverse sequences were trimmed in the 
position in which the 25th percentile’s quality score got below 20. Alpha diversity and 
phylogenetic diversity analyses were also performed as in the QIIME2 tutorial. A 
sample depth of 543 and 1271 counts was chosen for the individually caged and co-
housed mice fitness experiments, respectively, in order to exclude as few samples 
as possible without lowering too much the number of retained sequences per sample. 
For taxonomic analysis, OTU were picked by assigning operational taxonomic units 





The selection coefficient of the in vivo competitions was tested for significance 
using R software, through an F-statistic on a predictive linear model of the 
mutant/sensitive or double mutant/ single mutant ratio over time, generated through 
the observed ratio on sampled time-points from 24, 48, 72, 96 and 120 hours after 
gavage. The null hypothesis was that the slope was equal to 0. When the null 
hypothesis was rejected (p-value < 0,05), the mutant was considered to have a cost 
if the slope of the model was negative and to have a fitness benefit if the slope was 
positive. F tests were performed using the FTEST function on Microsoft Excel. 
Normality of each treatment was tested through the Shapiro Wilk test and normality 
of the treatments involving competitions in the presence of microbiota was further 
tested through Kolmogorov-Smirnov test on GraphPad. 
Bacterial load constancy was tested in R, through an F-statistic on a predictive 
linear model of the total load over time, generated through the loads on sampled 
time-points from 24, 48, 72, 96 and 120 hours after gavage. Null hypothesis is that 
the slope is equal to 0, and would be rejected when the p-value < 0.05. If the null 
hypothesis was rejected, the bacterial load would be considered to change 
consistently over time. For the competitions involving the resident E. coli, bacterial 
loads in germ-free and SPF mice were compared in GraphPad, through a Mann 










Streptomycin detection test 
Fecal pellets originating from mice not treated with antibiotics were collected. 
The pellets were suspended in PBS, homogenized and stored in 15% glycerol (v/v) 
at -80ºC. The suspension was thawed and further filtered to remove both the fecal 
content and bacteria. To facilitate E. coli growth, the filtrate was mixed in a 4:1 ratio 
with LB, generating what we refer in here as fecal medium. By adding streptomycin, 
we have generated fecal medium with increasing concentrations of the antibiotic 
(two-fold increases, from 0.5 to 16 µg/ml, capturing the wild-type MIC of 2 µg/ml when 
grown in LB). We used these media to compete, in a 1:1 ratio, the mutants carrying 
either rpsL K43R, rpsL K43T and rpsL K43T rpoB H526Y against the sensitive strain, 
for 24h, at 37ºC. We then calculated the selection coefficients, as described for the 
other in vitro competitions. The values between 1 and 8 were used to build calibration 
curves. 
We then generated fecal medium using our experimental samples, collected 4 
hours after gavage. We competed the mutant carrying rpsL K43R against our wild-
type strain and calculated the selection coefficients. By fitting the selection coefficient 
values in the corresponding calibration curve, we were able to estimate an “in-
sample” estimation of streptomycin concentration. Fecal medium originated from 
mice under continuous streptomycin was used as a positive control. 
In the 3 calibration curves, for concentrations below 1 µg/ml, the selection 
coefficients were similar to the ones in the absence of streptomycin. As both our 
calibration and experimental samples were diluted by 50% (v/v) when their frozen 










Environment-dependence of resistance mutations and epistasis 
The mutations under study were previously shown to have environment-
dependent fitness effects and epistasis in a similar genetic background 274. To make 
sure that our gat negative strains bearing these mutations kept the environment-
dependence, we measured the fitness effect of the resistance conferring mutations 
in two nutritionally distinct media – LB and minimal medium with glucose - by 
competing the strain bearing the mutation rpsL K43T, which confers resistance to 
streptomycin, the one bearing the mutation rpoB H526Y, conferring resistance to 
rifampicin, and the double mutant rpsL K43T rpoBH526Y which has both resistances, 
with their isogenic wild-type. 
We have found distinct costs for each of our resistant strains in the two media 
(Table 1), confirming that the costs of these mutations are environment-dependent 
in the E.coli K-12 MG1655 gatZ knock-out. Moreover, as observed before in a gat 
positive background, epistasis is still negative in LB medium and positive in minimum 
medium with glucose, confirming the environment-dependence of the fitness effect 










Table 1 – Fitness effects and epistasis between resistance mutations in vitro. 
Fitness effects of antibiotic resistance mutations - StrR (rpsL K43T), RifR (rpoB H526Y), 
StrRRifR (rpsL K43T rpoB H526Y) - in the ∆gatZ pre-adapted background when competing 
against the isogenic susceptible strain (also ∆gatZ background) in Luria Broth (LB) and in M9 
salts minimal medium supplemented with 0.4% glucose (MM). The average selection 
coefficient per generation and 2 times the standard error are shown. Epistasis was measured 
using the additive model. The error for epistasis was calculated through the error propagation 







Epistasis in LB 
Epistasis in 
MM 
StrR -0.11 ± 0.02 -0.16 ± 0.02   
RifR +0.03 ± 0.03 +0.14 ± 0.03   
StrRRifR -0.19 ± 0.03 +0.05 ± 0.03 -0.11 ± 0.03 0.07 ± 0.02 
   Negative Positive 
 
 
Costs of antibiotic resistance in the absence of microbiota 
To evaluate competitive ability in a mammalian host, we decided to measure 
the fitness effects of the resistance mutations when E. coli is colonizing the mouse 
gut in the absence and presence of other bacterial species (Figure 1). We 
rationalized that the presence and activity of other species would likely change the 















Figure 1- Scheme of the in vivo experimental design. This design was used to determine 
the fitness costs of resistance in mice mono-colonized or with a complex microbiota. For mice 
with microbiota, a one-week course of streptomycin treatment had to be given to break 
colonization resistance. The gavage with the experimental E. coli was performed two days 
later in order to give mice time to excrete streptomycin. 
 
We assayed the competitive ability of each K-12 resistant strain by competing 
the mutants with their isogenic wild-type in mono-colonized germ-free mice (Figure 
2, left panels). A fitness cost per day was estimated for all of the resistance mutations, 
with costs of SStrR/day = -0.20 [± 0.09, 2x standard error (SE)], SRifR/day = -0.25 (±0.08) 
and SStrRRifR/day= -0.44 (± 0.10). These are average values, and the fitness effect is 
similar across biological replicas for each competition, with the slope of the selection 
coefficient being significantly negative for every mouse (Table S1). Assuming 26.2 
generations per day in germ-free mice, as observed by Barroso-Batista et al. 411, the 
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estimated costs per generation are SStrR = -0.008 (± 0.003), SRifR = -0.009 (±0.003) 
and SStrRRifR= -0.017 (± 0.004). These fitness effects are lower in magnitude when 
compared with the fitness effects in vitro (Table 1), suggesting that for the K-12 
genetic background, negative selection on traits affected by these resistance 
mutations could be weaker in germ-free mice than in vitro. As none of the costs 
correspond to the values observed in LB nor in minimal medium with glucose, neither 
of the two media was able to predict the fitness effects of resistance in the 
mammalian gut. Additionally, the cost of the double mutant is not significantly 
different than the sum of the costs of the single resistant mutants, indicating the 
absence of epistasis between these mutations in the germ-free mouse gut. This 
observation diverges with our results in rich medium, in which epistasis is negative, 
and in minimal medium with glucose, in which it is positive (Table 1), showing yet 
again that epistasis is environment-dependent 196,274 and that our in vitro competitions 




























Figure 2- Early fitness effects of resistance after antibiotic treatment are host-specific 
in the presence of microbiota. Logarithm of the resistant mutant : wild-type ratio over time 
for rpsL K43T (Str
R
), rpoB H526Y (Rif
R




) mutants, both 
in mono-colonized mice and in mice with microbiota. The slope of the regression is an 
estimate of the selection coefficient per day. 
 
Our results suggest than in the absence of other bacteria strains, the double 
mutant is the less fit genotype. However, there have been reports of non-transitivity 
in evolving bacteria populations 412, in which, for instance, a genotype would 
outcompete its recent predecessor but not their ancestral 413. To control the possibility 
of non-transitive interactions in the mammalian gut, we performed competitions 
between the double resistance against its single counterparts (Figure S1A, left 
pannels). We have measured a cost of SDM vs StrR/day = -0.26 (± 0.07) and SDM vs RifR/day 
= -0.21 (± 0.05), with the costs of the rifampicin and of the streptomycin mutations 
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being very similar to the ones observed previously in the competitions involving the 
wild-type (Figure S1B). The costs of these mutations are therefore transitive in the 
germ-free gut. Furthermore, our results suggest that the fitness effects of resistance 
are measurable, which allows us to predict the fate of resistance in this system. Still, 
strong beneficial mutations could occur before the resistant strains’ extinction and 
change the outcome predicted by the competitions. 
 
The effect of microbiota in the cost of resistance 
A key aspect regarding the mammalian gut is the presence of many bacterial 
species. To understand if inter-species interactions affect the costs of antibiotic 
resistance, we performed competitive fitness assays in specific pathogen free (SPF) 
mice, which have a complex microbiota. 
We have observed a clear influence of the microbiota in the fitness effects of 
antibiotic resistance mutations. Strikingly, the fitness effects show wide variation 
across hosts for all treatments, suggesting host-specificity. For instance, we have 
observed strong deleterious effects of resistance in some mice while in others no 
significant cost was found, with the resistant strain maintaining or even rising in 
frequency (Figure 2, right panels). On average, the fitness effects brought a cost in 
all treatments (SStrR/day = -0.68 (± 0.58, 2xSE), SRifR/day= -0.30 (± 0.48) and SStrRRifR/day= 
-0.34 (± 0.35), but the clear disparity between the selection coefficients across mice 
show us that in this experimental system, individual resistance costs are hard to 
predict. The observed variation is unlikely to be driven by frequency dependent 
selection, as the initial frequency of the resistant strain is not predictive of the 
resistance fate (e.g.: two streptomycin resistant mutants that were at similar 
frequency at the beginning had different fates; one declined in frequency while the 
other increased in frequency). 
The variation is also unlikely to be due to the occurrence of compensatory 




to have an early influence in the estimated fitness effects. Moreover, the majority of 
the mouse competitions can be fairly explained by a linear regression (Table S2), 
suggesting that in the majority of cases, selection remains constant throughout the 5 
days. This would not be expected if the resistant strains acquired beneficial 
mutations. Still, in a few cases, the log (resistant/sensitive) deviated from a linear line 
during this period (Figure 2), revealing that selection can change during this early 
colonization. However, it is not clear if this is due to beneficial mutations, or actually 
due to an effective change in the environment, which could be driven by a changing 
microbiota. 
During SPF mouse colonization, we gave a streptomycin treatment in order to 
break colonization resistance. To exclude an effect of streptomycin in our 
competitions, we have designed a protocol to test its presence through a competition 
method (Figure S2). We have competed a resistant strain carrying the mutation rpsL 
K43R against the wild-type in LB fecal medium made with our filtered samples, taken 
4 hours after colonization (see Methods) and compared the selection coefficient 
values with the respective calibration curve, generated through competitions in 
different streptomycin concentrations (Figure S2A). We have observed that 
streptomycin was below our threshold level of detection (2ug/ml), and as such, 
unlikely to be involved in the outcome of the competitions (Figure S2B). 
   
Antibiotic perturbation increases variation in microbiota composition 
We followed up with a 16S rRNA analysis of the microbiota of a sub-sample of 
the SPF mice, for which we were able to collect stool samples before streptomycin 
treatment and 24 hours after the gavage. These last samples correspond to the first 
time-points that were used to measure selection coefficients, and as such, are 
representative of the microbiota that our strains encountered during the fitness assay. 
Our goal was to confirm that the treatment was inducing dysbiosis and leading to 
distinct microbiota profiles across hosts. 
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We have found a range of different microbiota compositions both before and 
after the antibiotic treatment (Figure 3A), setting them as a varying factor. 
Furthermore, the treatment reduced alpha diversity (p<0.001, Kruskal-Wallis test) 
and increased the variation of the host microbiota (Figure 3B). These results suggest 
that the microbiota profiles in our competitions are a combination of pre-existing 
differences in microbiota composition with antibiotic-driven dysbiosis. We did not 
observe an association between a specific taxonomic group and the absence of cost 
(ANCOM analysis), nor did we see a significant relationship between alpha diversity 




Figure 3 – The effect of antibiotic treatment in microbiota composition. A) Microbiota 
composition at the phylum level of mutant versus wild-type competitions, before and after 
antibiotic treatment, estimated through 16S-based metagenomic analysis. B) PCoA of an 







Normalization of the microbiota reduces variance of fitness effects  
At this point, it was still not clear if a shared microbiota composition could lead to a 
similar fitness phenotype. Mice are coprophagic 414 sharing microbiota while living 
together 415, so to test if the microbiota composition could account for the 
personalized fitness effects, we performed competitions in mice co-housed until E. 
coli colonization. 
We observed a reduced variance for the fitness effects in the co-housed mice when 
compared with individually caged ones (Figure 4A-B), with a significantly lower 
variance for the single streptomycin and the double mutant competitions (pStrR = 
0.005, pStrRRifR = 0.04, F-test; Figure 4B). Furthermore, the intermediate variance 
in co-housed mice was not significantly different from the low variance of the germ-
free competitions, with the outcome of the competitions becoming more similar 
across hosts within the first 5 days of competition for all of the resistant strains, 
although without a significant cost for the double mutant competitions (Table S3). 
Besides displaying an effect of antibiotic perturbation (Figure 4C), 16S metagenomic 
analysis of the microbiota composition shows a clear co-house identity for all of the 
mice 24 hours after colonization (Figure 4D), confirming a successful normalization 








Figure 4 - Co-housing homogenizes the fitness effect of resistance. A) Logarithm of the 
resistant : wild-type ratio overtime for rpsL K43T (StrR), rpoB H526Y (RifR), and rpsL K43T 




antibiotic treatment. B) Boxplot of the mean and the standard deviation of the fitness effect of 
resistance measured in mono-colonized, individually caged and co-housed mice. F-tests to 
detect differences in variance were performed (*p<0.05;**p<0.01). C) PCoA of an unweighted 
unifrac of the co-housed samples, before antibiotic treatment and 24 hours after colonization, 
showcasing the effects of antibiotic perturbation. D)  PCoA of an unweighted unifrac of the 
samples at 24 hours after colonization, depicting co-house identity. For both PCoA, dashed 
lines correspond to 95% confidence intervals. 
 
Extended competitions reveal a late disadvantage of multi-resistance 
Despite the early fitness effects of resistance after a microbiota perturbation 
being so variable, the long-term effects could be more predictable, namely if the 
microbiota would recover to a state in which its competitive ability is similar across 
mice. On the other hand, adaptive and compensatory evolution could affect the 
competitive ability of the strains. To query about the long term  of multi-resistance, 
we have prolonged the fitness assay for a subset of 8 mice (2 in which the double 
mutant was in higher frequency than the wild-type 5 days after gavage, and all of the 
double mutant competitions with the single resistants), and checked for the strain 
frequency 3 weeks after the previous sampling event, around 1 month after the 
gavage. In all of them, the frequency of the double mutant decreased (Figure S3A-
B), even in one mouse in which it was previously close to fixation (frequency of 99%). 
While we have not sequenced the strains nor the microbiota, these results suggest 






The effect of microbiota in the cost of resistance in a mouse adapted strain 
It is known that the cost of antibiotic resistance mutations is determined in part 
by the strain’s genetic background 177. To check if microbiota could affect the cost of 
resistance in a natural strain, we have designed a competition between a 
streptomycin resistant resident E. coli (rpsL K88R), isolated from fecal samples of a 
streptomycin treated mouse 66, and an isogenic double resistant strain (rpsL K88R 
rpoB H526Y). The double mutant bears the same rifampicin resistance mutation as 
the previously tested E. coli K12. We have chosen to use two streptomycin resistant 
strains to immediately exclude a direct effect of streptomycin in the competing strains, 
without need of further testing. Once again, we performed competitions both in germ-
free and in SPF mice (Figure 5A). In the absence of microbiota, we have observed 
a strong deleterious fitness effect of rifampicin resistance in the resident E. coli’s rpsL 
K88R background [SRifR/day germ-free = -0.86 (± 0.15, 2xSE)], suggesting that in the 
mouse gut, in the absence of other bacteria, the rpoB H526Y mutation causes 
maladaptation. All of the slopes were significantly negative (p<0.05, F test), although 
in a single mouse, one of the slopes lost steepness after 2 days. As this was a single 
occurrence in all of the germ-free mice tested in this project (1 in 21 mice), it could 
be the result of a rare event, such as early adaptation or compensation. Although all 
of the mice were treated with utmost care to keep the monocolonization status, a 
contamination during the experiment can also not be excluded. 
Regarding the SPF mice, we have observed variation of the fitness effects on 
the resident E. coli background, with 2 of the 6 mice having significantly negative 
slopes, while the other mice had a non-significant selection coefficient (Table S4). 
Curiously, the average cost of resistance was more than 3 times lower than in germ-
free mice [SRifR/day SPF = -0.26 (±0,22) vs SRifR/day GF = -0.86 (± 0.15); p=0.002, Mann-
Whitney U test; Figure 5B], suggesting that in an environment with strong inter-
species competition, resistance is less disadvantageous. As with the competitions 
involving E. coli K-12, in 2 mice we observe fluctuations in the strain vs strain ratio, 




days of competition. Altogether, these observations indicate that the fitness effect of 
resistance mutations in natural strains can also be changed by microbiota. However, 
the magnitude of the variance is not significantly higher in SPF mice for the resident 
competitions (σ2SPF = 0.07 vs σ2GF = 0.03; p=0.77, F-test), which might nonetheless 
be related with the lower average cost of rifampicin resistance in SPF mice. 
 
Figure 5 – Distinct fitness effects of a rifampicin resistance mutation in the 
streptomycin resistant, resident background in the absence and presence of 
microbiota. (A) Logarithm of the double mutant : single mutant ratio over time in mono-
colonized mice and in mice with microbiota. (B) Boxplot of the mean and the standard 
deviation of the fitness effect of resistance measured in mice mono-colonized and with 
microbiota. The distribution of the fitness effects between the two treatments is significantly 










Causes for variation, nutrition and cross-feeding 
Our experiments had as an objective to determine of the fitness effect of 
resistance mutations in the mammalian gut. As the interactions between bacterial 
species can have a great impact on their competitive ability and diverse microbial 
communities are prevalent in nature 416, we also aimed to determine the contribution 
of the gut microbial community in the cost of these mutations. While colonization 
resistance against our E. coli strains did not allow to study how an unperturbed 
community affects the fitness of resistant strains, we are assessing the costs of 
resistance in an increasingly important environment to understand its maintenance: 
the mammalian gut after an antibiotic treatment. 
In individually caged SPF mice, we have observed a variable fitness effect of 
resistance mutations across hosts. As we do not see such variation of the fitness 
effects in germ-free mice and as we observe a clear reduction of the differences 
through co-housing, our observations suggest that selection is acting unequally 
across mice due to the activity of microbiota. In accord with what has been reported 
in the literature 417,418, we see a dramatic decrease in microbiota diversity following 
antibiotic treatment, leading to different microbiota compositions across mice at the 
phylum level. These differences in microbiota composition are a change in the 
environment and are likely to be an important source of the variance between hosts.  
It is known that the gut microbiota can modulate the host immune system 419,420, 
which in turn has a prominent role in the colonization by and in the control of 
microbiota members 421,422. However, a simpler explanation for the observed variation 
is related with nutritional niches. The gut is an environment with strong competition 
for resources, and microbiotas with disparate species can differ in their metabolic 
abilities, leading to distinct levels of competition for the different gut resources. It has 




change greatly in the presence of other community members 420,423,424, so the 
elimination of bacteria with specific functions can cause adjustments on the metabolic 
activity of other species and further differentiate individual microbiotas. In particular, 
an altered microbiota can offer different cross-feeding opportunities. Pair-wise cross-
feeding interactions between gut bacteria were shown to occur, both in vitro 425 and 
in germ-free mice 423, and higher order cross-feeding interactions, are thought to be 
involved in complex microbial communities 426,427, with a recent empirical work 
showing them to be an emerging property of large microbial communities 428. 
Furthermore, the disruption of cross-feeding has functional consequences for the 
microbiota, inclusively at the level of host-microbe interactions 420. It is thus intuitive 
that the alterations in terms of microbiota composition, with consequences at the level 
of nutrient availability, gene expression and on cross-feeding interactions, together 
with the gut spatial structure and the consequent local competition, can generate 
singular environments in each host. This in turn can make the fitness effects of 
resistance personalized.  
In order to colonize the mice that had resident microbiota, we had to break 
colonization resistance by giving a streptomycin treatment for a week. A two-day 
period of recovery followed, to clear the streptomycin from the mouse before the 
gavage. We have tested its presence through a competition method and we did not 
detect an effect of residual streptomycin in our samples. We are aware that our test 
is not highly sensitive to trace amounts of streptomycin (it cannot detect 
concentrations lower that 2 µg/ml in our experimental samples). However, it has been 
observed that streptomycin is quickly removed from mice following oral 
administration 429. On another note, a recent study on pig fecal medium shows that 
the presence of the fecal community increases the minimum selective concentration 
of gentamicin and kanamycin on sensitive strains of E. coli by more than one order 
of magnitude 430. Such a protective effect, if applicable for other antibiotics, would 
further reduce the risk of an effect of residual streptomycin. Furthermore, we see 
different outcomes in the competitions between two streptomycin resistant strains 
(StrRRifR vs StrR, Figure S1A) and between two susceptible strains (RifR vs WT, 
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Figure 2) in individually caged mice and lower selection coefficient variation in the 
co-housed competitions (Figure 4), reinforcing that the observed disparities in the 
former are due to the action of microbiota following the antibiotic treatment, and not 
due to a direct action of the drug on the competing strains. The dysbiotic state caused 
by the antibiotic treatment is likely to be the main reason for the observed costs. 
However, the data in Chapter III hints that pre-existing differences in the microbiota 
might be partially responsible for the outcome of the antibiotic treatment, both at the 
level of microbial composition and on its consequential fitness costs. 
For some of the competitions involving the double mutant, we have extended 
the sample collection for roughly 1 month after gavage. In these, we could observe 
that the double mutant would lower in frequency regardless of the dynamics from the 
early colonization. It has been observed in humans that, after the challenge with an 
antibiotic, microbiota begins to return to their initial state. However, this recovery is 
partial 431,432, with some members being lost from the community 417,418, and thus 
antibiotic treatment may cause a shift to alternative stable states 432. It is possible that 
the microbiota in the different mice are converging to a state in which a cost for 
resistance is expressed. Another more farfetched, but still plausible hypothesis has 
to do with constraints in the evolution of the multi-resistant strain. The high pleiotropy 
of the resistance mutations could cause epistasis between them and mutations that 
would be adaptive in a wild-type background. As genetic interactions generate 
rugged fitness landscapes 433, the double mutant could get more easily stuck on a 
sub-optimal fitness peak, which would limit the access to adaptive mutations when 
compared to a less epistasis-restricted single mutant or wild-type strain. Our 
observations are clearly insufficient to understand the long-term fate of resistant 
strains. Besides, we do not know the proximate cause for the late cost of resistance. 
However, the results suggest that the fitness effects converge across hosts in the 





Mutation nature and pleiotropy 
The mutations under focus have previously been shown to have disparate 
fitness effects in two distinct nutritional environments 274, which still holds for the 
mutants used in this study (Table 1). The double mutant, for instance, has a fitness 
advantage in minimal medium with glucose when competing with the wild-type strain, 
and a disadvantage in LB. It is reasonable to assume that in an environment in which 
glucose is the main carbon source, this mutant is more likely to have an advantage 
than in an environment in which glucose is depleted by other microbes. Following 
this logic, any gut nutrient for which the consumption efficiency is different in the 
resistant and wild-type bacteria could be an environmental factor driving selection. 
While we are currently not aware of the fitness effect of these mutations in the 
presence of other gut nutrients, it is expected that they exist. Point mutations on the 
rpoB and rpsL genes, such as the ones involved in this study, can be highly 
pleiotropic 170,172,434. This might be related with the fact that some streptomycin 
resistance mutations can affect translation speed and accuracy 435, while certain rpoB 
mutations can affect transcription speed 436 and fidelity 437,438. Cellular processes that 
depend of the effectiveness of transcription and translation, such as the activation or 
repression of operons linked to nutrient uptake and consumption, are likely to be 
affected. Although catabolite-repression is known to occur in bacteria, including E. 
coli 439, bacteria can find a multitude of niches when colonizing the mammalian gut. 
Successful species must have been selected to readily change their expression 
according to the niche opportunities or to simultaneously utilize multiple substrates 
440.  E. coli MG1655 grown in mucus (mimicking the gut nutritionally) has been shown 
to express genes involved in catabolism of different sugars, such as N-
acetylglucosamine, sialic acid, fucose, glucosamine, ribose, glucuronate, 
galacturonate, gluconate and maltose 441. Additionally, we are measuring fitness at 
the population level. It is very likely that in the gut, individual E. coli cells are 
experiencing different niches, while the population as a whole is consuming different 
carbon sources simultaneously 397. Therefore, the fitness burden of the resistance 
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mutation will be a net effect of all affected pathways, whether they are simultaneously 
active or not.  
We suspect that our observations are also true for other mutations affecting 
traits under selection. Consistent with this hypothesis, Barroso-Batista et al. have 
observed a higher variation for the fitness effect of a mutation in the gat operon in 
SPF mice, when compared with germ-free 411. As the gat operon is involved in the 
consumption of galactitol, this observation suggests that mutations that affect the 
consumption of a gut nutrient can produce a different fitness effect across hosts, and 
that pleiotropy is not required. 
 
In vitro predictions and future approaches to measure fitness costs 
We have observed that the costs of resistance of the mutations under study in 
germ-free mice are different from the in vitro competitions in LB and minimal medium 
with glucose, and as such, not predictable by these results. Both media are 
commonly used in microbiology, and this observation raises the question of how 
meaningful are the resistance costs measured using standard laboratory media. 
Although these media are an asset for growing model bacteria, questions related with 
fitness effects of mutations in natural environments should be addressed either in in 
vitro media with a similar composition to those environments, or in those 
environments themselves. Additionally, our in vivo results suggest that microbial 
communities are an essential environmental factor determining the fitness effects of 
resistance. Alternative ex vivo models, such as microfluidics intestine chips are 
currently being developed 442, and using these environments in future studies to 
evaluate the cost of resistance, both in the presence and absence of a microbiome, 
could prove to be a valid alternative in predicting the cost of resistance. 
We were not able to determine which microbiota members were affecting the 
fitness of our resistant strains. This might have had to do with the fact that we had an 




reducing our statistical power to discriminate specific taxa. On the other hand, as the 
streptomycin and rifampicin single mutants have different fitness in both LB and 
minimal medium with glucose, it is entirely possible that the two are not favored by 
the same microbiota composition. Since the fitness effects of resistance are allele 
specific 192, a favorable microbiota might be so in a resistance-specific or even in an 
allele-specific way. Following our observations, studying if and how specific 
microbiota members modulate the cost of resistance is a promising research topic, 
which might bring further insights concerning how resistance is maintained in nature. 
In any regard, future studies on antibiotic resistance in natural and clinical settings 
should take the metagenome into account as an important factor.  
 
Natural strains and generalizations 
While competing a single and a double resistant resident E. coli, we have 
observed a much higher average cost per day of rifampicin resistance in the germ-
free gut compared with the SPF mouse gut. At a first glance, this suggests that the 
maladaptation caused by the rpoB H526Y mutation is higher in the absence of 
microbiota. 
In the germ-free gut, in which selection is acting at the intra-species level, E. 
coli has a faster doubling time 411, and the resident E. coli reaches a higher bacterial 
load  when compared with the SPF mouse gut (averages of 1.3 x 1010  vs 2 x 108 
CFU per gram of feces, for germ-free and SPF, respectively; p<0.0001, Mann 
Whitney test). It is possible that the rpoB H526Y mutation is more disadvantageous 
in an environment in which more nutrients are available, and in which the resident 
has to divide faster. E. coli is one of the first colonizers in the gut, reaching very high 
loads before the expansion of anaerobes 373. To a certain extent, the germ-free gut 
mimics the environment in which natural E. coli colonizes the gut – an habitat that 
allows a great expansion of E.coli, and in which strong intra-species selection will 
favor fast cell division. In an environment in which there is strong inter-species 
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competition and the resources are scarcer, both strains are affected by the activity of 
the other microbes, which could lead to a smaller fitness difference in SPF mice.  
Curiously, we do not see such a difference in the average cost of this mutation 
in the E. coli K-12 - the germ-free cost is smaller than in the resident, and similar to 
the average cost in SPF mice. It is known that the fitness effect of a mutation can 
vary with the genetic background 443. It is possible that the most relevant phenotypic 
aspects for the germ-free colonization are less affected by the rpoB mutation in the 
K-12 background. On the other hand, the resident strain has been evolving in the gut 
ecosystem and should be more well adapted to readily colonize the mouse intestine 
than the K-12 strains. As a genotype that is closer to a fitness peak, mutations in the 
resident background are more likely to have a deleterious effect, particularly when 
they can affect multiple phenotypes. 
Although we have observed variation in the fitness effect of rifampicin 
resistance in the presence of microbiota, including dynamic shifts during the 
competition, it was less wide than in the K-12 background. Assuming that lower 
bacterial loads reflect a lower rate of cell division, the resident double mutant might 
be matching closely the wild-type concerning growth-related traits in SPF mice, 
leading to a small magnitude of costs and benefits. We did not perform metagenomic 
analysis for these competitions, but as the hosts are from distinct litters, the 
microbiota composition should still differ. Thus, the lower variation is more easily 
explainable through similar growth phenotypes between these two strains in the 
presence of other competitors. 
These results alone do not clearly support or disprove the variation of the 
fitness effects of resistance in natural strains, and further research should address 
the generality of our observations at different levels: at the level of natural strains, at 
the level of taxa  - asking if the costs of resistant bacteria from other phyla is also 
variable after an antibiotic treatment, at the level of the resistance profile - if it is 
specific for rifampicin and streptomycin resistance - or antibiotic target - if variation 




and translation - and how does microbiota affect the cost of resistances with a 
different genetic nature, such as the ones encoded through resistance cassettes. As 
these can code for a multitude of resistance mechanisms and can be shared through 
horizontal gene transfer, they had a significant contribution in the spread of antibiotic 
resistance following the golden age of antibiotics and are seen as an epidemiological 
threat 444. Studies regarding microbiota composition and how it affects the selection 
on mobile genetic elements carrying resistance genes could indeed bring important 




































Figure S1 – Transitivity and absence of epistasis in vivo, in the absence of microbiota. 
(A) Logarithm of the resistant mutant : wild-type ratio over time for the double mutant while 
competing with the single mutants. As in the competitions with the wild-type, the selection 
coefficient can vary between animals in the presence of microbiota. (B) Selection coefficients 
for the resistance mutations in the absence of microbiota (germ-free). Notice that the cost of 
a mutation in the wild-type background is similar to the cost in a resistant background. In the 







Figure S2 - Indirect estimation of streptomycin concentration in fecal samples. 
(A) Effect of different concentrations of streptomycin in pairwise competitions between E. coli 
MG1655 resistant to streptomycin (rpsL K43T or rpsL K43R single mutants or double mutant 
rpsL K43T rpoB H526Y) against a susceptible strain in fecal medium supplemented with LB, 
in the presence of known streptomycin concentrations. The effects with rpsL K43R were used 
to generate a calibration curve.  (B) Estimated streptomycin concentration in fecal samples 
collected 4 hours after gavage of E. coli, through competitions in the respective fecal medium. 
The method does not allow for the detection of streptomycin below 2μg/ml of streptomycin, 
























Figure S3 - Extended competitions suggest convergence of the double mutant 
frequency. (A) Dynamics of the double mutant frequency in a subset of mice, extended up 
to 4 weeks after colonization. (B) Frequency of the double mutant in each of the sampled 
mouse after 5 days and 4 weeks of colonization. For mice DS3 and DR3, the late time-point 
corresponds to day 26, while for the other mice it corresponds to day 28 after colonization. 
Although we have observed a variable fitness effect of multi-resistance in the first 5 days, the 








 Frequency double mutant 
Mouse Day 5 Week 4 
SR4 0.99 0.13 
SR5 0.76 0.04 
DS1 0.07 0.01 
DS2 0.21 0.03 
DS3 0.11 0.02 
DR1 0.94 0.13 
DR2 0.95 0.57 







Table S1 – Outcome of the competitions for the E.coli K-12 MG1655 background in 
germ-free mice. The selection coefficient per day for each mouse is presented, and within 
brackets is shown the standard error. Significant values were obtained through an F-statistic 
for the slope of the linear model of the selection coefficient (ln(mutant/wild-type) or ln (double 
mutant/single mutant) over time). Fitness effects with a significant score and a positive slope 
were considered a benefit, while fitness effects with significant scores and a negative slope 
were considered a cost. 
Mouse Competitors Sday R2 Fitness effect 
S1 StrR vs Wt -0.17 (0.04 SE) 0.84 Cost 
S2 StrR vs Wt -0.29 (0.05 SE) 0.92 Cost 
S3 StrR vs Wt -0.14 (0.03 SE) 0.87 Cost 
R1 StrR RifR vs Wt -0.28 (0.04 SE) 0.94 Cost 
R2 StrR RifR vs Wt -0.17 (0.05 SE) 0.78 Cost 
R3 StrR RifR vs Wt -0.30 (0.03 SE) 0.98 Cost 
SR1 StrR RifR vs StrR -0.39 (0.02 SE) 0.99 Cost 
SR2 StrR RifR vs StrR -0.54 (0.07 SE) 0.95 Cost 
SR3 StrR RifR vs StrR -0.38 (0.03 SE) 0.98 Cost 
DS1 StrR RifR vs StrR -0.32 (0.04 SE) 0.97 Cost 
DS2 StrR RifR vs StrR -0.21 (0.06 SE) 0.83 Cost 
DS3 StrR RifR vs StrR -0.26 (0.03 SE) 0.95 Cost 
DR1 StrR RifR vs RifR -0.18 (0.02 SE) 0.96 Cost 
DR2 StrR RifR vs RifR -0.26 (0.01 SE) 0.99 Cost 











Table S2 – Outcome of the competitions for the E.coli K-12 MG1655 background in all 
single-housed specific pathogen free mice. The selection coefficient per day for each 
mouse is presented, and within brackets is shown the standard error. Significant values were 
obtained through an F-statistic for the slope of the linear model of the selection coefficient 
(ln(mutant/wild-type) or ln ((double mutant/single mutant) over time). Fitness effects with a 
significant score and a positive slope were considered a benefit, while fitness effects with 
significant scores and a negative slope were considered a cost. 
 
Mouse Competitors Sday R2 Fitness effect 
S1 StrR vs Wt -1.4 (0.2 SE) 0.93 Cost 
S2 StrR vs Wt -1.4 (0.6 SE) 0.37 Neutral 
S3 StrR vs Wt 0.762 (0.2 SE) 0.25 Benefit 
S4 StrR vs Wt -1.3 (0.1 SE) 0.77 Cost 
S5 StrR vs Wt 0.07 (0.08 SE) 0.24 Neutral 
S6 StrR vs Wt -1.2 (0.1 SE) 0.27 Cost 
S7 StrR vs Wt -0.663 (0.1 SE) 0.79 Cost 
S8 StrR vs Wt -0.24 (0.06 SE) 0.90 Cost 
R1 RifR vs Wt -0.71 (0.04 SE) 0.99 Cost 
R2 RifR vs Wt 0.2 (0.6 SE) 0.03 Neutral 
R3 RifR vs Wt -0.4 (0.2 SE) 0.58 Neutral 
R4 RifR vs Wt -0.2 (0.1 SE) 0.62 Neutral 
R5 RifR vs Wt 0.5 (0.3 SE) 0.51 Neutral 
R6 RifR vs Wt -1.1 (0.2 SE) 0.90 Cost 
SR1 StrR RifR vs Wt -0.8 (0.1 SE) 0.94 Cost 
SR2 StrR RifR vs Wt -0.6 (0.3 SE) 0.58 Neutral 
SR3 StrR RifR vs Wt -0.4 (0.2 SE) 0.70 Neutral 
SR4 StrR RifR vs Wt 0.4 (0.2 SE) 0.60 Neutral 
SR5 StrR RifR vs Wt -0.3 (0.1 SE) 0.55 Neutral 
SR6 StrR RifR vs Wt -0.4 (0.3 SE) 0.39 Neutral 
DS1 StrR RifR vs StrR -0.39 (0.035 SE) 0.98 Cost 
DS2 StrR RifR vs StrR -0.03 (0.04 SE) 0.17 Neutral 
DS3 StrR RifR vs StrR -0.4 (0.2 SE) 0.61 Neutral 
DR1 StrR RifR vs RifR 0 (0.1 SE) 0.00 Neutral 
DR2 StrR RifR vs RifR 0.29 (0.05 SE) 0.93 Benefit 






Table S3 –– Outcome of the competitions for the co-housed mice. The selection 
coefficient per day for each mouse is presented, and within brackets is shown the standard 
error. Significant values were obtained through an F-statistic for the slope of the linear model 
of the selection coefficient (ln(mutant/wild-type) over time). Fitness effects with a significant 
score and a positive slope were considered a benefit, while fitness effects with significant 
scores and a negative slope were considered a cost. 
 
Mouse Competitors Sday R2 Fitness effect 
S1-CH StrR vs Wt -1.25 (0.04 SE) 0.99 Cost 
S2-CH StrR vs Wt -1.25 (0.07 SE) 0.99 Cost 
S3-CH StrR vs Wt -1.47 (0.11 SE) 0.98 Cost 
S4-CH StrR vs Wt -1.41 (0.08 SE) 0.99 Cost 
S5-CH StrR vs Wt -1.2 (0.2 SE) 0.93 Cost 
S6-CH StrR vs Wt -1.25 (0.16 SE) 0.96 Cost 
R1-CH RifR vs Wt -0.5 (0.2 SE) 0.74 Neutral 
R2-CH RifR vs Wt -0.84 (0.1 SE) 0.94 Cost 
R3-CH RifR vs Wt -0.1 (0.5 SE) 0.01 Neutral 
R4-CH RifR vs Wt -0.6 (0.1 SE) 0.86 Cost 
R5-CH RifR vs Wt -0.9 (0.1 SE) 0.93 Cost 
R6-CH RifR vs Wt -1.06 (0.08 SE) 0.98 Cost 
DM1-CH StrR RifR vs Wt -0.3 (0.2 SE) 0.56 Neutral 
DM2-CH StrR RifR vs Wt -0.3 (0.2 SE) 0.47 Neutral 
DM3-CH StrR RifR vs Wt -0.1 (0.1 SE) 0.13 Neutral 
DM4-CH StrR RifR vs Wt -0.3 (0.1 SE) 0.64 Neutral 










Table S4 – Outcome of the competitions between a rifampicin resistant and a rifampicin 
sensitive strain, both with a gut-adapted genetic background. The two strains bear the 
K88R mutation, which confers streptomycin resistance. The selection coefficient per day for 
each mouse is presented, and within brackets is shown the standard error. Significant values 
were obtained through an F-statistic for the slope of the linear model of the selection 
coefficient (ln (double mutant/single mutant) over time). Fitness effects with a significant score 
and a positive slope were considered a benefit, while fitness effects with significant scores 
and a negative slope were considered a cost. 
Mouse Host Status Sday R2 Fitness effect 
GF1 Germ-Free -0.9 (0.1 SE) 0.95 Cost 
GF2 Germ-Free -1.0 (0.1 SE) 0.96 Cost 
GF3 Germ-Free -0.9 (0.1 SE) 0.96 Cost 
GF4 Germ-Free -0.5 (0.1 SE) 0.83 Cost 
GF5 Germ-Free -1.0 (0.1 SE) 0.95 Cost 
GF6 Germ-Free -0.87 (0.06 SE) 0.99 Cost 
SPF1 SPF -0.7 (0.3 SE) 0.60 Neutral 
SPF2 SPF -0.14 (0.04 SE) 0.80 Cost 
SPF3 SPF -0.2 (0.1 SE) 0.43 Neutral 
SPF4 SPF -0.24 (0.09 SE) 0.69 Neutral 
SPF5 SPF 0.1 (0.1 SE) 0.11 Neutral 














Chapter III – Adaptation prevails over compensation 






Adaptation prevails over compensation in the 
mouse gut 
 
Parts of this chapter are included in a manuscript submitted for publication. 
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The acquisition of antibiotic resistance typically implies a fitness cost in the 
absence of antibiotics. Despite this fact, antibiotic resistance has been spreading 
over time, and resistant bacteria persist in bacterial communities. The maintenance 
of resistant bacteria can be explained by many factors, including biotic interactions 
and the evolution through compensatory mutations. Still, the adaptation of 
commensal strains harboring single or multiple costly chromosomal resistance 
mutations remains unexplored. We have evolved mutants harboring streptomycin 
and rifampicin resistance mutations and the respective double mutant in the 
mammalian gut, in the presence of distinct bacterial communities. We have found 
that adaptative mutations are ubiquitous during the evolution of these strains, while 
classical compensatory mutations are not. Furthermore, the occurrence and pace of 
compensation was markedly different across mouse litters which had a distinct 















Bacteria can acquire antibiotic resistance through horizontal gene transfer of 
accessory elements encoding resistance genes and through chromosomal mutations 
that modify the target of resistance  9. While horizontal gene transfer has been found 
to be common 53 and is recognized as the main driver of the early spread of resistance 
across pathogens 46,55, resistance mutations occur spontaneously, inclusively in 
bacteria that do not have the ability to acquire and retain foreign genetic material. 
One key example is the human pathogen Mycobacterium tuberculosis, capable of 
accumulating mutations that alter cellular antibiotic targets 445 and display extensive 
drug resistance to multiple antibiotics 446. Resistance through target modification is 
effectively a ubiquitous mechanism of resistance, as examples of clinical strains 
carrying antibiotic resistance mutations are found for every class of antibiotics 123. 
Hence, studying how resistant mutations subsist and disseminate in bacterial 
populations is of crucial importance to contain the antibiotic resistance threat. 
Most resistance-conferring chromosomal mutations change cell machinery 
components into a non-optimal state,  affecting metabolic and physiological 
processes of the cell  169 and leading to deleterious effects in the absence of the drug 
8,9,176. Various biological phenomena allow bacteria carrying antibiotic resistance 
mutations to reduce or bypass these effects,  such as mutations with background-
specific beneficial effects 447, environment-dependent fitness effects 272,274 and 
positive epistasis, either between chromosomal resistance mutations 192 or between 
chromosomal mutations and plasmids encoding for resistance 285. However, the 
maintenance of resistance can also be a product of the evolution of resistant strains 
towards a higher fitness, namely through the acquisition of compensatory mutations 
[e.g. 177,191,196,249]. 
While adaptive mutations in general can confer a benefit to bacteria 
irrespectively of their resistance profile, compensatory mutations have background-
specific effects, and are selected because they ameliorate the fitness of resistant 
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strains, either by counter-acting the metabolic impairments caused by the resistance 
mutation 169 or the negative epistatic effects between resistance mutations 196. These 
mutations are particularly troublesome clinically, as they are frequently found in clinic 
isolates  241,243,244,448, most often allow fitness restoration without the loss of resistance 
8 and further hinder reversions due to their epistatic nature 449. Besides mitigating 
fitness costs, compensatory mutations can also promote the recovery of relevant 
phenotypes affected by the resistance mutations, such as virulence in Salmonella 
enterica serovar Typhimurium during mouse infection 190. 
Compensation can occur through intragenic mutations, on the gene conferring 
the resistance, or through mutations on other genes with a closely associated 
function 169. Additionally, mutations outside coding regions may also compensate for 
the cost of resistance through changes in gene expression 196. As resistant bacteria 
can ameliorate fitness through a broad range of gene targets, compensation is much 
more common than genotypic reversions — back mutations on the resistance locus 
that rescue both fitness and drug sensitivity 191,239,240,247,248. Second site mutations 
can also cause resistance decline in the absence of antibiotics. In some situations, 
phenotypic reversions leading to full recovery of sensitivity have been reported — 
196,263–265. 
The compensatory evolution of bacteria carrying resistance mutations has 
been followed in several in vitro studies e. g. [196,205,239,240,242,262,450] and also in animal 
experiments 190,191,242. One of the latter studies compares the evolution of Salmonella 
enterica serovar Typhimurium carrying either streptomycin or fusidic acid resistance 
mutations in LB medium and during mouse infection. By sequencing the genes with 
the resistance mutations and previously known extragenic targets, the authors have 
observed selection for different compensatory mutations in the two environments, 
with a different proportion of intragenic mutations, extragenic mutations and genetic 
reversions 191, highlighting the importance of studying the evolution of resistant 




As shown in Chapter II, in the antibiotic-treated mammalian gut, the cost of 
resistance is host-specific in the presence of microbiota. As the strength of selective 
pressures favoring compensation depends on the fitness effect of the resistance 
mutation, the occurrence and spread of compensatory mutations could also be host-
specific. In fact, a simple ecological model of resource competition based on 
metabolic trade-offs 451 corroborates the observed microbiota-dependent fitness 
costs when applied to our data and predicts a varying onset of selective pressure 
towards compensation (Amicone & Gordo, personal communication). Furthermore, 
strong selective pressures towards metabolic adaptation to the mouse gut have been 
observed in commensal E. coli 398,452 and it is still not clear if in the mouse gut, a strain 
bearing costly, resistance mutations is more likely to evolve through compensation 
or prioritize mutations that promote environment adaptation. To address these 
questions, we have evolved and sequenced single and double resistant E. coli in the 




Eschericha coli and mice strains 
For our experiments, we used fluorescence-labeled, E. coli K-12 MG1655-
derived strains, with different antibiotic resistance profiles, including strains bearing 
either a point mutation conferring streptomycin resistance, a point mutation 
conferring rifampicin resistance or both mutations. 
The point mutations conferring resistance in our K-12 strains, rpsL K43T and 
rpoB H526Y, were generated by Trindade et al. in a K-12 MG1655 genetic 
background, and confer streptomycin and rifampicin resistance, respectively 192. 
These mutations were moved into isogenic, YFP and CFP fluorescent-labeled strains 
by Moura de Sousa et al. (2017). Since the gat operon was found to be a mutation 
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hotspot under strong selection in the mouse gut for K-12 MG1655 derived strains 
395,398, we modified our strains to a galactitol negative phenotype via a knock-out of 
the gatZ gene. P1 transductions 403 were performed to substitute the whole gatZ gene 
from our strains with a kanamycin resistance cassete, using E. coli JW2082-1 from 
the KEIO collection 404 as a donor for the transduction. P1 transductions were also 
used to insert the point mutation rpoB H526Y in the wild-type background and to pass 
the gatZ deletion from the wild-type strains to the isogenic antibiotic resistant strains 
which carried either the point mutation rpsL K43T or both rpsL K43T and rpoB H526Y 
mutations (StrRRifR). The resulting streptomycin resistant (StrR) strains LC81 and 
LC82 (YFP/CFP, respectively), the rifampicin resistant (RifR) strains RB933 and 
LC84b (YFP/CFP, respectively), and the double resistant (StrRRifR) strains LC85, 
LC86 (YFP/CFP, respectively) were used to colonize mice to perform the evolution 
experiment. All of these strains possess a chloramphenicol resistance cassete 
associated with their fluorescent protein, as well as the kanamycin resistance 
cassete. As this study is focused on streptomycin and rifampicin resistance, I will be 
designating our strains as single or double mutants. 6-to-8 week-old female 
C57BL/6J specific pathogen free (SPF) mice were used as hosts for the in vivo 
evolution experiment. 
 
In vivo evolution 
To evolve the resistant strains in SPF mice, we used a streptomycin treatment 
in order to break the colonization resistance 405. Mice from the same litter were 
separated into individual cages and given autoclaved drinking water containing 
streptomycin sulfate (5g/L) for seven days, and then were given regular autoclaved 
drinking water for 2 days, in order to wash out the antibiotic from the gut. After 4 hours 
of starvation for food and water, the mice were gavaged with 100 µl of a ≈109 cells/ml 
suspension with a 1:1 ratio of the two isogenic strains. This protocol was applied to 




To make the suspension, the strains were streaked from stocks in LB agar with 
antibiotics corresponding to their resistance two days before gavage and incubated 
for 24 hours, followed by an overnight culture of a single colony for each biological 
replicate in BHI (brain heart infusion) medium with the corresponding antibiotics 
(concentrations of 100µg/ml). The cultures were then diluted 100-fold and grown in 
BHI medium until an OD600nm ≈ 2. An equal volume of the suspensions was mixed. 
Mice fecal pellets were collected 24 hours and every 48 after gavage, for 29 days, 
and collected once more, at the 39th day of colonization. Upon collection, the samples 
were suspended, diluted in PBS and plated in LB agar plates with chloramphenicol 
(30µg/ml). Plates were incubated overnight and the frequencies of CFP- or YFP-
labeled bacteria were assessed by counting the fluorescent colonies with the help of 
a fluorescent stereoscope (SteREOLumar, Carl Zeiss). The samples were also 
stored in 15% glycerol at -80°C for future experiments. 
 
Reversion test 
To test for antibiotic resistance reversion, following the plating of the diluted 
samples in LB medium plates supplemented with chloramphenicol (30µg/ml), up to 
153 random colonies per tested sample were grown in solid LB with no antibiotic, and 
passed with a replicator into LB agar with streptomycin (100 µg/ml), with rifampicin 
(100 µg/ml), with both antibiotics and with no antibiotic (control). If an evolved clone 
would be sensitive to an antibiotic for which the ancestral was resistant, we would 






DNA extraction for population sequencing 
In order to perform population sequencing, PBS suspended dilutions of the 
fecal samples were plated in LB plates supplemented with chloramphenicol 
(30µg/ml). The dilutions were done in order to obtain between 500 and 5000 cells of 
E. coli. We use a high number of colonies to allow for a good resolution regarding the 
detection of low frequency mutants, while the growth in a structured environment can 
diminish the over-representation of putative fast-growing mutants. The colonies were 
then scrapped and resuspended in PBS, and genomic DNA was extracted using a 
standard phenol / chlorophorm method 453. 
 
DNA extractions and whole-genome sequencing analysis 
Concentration and purity of DNA were quantified using Qubit and NanoDrop, 
respectively. The DNA library construction and sequencing were carried out by the 
IGC genomics facility. Each sample was pair-end sequenced on an Illumina MiSeq 
Benchtop Sequencer. Standard procedures produced data sets of Illumina paired-
end 250 bp read pairs. The reads were filtered using SeqTk version 1.0-r63.  For 
whole genome sequencing, the mean coverage after filtering for the different samples 
was as follows: 168x and 175x for StrR1 day 19 and day 39, respectively; 238x and 
194x for StrR2 day 19 and day 39, respectively; 164x and 159x for RifR1 day 19 and 
day 39, respectively; 226x and 202x for RifR2 day 19 and day 39, respectively; 148x 
and 156x for StrR RifR1 day 19 and day 39, respectively; 213x and 220 for StrR RifR2 
day 19 and day 39, respectively. Sequences were analyzed using Breseq version 
0.31.1, using E. coli K12 genome NC_000913.3 as a reference, with the 
polymorphism option selected, and the following parameters: (a) rejection of 
polymorphisms in homopolymers of a length greater than 3, (b) rejection of 
polymorphisms that are not present in at least 3 reads in each strand, and (c) 




(d) rejection of polymorphisms with less than 3 of coverage in each strand and (e) 
rejection of polymorphisms with less than 1% frequency. All other Breseq parameters 
were used as default. Hits that were present in all of our ancestral mutants, as well 
as homopolymers were discarded. Hits that were likely to be due to misalignment of 
repetitive regions were also discarded. Regarding the downstream analysis, target 
genes that appeared only in one sample and had a frequency lower than 5% were 
not considered. 
In order to perform amplicon sequencing, samples were processed as for 
population sequencing, for every time-point of the double mutant evolution.  Specific 
primers containing overhang adaptor regions were designed and used to amplify 
≈400 base pair genome regions harboring the rpsD Q54L and rpoC A784V mutations, 
detected on the double mutant background by whole genome sequencing. For each 
sample, PCRs were performed using the Phusion high fidelity polymerase following 
the Phusion protocol (https://international.neb.com/Protocols/0001/01/01/pcr-
protocol-m0530). The annealing temperatures were adjusted, corresponding to the 
primer sequences without the adaptor overhangs. PCRs for inserting indices and 
Illumina sequencing adapters were performed by the IGC Genomics Facility, 
following an online library preparation guide (https://web.uri.edu/gsc/files/16s-
metagenomic-library-prep-guide-15044223-b.pdf). Samples were then pair-end 
sequenced by the Facility on an Illumina MiSeq Benchtop Sequencer, following 
Illumina recommendations. 
The DADA2 R package 409 was used to filter and trim the amplicons, remove 
the adaptors, merge forward and reverse sequences and exclude chimeras. After 
these operations, the mean coverage of the rpsD amplicon ranged from 14899x to 





To assess the gut microbiota composition of mice, we extracted DNA from fecal 
samples from the evolution experiment 17 days after gavage, corresponding to the 
last time-point before the first sequencing event. Fecal DNA was extracted with a 
QIAamp DNA Stool MiniKit (Qiagen), according to the manufacturer’s instructions 
and with an additional step of mechanical disruption 406. 16S rRNA gene amplification 
and sequencing was carried out at the Gene Expression Unit from Instituto 
Gulbenkian de Ciência, following the service protocol. For each sample, the V4 
region of the 16S rRNA gene was amplified in triplicate, using the primer pair 
F515/R806, under the following PCR cycling conditions: 94 ºC for 3 min, 35 cycles of 
94 ºC for 60 s, 50 ºC for 60 s, and 72 ºC for 105 s, with an extension step of 72 ºC 
for 10 min 407. Samples were then pair-end sequenced on an Illumina MiSeq 
Benchtop Sequencer, following Illumina recommendations. 
QIIME2 408 was used to analyze the 16S rRNA sequences by following the 
authors’ online tutorials (https://docs.qiime2.org/2018.11/tutorials/). Briefly, the 
demultiplexed sequences were filtered using the “denoise-single” command of 
DADA2 409, and forward and reverse sequences were trimmed in the position in which 
the 25th percentile’s quality score got below 20. Alpha diversity, beta-diversity, and 
phylogenetic diversity analyses were also performed as in the QIIME2 tutorial. The 
sample depth was adjusted to 789 – the number of sequences of the sample with the 
lowest number, excluding the control. 
Alpha-diversity was estimated through the Shannon vector and significance 
was assessed through the Kruskal-Wallis test. An ANCOM 454 was performed in order 
to assess if specific microbiota members were associated with each litter. For 
taxonomic analysis, OTU were picked by assigning operational taxonomic units at 







Litter-specific occurrence of compensatory mutations 
To study how resistant commensal bacteria evolve in the mammalian gut, we 
have followed the evolution of E. coli strains resistant to streptomycin, rifampicin or 
both drugs combined for up to 6 weeks of evolution. Since we have previously 
observed a microbiota-related, variable fitness cost, and are aware that microbiota 
composition is more similar in mice from the same litter than in mice from different 
litters 361,455, we have colonized two separate cohorts of mice, a design in which the 
same resistant background colonizes two mice from different parents (Figure 1A). 
The two cohorts were expected to have different microbiota composition, and such 
difference between litters was confirmed through 16S rDNA analysis 17 days after 
gavage — the closest time-point before the first sequencing event — with a significant 
over-representation of the Verrucomicrobia phylum in microbiota from litter 1, namely 
from the Akkermansia genus (W=10, ANCOM analysis). Remarkably, despite going 
through perturbations such as antibiotic treatment and the colonization with our E. 
coli strains, after 26 days, the microbiota of the 3 mice in cohort 1 are very similar 
regarding their composition (Figure 1B). The microbiota in cohort 2 however varied 
between the hosts. Noticeably, the phylum Bacteroidetes was not present at all in the 
mouse from cohort 2 hosting the single streptomycin resistant mutant, StrR2 (Figure 
1C). No significant variation in alpha diversity between the two cohorts was found 
(p=0.827, Kruskal-Wallis test). 
To detect mutations in the evolved strains, we proceeded by performing whole 
genome population sequencing at two time-points, around week 3 and 6 after 
gavage. To identify bona fide compensatory mutations in particular, we relied on the 
fact that these mutations have been studied extensively in vitro, in different medium 
and bacterial species [e.g. 190,196,239,240,258]. The remaining mutations were classified 
here as adaptive. 
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We have observed a wide array of mutation targets, with a constant presence 
of adaptive mutations in all sequenced samples. Overall, 17 genes and 10 intergenic 
regions were targeted for global adaptation, including mutations shown to be 
adaptive during E. coli colonization of streptomycin treated mouse gut (Table S1). 
Not a single mutation was found in all mice, and only 12 out of 27 targets (44%) were 
found in 2 or more genetic backgrounds, suggesting that our evolution experiment 
did not saturate the loci in which beneficial mutations can occur. Within these 
adaptive targets, mutations in the coding sequence of the genes frlR, spoT and kdgR, 
as well as in the intergenic regions of dcuB-dcuR and in ymfE-lit occurred only in one 
of the litters.  A single adaptive mutation managed to reach fixation – the tdcA D44G 
mutation in the rifampicin resistant background. 
Classical compensatory mutations, however, were found to vary between 
hosts, with a temporal signal of compensatory evolution (Figure 1D). In the first 
cohort of mice, at least one compensatory mutation was detected in all resistance 
backgrounds, by the 3rd week of evolution, while in the second cohort, compensation 
was only detected for the streptomycin resistant strain (Figure 1D), and even so, at 
low frequency (≈8% at day 19; Figure 1E-F). Strikingly, no compensatory mutations 
were detected for the double mutant in mice from the second cohort in the 6th week 
of evolution, while adaptive mutations were already present at week 3, suggesting a 








Figure 1 - Dynamics and genetic basis of compensatory evolution of AR strains across 
hosts. (A) Experimental set up to study the adaption pattern of resistant strains (StrR, RifR 
and StrRRifR). Mice from the same sex and litter were co-housed since birth to homogenize 
the microbiota across litters. Afterwards, one mouse from each litter was colonized with one 
of the resistant backgrounds. (B) PCoA of an unweighted unifrac of the mice at week 3. 
Dashed lines correspond to 95% confidence intervals. Mice from the same litter cluster 
together and have a more similar microbiota. (C) Microbiota composition at the phylum level 
of the mice from the two different litters 3 weeks after colonization. (D) Comparison of the 
number of putative adaptive and compensatory mutations present in the adapted resistant 
populations after 3 and 6 weeks in the mice gut with different microbiotas. (E) Frequency of 
the detected adaptive and compensatory mutations at week 3 and week 6. (F) Genetic basis 
of the bona fide compensatory mutations detected after 3 or 6 weeks of adaptation in the gut. 
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Nature of classic compensatory mutations 
For the single streptomycin resistant mutants, we detected as compensatory 
targets a mutation on rpsL itself, and extragenic mutations on genes coding for other 
ribosome subunits, rpsE and rpsD (Figure 1E). These genes have been shown to be 
compensatory targets for streptomycin resistance 190. In fact, the mutations rpsD 
Q54R and rpsE V123A and the locus rpsE T103 have been previously described as 
compensatory for the equivalent allele rpsL K42N in Salmonella enterica ser. 
Typhimurium 240. 
In single rifampicin resistant mutants, we have observed two small deletions 
within the rpoB gene itself, one in each mouse. The two mutations are located in the 
same locus, as the deletions overlap (both delete amino acids 957 to 965), and both 
maintain the gene in-frame, as the two deletions englobe a number of base pairs 
multiple of 3. Mutations on rpoB compensating for fitness costs have been previously 
observed 239,245,258. Still, to the best of my knowledge, a rpoB deletion was reported 
as a putative compensatory target only once 196, during the evolution of a double 
mutant for rifampicin and streptomycin resistance. The mutation was also an 
in-frame deletion and was located close to ours (deleting RNA polymerase amino 
acids 1010-1012), so it could be compensating for rifampicin resistance through a 
similar mechanism. The frequency of this mutation in the first litter, however, lowers 
drastically between day 19 and 39 (from 46.7% to 6% - Figure 1E), suggesting that 
other mutations conferring a stronger fitness benefit have emerged in the population. 
Focusing on the double mutant, we have detected mutations on the genes rpsD 
and rpoC, which have been described as compensatory targets for streptomycin and 
rifampicin respectively, and were hit during the evolution of the isogenic double 
mutant in LB medium, in the absence of antibiotics 196. Curiously, the rpsD Q54L 
mutation affects the exact same codon as one detected in the single streptomycin 




compensation. The rpoC A784V mutation occurred only in the double resistant 
background, both in our and in the aforementioned study 196. 
 
Amplicon sequencing suggests clonal interference between the double 
mutant’s evolving lineages 
Focusing on the study of the double mutant, we wanted to pinpoint the 
occurrence of compensatory mutations in the first cohort and further confirm that 
none occurred in the second cohort. To do so, we have performed amplicon 
sequencing throughout every sample of the double-mutant evolution of two ≈400 bp 
genome regions, centered on the observed compensatory mutations. In the first 
cohort, we have observed the rpoC A784V mutation appearing as early as 7 days 
after gavage and the mutation rpsD Q54L around 27 days post colonization (Figure 
2). The appearance of the rpoC mutation coincides with the fluorescent marker 
dynamics favoring the YFP background, strongly suggesting that the rpoC A784V 
was under positive selection shortly after its appearance. This mutation rose in 
frequency until day 17, after which it suffered small fluctuations until around day 29, 
suggesting clonal interference between the lineage bearing this mutation and others, 
possibly carrying adaptive mutations.  Between day 29 and 39, the frequency of rpoC 
A784V declined while rpsD Q54L rose in frequency. As the frequency of the first 
mutation decayed after the appearance of the second, clonal interference between 
the two compensated lineages might have ensued. For the second cohort, we did not 
detect any mutation on the selected regions. While we did not extend our analysis to 
other classical compensatory targets, the absence of compensatory mutations in 
these loci together with the whole genome sequencing data support the idea that 





Figure 2 – Frequency over time of candidate compensatory mutations for the double 
mutant in litter 1 and litter 2. Dynamics suggest clonal interference between clones carrying 
distinct compensatory mutations in litter 1. No compensatory mutations in these loci were 
detected in litter 2. 
 
 
Within-host evolution did not lead to reversion of resistance 
Unlike other studies regarding E. coli’s in vivo adaptation 395,398,411,452, ours does 
not involve a continuous antibiotic treatment, and evolution is occurring in a 
streptomycin and rifampicin cleared environment. As such, lethal selective pressures 
favoring resistance phenotypes are absent, and phenotypic reversions are allowed 
to occur. To look out for these rare phenomena during the evolution of resistant 
strains, we have performed a phenotypic reversion test by selecting single clones 
from within the evolved samples and test them for antibiotic resistance to 
streptomycin, rifampicin and both drugs together. All of the sampled colonies 
maintained their resistance profiles – no phenotypic reversions were found and, as 







Microbiota effects on the onset of compensatory mutations 
Compensatory mutations are background-specific and ameliorate the fitness of 
a resistant background by counteracting the phenotype of the resistance mutation. 
Therefore, the onset of compensatory mutations should be intimately dependent on 
the presence or absence of a fitness cost of resistance. While performing an evolution 
experiment in commensal E. coli strains carrying resistance mutations, we have 
observed an earlier onset of compensation in one cohort of hosts when compared 
with the other, for all tested resistant backgrounds. Both cohorts belong to an inbred, 
isogenic line of mice, and as such, the only known biological difference between the 
cohorts lies in their gut microbiota composition, which in turn determines the niches 
under inter-species competition. The cohort in which compensatory mutations 
occurred early had a similar microbiota composition across mice. The inter-species 
competition driven by those microbiota communities may have led to the expression 
of a fitness cost of our selected antibiotic resistance mutations, prompting a selective 
pressure towards compensation. 
The cohort with earlier compensation had an over-representation of the 
Akkermansia genus. The single species of this genus known to be present in the 
mammalian intestine, Akkermansia municiphila, is a Gram-negative, anaerobic 
intestinal mucin-degrading bacteria 456,457. A. municiphila has a relevant relationship 
with the mammalian host, triggering host immune and metabolic responses and 
leading to an increased mucus thickness and gut barrier function 458. Additionally, it 
releases nutrients from mucin and produces short-chain fatty acids, beneficial to the 
host and the other microbiota members 458. Hence, Akkermansia modifies the 
intestinal niche, impacting the microbiota ecology. The levels of A. municiphila are 
negatively correlated with different diseases, such as IBD 459, ulcerative colitis 460, 
obesity 461–463, and diabetes 464. While the role of A. municiphila in the prevention or 
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mitigation of these diseases is not fully understood, A. municiphila could act as a 
reporter of the host’s gut health. Under this assumption, the shared microbiota 
composition in first cohort might reflect a “healthier” microbiota state, in which the 
typical functions of gut commensals were less affected (resistance) by or recovered 
faster (resilience) from the antibiotic perturbation 465. 
It is tempting to wonder if Akkermansia on its own could be interacting with 
resistant E. coli in such a way that resistance would bring a cost. However, our 
resistant strains express a cost on their own in the absence of microbiota (Chapter 
II) — in the presence of a naïve immune system and without interspecies competition. 
As in SPF mice, the cost varies in dysbiosis (Chapter II), the absence of cost in 
particular hosts might derive from imbalanced interspecies competition together with 
the ablation of cross-feeding, which on its own leads to the loss of nutritional niches 
and affects host-microbe interactions 420. A potential role of Akkermansia is likely to 
be related with its modulation of the immune system and with its ability to support 
other bacteria, leading to the restoration of alternative nutritional niches and providing 
competitive challenges for which wild-type and compensated strains are more fit to 
face. 
Regarding other taxa, we have observed differences in composition between 
cohorts within the Firmicutes phyla, and these could also have contributed to the low 
level of parallelism and to the variable onset of compensatory mutations. 
Furthermore, we are not taking into account variation at lower taxonomic levels nor 
polymorphisms within the resident bacteria. As a single gene loss or gain of function 
can change drastically a strain’s competitive ability in the mouse gut 397,398, intra-
species variation might underlie phenotypes that interfere with the cost of antibiotic 
resistance mutations and influence which adaptive and compensatory mutations are 






Predictability of antibiotic perturbation 
Our experiment involves a microbiota perturbation which typically decreases 
diversity 417,418,432,466,467. Even so, the two cohorts could be grouped and distinguished 
through 16S metagenomic analysis, with one of the cohorts presenting strikingly 
similar microbiota composition between the different mice after antibiotic treatment 
and prolonged colonization with our resistant strains. This mark of identity suggests 
that some microbiota communities might react to antibiotic perturbation in a 
predictable way. Accordingly, a recent study following the microbiota composition in 
healthy human volunteers shows a consistent association between the presence of 
a Bacteroides enterotype and lower initial microbiome diversity before treatment with 
the bloom of the opportunistic pathogen Enterobacter cloacae after exposure to the 
antibiotic 468. These findings highlight a link between the microbial community before 
and after perturbation and also suggest a degree of predictability. Success at 
predicting individual consequences of harsh microbiota perturbations such as 
antibiotic medication would be an extraordinary asset to select appropriate, 
personalized treatment and to prevent microbiota related diseases. As the cost of 
antibiotic resistance and the evolution of resistant strains seem to be associated with 
microbiota, these predictions could also be useful to minimize the rise of antibiotic 
resistant bacteria as well.  
 
Nature of compensatory mutations 
In the both single and double streptomycin resistant background, we have 
observed the occurrence of mutations in classic compensatory targets, namely, in 
rpsL, the gene containing the antibiotic resistance mutation, and in other genes 
encoding for ribosomal subunits, rpsD and rpsE. Streptomycin resistance mutations 
can confer a restrictive phenotype, which is characterized by an increased rate of 
proofreading, leading to a higher translation accuracy and a lowered peptide 
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elongation rate 240,256. Effectively, the equivalent to our rpsL K43T mutation has been 
shown to decrease peptide elongation rate in a different strain of E. coli 256, besides 
conferring a high cost in minimal medium - a similar fitness phenotype as ours. While 
we did not test for peptide elongation rate in our single streptomycin resistant mutant, 
it is very likely that it corresponds to a restrictive phenotype. Compensatory mutations 
targeting the ribosome can restore the elongation speed and error rate of 
streptomycin resistant mutants 190,240, and the restoration of this phenotype is typically 
associated with a fitness recovery towards the wild-type’s 240,256. Our mutations in 
classic compensatory targets could, therefore, be restoring the ribosome translation 
speed and accuracy in order to abolish the pleiotropic effects of the resistance 
mutation. 
We have observed rare putative compensatory mutations in the form of intra-
gene deletions, in a region of the rpoB gene that is not usually associated with 
compensation. The locus is located in a eubacteria-specific, non-essential region of 
the gene 469,470, which is thought to be an exposed loop, allowing the flanking domains 
to interact and perform the enzyme’s catalytic function 469. The deletions allow the 
maintenance of essential regions of the rpoB gene in frame, presumably to not hinder 
RNA polymerase’s essential functions. A potential compensatory role of the deletion 
could be adjusting the distance between the flanking RNA polymerase domains. 
Curiously, resistance-conferring indels can have their fitness cost mitigated by 
compensatory amino acid substitutions 246. The process of using a SNP to 
compensate a length defect is seemingly the evolutionary inverse process of what 
we have observed. Both findings suggest genome versatility of resistant bacteria, 
and an extended mutational repertoire by which the fitness cost of rifampicin 
resistance might be mitigated. 
The putative compensatory target rpsD Q54 has emerged in both single and 
double streptomycin resistant backgrounds, but rpoC A784V was restricted to the 
double resistant background in our study, as well as in another regarding in vitro 
evolution in LB medium 196. While rpoC mutations are known to compensate the cost 




conferring benefits for the double mutant only. In fact, another rpoC mutation (rpoC 
Q1126K) was shown to give a fitness benefit to the double mutant, but not to the 
single rifampicin resistant background, compensating specifically for the genetic 
interaction between the rpsL K43T and rpoB H526Y alleles, possibly by being 
mechanistically linked to transcription-translation coupling 196. Moving our rpoC 
mutation to the single rifampicin and double mutant backgrounds and measuring their 
fitness effects would help us understand if it is compensating the cost of the rpoB 
H526Y mutation or of the epistatic effect between the two resistance mutations. 
 
Nature of adaptive mutations 
Roughly half of the mutations that we are addressing as adaptive were present 
in a single resistant background, reflecting a low level of parallelism at the gene level. 
However, most of the mutation targets were described before in in vivo adaptation 
studies. In the mouse gut, an environment with a degree of structure and a variety of 
nutritional niches, the existence of multiple paths to a higher fitness is to be expected. 
Most likely, the adaptive targets were not exhausted in our experiment even after 
around 40 days of evolution. On the other hand, some of the metabolic targets might 
be under negative epistasis with each other 395, which would also hinder parallelism 
for adaptive mutations between populations. 
Focusing on metabolic genes, their nature combined with their previous 
observation suggests an adaptive role. Still, the specific mutations that we observe 
may be a result of shifted fitness landscapes in the resistant mutants due to the 
pleiotropy of the resistance genes. As with other rifampicin 239 and streptomycin 435 
resistance mutations, rpoB H526Y and rpsL K43T are likely to alter transcription and 
translation efficiency (respectively). In such a scenario, the strains can recover their 
fitness either by compensatory mutations acting on these phenotypes, or by 
correcting downstream effects of the resistance mutations. The latter hypothesis is 
particularly plausible for the tdc operon and the spoT gene. 
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Our rifampicin resistant mutants have acquired mutations in the tdcA gene and 
in the tdcA-tdcR intergenic regions, with the tdcA D44G point mutation reaching 
fixation in one of the mice. tdcA is required for the autoregulation of the tdc promoter 
471, while its expression requires a polypeptide coded by tdcR 472. Assuming that 
these mutations did not raise in frequency by hitchhiking on others, selection must 
have acted on the expression levels of the operon. tdc encodes for the transport and 
anaerobic degradation of L-threonine and serine 473,474, allowing their use as a source 
of energy and cell metabolites, and it is the single operon in E. coli MG1655 whose 
transcription is not blocked in the presence of rifampicin – it is actually upregulated 
in the presence of the drug, suggesting a distinct regulatory mechanism of 
transcription 475. Having this into account, it is possible that our rifampicin resistant 
mutant has an altered tdc expression, or that the expression of the operon relative to 
the rest of the genome is changed when compared with the wild-type’s. The lack of 
an optimal expression of tdc genes, or of genes downstream of tdc for rpoB H526Y 
mutants could lead to metabolic imbalances and a cost in the in vivo context. 
Intriguingly, spoT was targeted in both the single streptomycin and single 
rifampicin resistant backgrounds through distinct point mutations. We are not aware 
of the effect of these mutations – they may be affecting the two strains’ phenotypes 
in a different way. SpoT regulates the “alarmone” ppGpp, a nucleotide that mediates 
the stringent response - an adjustment of cellular activity affecting the rate of RNA 
accumulation, the synthesis and breakdown of metabolites and macromolecules 
upon amino-acid starvation 476. The nucletide ppGpp binds directly to RNA 
polymerase to elicit the response 477, but certain rpoB mutants have been shown to 
have a stringent phenotype even in the absence of ppGpp 477–479. The effect of ppGpp 
could be affected in our rifampicin resistant mutant, and in such a situation, adjusting 
the levels of ppGpp through a spoT mutation could be beneficial.  
On the other hand, a molecular study shows that ppGpp can affect the accuracy 
of translation by managing the ratio of different tRNA 480. The mutation in spoT could 
therefore be indirectly compensating phenotypic effects of the rpsL K43T mutation 




of iraP, a stabilizer of rpoS 481, the master regulator of the general stress response in 
E. coli 482. Strikingly, in Salmonella enterica var. Typhimurium, a streptomycin 
resistance mutation on an equivalent locus (rpsL K42N) leads to a lower production 
of the rpoS protein on its own 271. It is possible that the regulation of starvation or 
other stress responses is also affected in our resistant strains, requiring an adjusted 
spoT activity in stressful or resource-depleted environments to “compensate” a lower 
level of rpoS. Notably, spoT mutations occurred in litter 1 only, despite occurring in 
two distinct genetic backgrounds. As the microbiota composition is remarkably similar 
within this cohort, a need to adjust the response to stress and/or starvation might 
have emerged due to inter-species competition. Curiously, in the rifampicin mutant, 
the spoT L103F point mutation has appeared and risen sharply in frequency between 
day 19 and 39 (Table 1), while the putative compensatory rpoB deletion has lowered 
in frequency drastically, suggesting a stronger beneficial effect of the spoT mutation. 
Clonal interference between lineages may have led to these inverted dynamics, but 
a change in the gut’s selective pressures between the two time-points cannot be 
discarded. 
Some of the “adaptive” targets are related by nature with our resistance 
mutations. The rrfH gene codes for 5S ribosomal RNA, an RNA component of the 
large subunit of the ribosome 483; clpX is a molecular chaperone and part of the clpXP 
and clpAXP protease complexes 484, which are related with viability in stationary 
phase 485. rimJ is an acetyltransferase acting on the 30S ribosomal protein S5, which 
is itself coded by the compensation target gene rpsE 486, and mukF, found at low 
frequencies in the double mutant background, codes for bacterial condensin, which 
is involved in chromosome partition during cell division 487. Each of the targets was 
found in a single resistant background, and while these genes have not been 
previously reported as compensatory mutations, we cannot fully exclude the 
possibility of them conferring background-specific fitness benefits in the gut 
environment. Growth condition-specific compensation targets were previously 
observed in the pathogen Salmonella enterica var. Typhimurium 191, so it would not 
be surprising to uncover new targets in our commensal E. coli. Placing these 
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mutations in clean backgrounds, both sensitive and resistant, and assessing their 
fitness in vivo could help exclude or reveal them as additional compensatory targets 
of resistance. 
 
The rarity of fixation 
In our study, a single adaptive mutation reached fixation during our evolution 
experiment. Furthermore, we have not observed fixation of any classical 
compensatory mutation. Our observations suggest an overall pattern of clonal 
interference, not only between putative compensatory mutations, but also between 
these and adaptive mutations. In other gut evolution studies involving E. coli K12, 
numerous adaptive mutations are detected, and as in here, most of the acquired 
mutations do not fix 395,398. Hence, the low rate of fixation seems to be a common 
feature in the in vivo adaptation of this E. coli K12 background. 
Bacteria can find a multitude of nutritional niches in the gut 488, and these niches 
are thought to be under intense resource competition 489. Cross-feeding interactions 
are a feature of the gut environment 490, contributing to a higher complexity of its 
ecology.  Thus, it is not surprising that multiple paths towards a higher fitness are 
available in such an environment. As multiple selective pressures are involved, some 
of them implying trade-offs between adaptive traits and leading inclusively to 
sympatric diversification 491, unconditionally beneficial mutations might be rare, even 







Absence of reversions 
Reversion of the rpoB H526Y mutation has been observed in vitro, in a single 
mutant isogenic to ours 196, and in vivo reversion of antibiotic resistance to 
streptomycin 190 and fusidic acid 191 have been previously observed on Salmonella 
infection models. Armed with this knowledge, we queried if a phenotypic reversion in 
our rifampicin and streptomycin resistant mutants could have occurred during our gut 
evolution experiment. However, the resistance phenotypes of our strains remained 
untouched during in vivo adaptation. One possibility is that reversions did not occur 
at all in our strains. Back mutations have a reduced mutational target size, as they 
imply the occurrence of a SNP in a specific locus, and as a consequence, are 
expected to be rare. In fact, several studies show that compensatory mutations are 
far more frequent than reversions 169. Regarding phenotypic reversions without a 
back mutation, they typically occur through compensatory mutations that restore the 
wild-type’s phenotype, leading to restored sensitivity 263. Still, this phenomenon is 
highly specific. While streptomycin resistance mutations leading to ribosome hyper-
accuracy can be reverted by mutations that lead to lowered accuracy in translation, 
the recovery of sensitivity is restricted to specific alleles 264. Supporting the rarity of 
these events, in a study in which genotypic revertants are found during successive 
infections by streptomycin resistant Salmonella typhimurium, none of the second-site 
compensatory mutations reverted resistance 190. 
Alternative explanations for the absence of genotypic and phenotypic 
reversions imply that they are not favored by natural selection. One possibility is that 
the reversion itself does not confer a fitness advantage. In Chapter II, we have 
observed a host-specific cost of resistance, inclusively hosts in which a cost was not 
found - reversion would not be favored in such scenario. The presence of 
compensatory mutations in litter 1 suggests that resistance had a cost in litter 1. 
However, in litter 2, classical compensatory mutations had a late onset, and did not 
occur at all in the double mutant, suggesting a low or non-existent cost of resistance. 
In this particular scenario, reverting to the wild-type background would not confer a 
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fitness benefit. Additionally, compensatory mutations interact epistatically with the 
resistance locus. If these mutations would confer a fitness benefit only in the 
presence of the resistance mutation, a negative genetic interaction with the wild-type 
allele could also impair reversions by selecting against sensitivity in the evolved 
strains. In fact, compensatory mutations with a deleterious effect in a sensitive 
background have been described 196, and such mutations would impair reversions. 
 It should also be noted that we have a limited number of sampled mice. We 
cannot exclude the possibility that with a higher number of hosts, covering for 
different microbiota compositions, we could have observed phenotypic reversions of 




Besides reproducing our observation of a variable onset of compensatory 
mutations, further experiments with a similar experimental design could help to better 
discern the genetic background-specificity of mutations, which could reveal new 
targets for compensation 196, as well as litter-specific adaptive mutations, which in 
turn could hint into host-specific adaptation or even expose epistatic relationships 
between adaptive mutations 395. A very recent work has performed the evolution of 
E. coli in germ-free mice 492 and has shown that a specific genetic adaptation in the 
gene lrp, encoding a global regulator of amino-acid metabolism, was predictably 
selected within two weeks of mono-colonization,  and the addition of a single member 
of the microbiota (Blautia coccoides) was enough to alter the gut metabolic profile 
and E. coli‘s evolutionary path, further showing reproducibility on in vivo systems in 
which microbiota is absent or controlled. Performing the evolution of each of the 
resistant backgrounds in germ-free mice, and in conventional mice from the same 
litter while warranting a similar microbiota composition before and during antibiotic 




In the previous chapter, we have performed competitions between a double 
resistant strain and its ancestral, a streptomycin resistant resident E. coli. It could be 
interesting to evolve these strains in the mouse gut as well. The single streptomycin 
resistant strain is presumably adapted to the gut environment, so further adaptation 
should reflect either host-specific or microenvironment-specific fitness determinants. 
The evolution of the double mutant strain however could allow us to evaluate the 
maladaptive impact of the acquired rpoB H526Y mutation in the resident background. 
Namely, it would be interesting to note if the mutant would evolve mainly through 
compensation due to the adapted resident background, or if this mutation would 
expand the adaptive targets of the double mutant, reflecting a shifted fitness 

















Table S1 – De novo mutations on AR E. coli genetic backgrounds during gut 
colonization. Genome position, mutation nature and frequency after 3 and 6 weeks of 
evolution are shown. Mutations in bold occurred in genes described in the literature as targets 
for compensation. In the gene column, references on mutational gene targets previously 
described in the literature are indicated after the mutation target. 





Gene Mutation Week 3 Week 6 
StrR 1 1198436 ymfE / lit +AATGAAAT 12.6% 13.6% 
  1466201 ydbA493 T→C  8.5%   
  2259422 psuK / fruA66  A→C  3.5% 8.5% 
  2406600 lrhA +TCGAGG   8.1% 
  2829125 srlR394 C→T  2.9%   
  2829468 srlR394 C→A  3.9% 11.1% 
  3444923 rpsE190,240 T→G  13.7% 15.6% 
  3444925 rpsE190,240 C→G  36.1% 57.8% 
  3474368 rpsL190,240 T→G  14.4% 6.8% 
  3504197 frlR394 G→A    10.9% 
  3823019 spoT493 G→A    51.8% 
  4542161 fimE66 IS5 +4 bp    60.8% 
  4542457 fimE66 IS1 +9 bp    12.2% 
  4640748 yjjY → / → yjtD395 IS5 +4 bp    3.3% 




  457912 clpX IS1 +9 bp  11.7%   
  570603 ybcK → / → ybcL IS2 +5 bp  2.6% 14.9% 
  972965 elyC G→T    11.5% 
  973071 elyC IS1 +9 bp    25.2% 
  973103 elyC IS5 +4 bp  4.1% 25.1% 
  973108 elyC G→T    7.7% 
  1466210 ydbA493 G→A    5.0% 
  1466438 ydbA493 T→G   5.0% 
  1909535 kdgR394 G→A  11.7% 21.3% 
  2765463 yfjL ← / ← yfjM +TATGGCAC   29.4% 
  2773761 yfjW T→C    5.5% 
  2829065 srlR394 C→T    9.8% 
  2829207 srlR394 G→A    4.4% 
  3441515 rpsD190,240 T→C    20.2% 
  3444862 rpsE190,240 A→G    52.1% 
  3444971 rpsE190,240 C→T 7.5%   
  4542308 fimE66 IS5 +4 bp  2.1% 26.5% 
  4542308 fimE66 IS5 +4 bp  10.2%   
  4542577 fimE66 IS1 +10 bp  61.3% 63.5% 
  4640605 yjjY → / → yjtD395 IS2 +5 bp    11.3% 
RifR 1 1198437 ymfE ← / → lit Δ8 bp    5.6% 
  1264717 hemA G→T    8.6% 
  2765412 yfjL ← / ← yfjM Δ8 bp  1.8%   
  3266935 tdcA  T→C  5.7%   
  3266993 tdcA C→T    100.0% 
  3267147 tdcA ← / → tdcR394 IS5 +4 bp    3.8% 
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  3504139 frlR394 C→T    10.4% 
  3822706 spoT493 C→T    76.1% 
  4184101 rpoB196,450 Δ39 bp  46.7% 6.0% 
  4439596 ytfK T→A  5.0%   
RifR 2 954669 focA ← / ← ycaO394 IS5 +4 bp  45.5% 52.9% 
  954678 focA ← / ← ycaO394 IS5 +4 bp    23.7% 
  1125778 rimJ394 IS1 +9 bp    34.3% 
  1198460 ymfE ← / → lit +AATGAAAT   8.5% 
  1466432 ydbA493 A→G  4.6%   
  1466438 ydbA493 T→G 4.7%   
  1909925 kdgR394 IS5 +4 bp   5.0% 
  1910031 kdgR394 IS2 +5 bp  2.5% 9.4% 
  2765411 yfjL ← / ← yfjM +GCACTATG   30.4% 
  2829687 srlR394 A→C  12.4% 16.2% 
  3267147 tdcA ← / → tdcR394 IS5 +4 bp    3.8% 
  4184117 rpoB196,450 Δ24 bp    8.6% 
  4348862 dcuB ← / ← dcuR394 IS5 +4 bp  3.2% 7.4% 
  4349082 dcuB ← / ← dcuR394 IS2 +5 bp    15.0% 
StrR RifR 1 533245 allR T→G  5.6% 6.7% 
  974859 mukF Δ3 bp  5.2%   
  3267149 tdcA ← / → tdcR394 Δ2 bp  55.5%   
  3441515 rpsD190,240 T→A    9.4% 
  3504101 frlR394 G→T  15.2% 8.2% 
  3504565 frlR394 C→T  3.2%   
  4187700 rpoC196,450 C→T  63.2% 42.6% 




  1466438 ydbA493 T→G   5.1% 
  2259416 psuK ← / ← fruA66 +AA   3.4% 
  3150816 yghA → / ← exbD C→T   6.2% 
  4348862 dcuB ← / ← dcuR394 IS5 +4 bp  12.2% 14.2% 
  4348971 dcuB ← / ← dcuR394 Δ98 bp  1.3% 4.2% 
  4348988 dcuB ← / ← dcuR394 IS2 +5 bp  11.6% 7.5% 
  4349082 dcuB ← / ← dcuR394 IS2 +5 bp   1.4% 
  4349103 dcuB ← / ← dcuR394 IS2 +5 bp    20.5% 
  4603111 yjjP ← / → yjjQ IS5 +4 bp   2.9% 



















Table S2 – Time-point sampling to detect phenotypic reversions during the evolution 
experiment. Stool samples were diluted and grown in LB with chloramphenicol to select E. 
coli strains. Random colonies were replicated into LB plates with streptomycin, with 
rifampicin, with both drugs and with no antibiotics. No reversions or gain of double resistance 
















StrR 1 102 153  152 113 115 635 0 
RifR 1 110 100  96 96 96 498 0 
StrRRifR 1 78 135  132 114 102 561 0 
StrR 2   144    144 0 
RifR 2   96    96 0 












Chapter IV – Frequency-dependent selection acting 
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Isabel Gordo and I designed this study. I have performed the competitions, the 
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The fitness effect of a mutation is a key factor in its spread. In most studies, 
fitness effects are measured either by comparing the growth rate of the mutant with 
a reference strain or by direct competition between the two in a 1 to 1 ratio. However, 
most ecological interactions are dynamic, changing selection according to the density 
and frequency of the genotypes. Still, most studies do not test for frequency 
dependence, overlooking potential bacterial interactions with an impact on fitness. 
Despite being associated with cross-feeding and leaky functions, it is not clear how 
common frequency dependent selection is. Here, we query about the existence of 
frequency dependent selection for polymorphisms in distinct cellular functions, and 
we do find a relationship between secretome functions and magnitude frequency-
dependent selection. Furthermore, to enquire for polymorphism stability in a natural 
environment, we have competed single gene deletion mutants lacking these 
functions and the respective wild-type strain in the mouse gut. A single mutant strain 
dominated the competition hinting that in the gut, strong Darwinian selection prevails 














When a new mutation occurs in a population, it does so at low frequency. The 
frequency of the new strain will then change, leading either to loss of the mutant, to 
its fixation or to its maintenance in a polymorphic population. While stochastic 
fluctuations, termed as “genetic drift”, can have a powerful role in the fate of new 
mutations, selection acts as an effective modifier of the frequency, benefiting the 
spread of mutations that confer a fitness advantage and hindering deleterious ones 
162. The fitness effect of a mutation is thus a key factor in its spread. 
In most studies with bacteria, the fitness effect of a mutation is typically 
measured in one of two ways. The first consists in measuring absolute fitness through 
the growth of the mutant strain, the estimation of its growth parameters, and the 
comparison of its growth-rate with a reference strain [e. g. 261,271,494,495]. While this 
method provides a proxy of fitness, other growth parameters contribute to it 496, and 
even when taking life-history parameters like the lag phase and the carrying capacity 
into account, the isolated growth does not integrate the parameters into a single 
competitive index, nor does take into account particular phenotypes that could foster 
interactions between strains competing directly. Addressing these limitations, the 
second widely used approach consists in 1:1 ratio, direct competitions between the 
mutant and a reference strain  [e. g.192,497–499], typically the isogenic wild-type 
background. These competition assays require a way to distinguish the strains 
(typically through auxotrophy, resistance or fluorescence markers) but allow 
integration of the differences across the full growth cycle 500, as well as putative 
interactions between the mutant and the reference strain. The 1:1 ratio is used 
because it allows the maximization of differences between the competing genotypes 
under the assumption of constant selection. However, most ecological interactions 
are dynamic, depending on the number of individuals and the proportion of each 
strain in the population and affecting fitness according to the density and frequency 
138 
 
of the genotypes 501,502. Still, in the absence of a priori expectations, most fitness 
studies do not take into account putative frequency-dependent events. 
Frequency-dependent selection is thought to be one of the main selective 
mechanisms through which diversity can be maintained 503,504. Negative-frequency 
dependent selection (NFDS) in particular, also known as stabilizing frequency 
dependent selection, is a form of selection in which the selective value of a variant is 
a function of its frequency in the population,  in such a way that a variant has a fitness 
advantage when rare and a fitness disadvantage when common, and can lead to a 
stable coexistence between variants 501,504. 
Frequency-dependent polymorphisms can be generated in clonal bacterial 
populations through evolution, even in simple, constant laboratory environments 
through cross-feeding 505 or adaptive radiation for the consumption of resources 506, 
but they have also been shown to occur in complex environments such as the 
mammalian gut, through metabolic adaptation 395. It is expected to occur for genes 
within the accessory genome 507, and there is evidence that leaky, public good-
related functions in particular can lead to frequency dependence 508,509. 
Despite the importance attributed to frequency dependent selection in the 
maintenance of polymorphisms, it is not well known how common it is, and how prone 
are distinct cellular functions, to be under this type of selection. To address these 
questions, we performed pair-wise competitions between a set of mutants, each 
carrying a single gene deletion for different functions, including core genes encoding 
for inner cell mechanisms to accessory genes implied in functions outside of the cell, 
against their isogenic wild-type at different frequencies, to look out for frequency-
dependent effects. We have also competed a subgroup of mutants, lacking leak-
prone genes, and the wild-type strain in the mammalian gut to enquire for 







Escherichia coli and mice strains 
For our experiments, we used fluorescence-labeled, E. coli K-12 MG1655-
derived strains, bearing single gene deletions of genes covering for different 
functions, ranging from core cellular processes to secretion. The list of genes can be 


















Table 1 – E. coli strains used in this study and the corresponding genotype.  
Strain Genotype 
JB 77 ΔlacIZYA::scar gatZ::IS1 galK::cat-YFP rpsL K43R 
JB 78 ΔlacIZYA::scar gatZ::IS1 galK::cat-CFP rpsL K43R 
LC6 JB78 ∆srlR::FRT-kan-FRT 
LC7 JB78 ∆tnaA::FRT-kan-FRT 
LC27 JB78 ∆yliH::FRT-kan-FRT 
LC29 JB78 ∆talB::FRT-kan-FRT 
LC31 JB78 ∆rpsT::FRT-kan-FRT 
LC32 JB78 ∆fkpB::FRT-kan-FRT 
LC34 JB78 ∆hepA::FRT-kan-FRT 
LC39 JB78 ∆cadA::FRT-kan-FRT 
LC40 JB78 ∆cadB::FRT-kan-FRT 
LC41 JB78 ∆cadC::FRT-kan-FRT 
LC46 JB78 ∆kefC::FRT-kan-FRT 
LC52 JB78 ∆tbpA::FRT-kan-FRT 
LC60 JB78 ∆pqqL::FRT-kan-FRT 
RB370 JB78 ∆hlyE::FRT-kan-FRT 
RB372 JB78 ∆htrE::FRT-kan-FRT 
RB374 JB78 ∆lamB::FRT-kan-FRT 
RB376 JB78 ∆cbrA::FRT-kan-FRT 
RB378 JB78 ∆gspK::FRT-kan-FRT 
RB380 JB78 ∆ompG::FRT-kan-FRT 
RB382 JB78 ∆yebF::FRT-kan-FRT 
RB384 JB78 ∆katG::FRT-kan-FRT 
RB414 JB78 ∆agp::FRT-kan-FRT 
RB416 JB78 ∆citT::FRT-kan-FRT 
RB418 JB78 ∆dcuB::FRT-kan-FRT 
RB422 JB78 ∆idnD::FRT-kan-FRT 
RB424 JB78 ∆katE::FRT-kan-FRT 
RB426 JB78 ∆dps::FRT-kan-FRT 
RB428 JB78 ∆entE::FRT-kan-FRT 
 
The mutants were constructed through P1 transduction 403, having as donors 
strains from the KEIO collection 404, which includes precisely defined, single gene 
knock-outs of all non-essential genes in E. coli K12. The genes are replaced by a 




transduction. Clean, single gene deletions were chosen as mutations because they 
allow the full abolishment of a gene’s function. On this chapter, JB77 will be 
considered as the wild-type, while individual mutant strains for a matter of 
convenience, will henceforth be called by their deleted gene. 
We have purposely included genes encoding for periplasm and outside of the 
cell functions (referred as “secretome” in this chapter), which are more likely to be 
involved in interactions, namely the genes agp, entE, gspK, hlyE, pqqL, tbpA and 
yebF , as well as the ones encoding E. coli peroxidases katE and katG, as it was 
previously shown that in a dependency context, a peroxidase producer and a 
beneficiary could show frequency dependent selection 509 We have also included 3 
genes from the same operon: cadA, coding a lysine decarboxilase, cadB, a lysine 
transporter and cadC, the cadBA transcription regulator, as the dynamics of a long 
term evolution experiment in the mouse gut suggest that this operon is under 
frequency-dependent selection 396. Some of the remaining genes are involved in 
nutrient metabolism and host adaptation, and while they could lead to frequency 
dependent selection via differential resource competition in complex environments 
such as the mammalian gut, they are not expected do so in a single carbon source, 
well mixed, in vitro environment. Our selection comprises both core and accessory 
genes, with a wide range of representation within the sequenced E. coli genomes 
(Table 2). Although some of these genes went through duplication events, none is 
duplicated in E. coli K12 MG1655 (checked through megablast in 
https://blast.ncbi.nlm.nih.gov/Blast.cgi). 
6-to-8 week-old C57BL/6J specific pathogen free (SPF) mice (2 male and 2 






Table 2 - Genes under study, their frequency in sequenced E. coli genomes and their 
described function. In bold are core genes, which are present in all strains and for which 
phylogenetic data does not suggest deletion or duplication events. Frequency and 
phylogenetic data were obtained through the PanX pipeline 510, and the gene annotation was 
collected through the EcoCyc database 511. 
Gene Frequency Annotation 
agp 0.98 Periplasmic acid glucose phosphatase 
cadA 0.94 Lysine decarboxylase CadA 
cadB 0.92 Cadaverine/lysine antiporter 
cadC 0.92 CadBA transcriptional regulator 
cbrA 0.99 Flavin adenine dinucleotide protein, colicin M resistance 
citT 1.00 Citrate carrier 
dcuB 1.00 Anaerobic C4-dicarboxylate transporter 
dps 1.00 DNA starvation/stationary phase protection protein 
entE 1.00 Enterochelin synthase subunit 
fkpB 1.00 Peptidyl-prolyl cis-trans isomerase 
gspK 0.54 Pseudo pillin of the type II secretion system 
hepA 0.99 RNA polymerase-associated protein 
hlyE 0.67 Hemolysin E 
htrE 0.79 Outer membrane usher protein 
idnD 0.42 L-idonate 5-dehydrogenase 
katE 0.99 Catalase-peroxidase HPII 
katG 1.00 Catalase-peroxidase HPI 
kefC 0.99 Potassium-efflux system protein 
lamB 1.00 Maltoporin 
ompG 0.95 Outer membrane protein G 
pqqL 0.96 Zinc protease 
rpsT 1.00 30S ribosomal protein S20 
srlR 0.99 Sorbitol operon repressor 
talB 1.00 Transaldolase 1 
tbpA 0.99 Thiamine binding periplasmic protein 
tnaA 0.99 Tryptophanase 
yebF 1.00 Protein carrier to the outside of the cell 





In vitro competitions and selection coefficient calculation 
In order to access the extent of frequency dependent selection in a simple 
environment, we performed pairwise competitions between the mutants and the wild-
type strain with 3 different mixing frequencies: 1:9, 1:1 and 9:1 mutant to wild type 
ratio. For future reference, I will be calling these mixing treatments as low, average 
and high frequency, respectively. 
The strains were grown in minimal medium with glucose [M9 salts, MgSO4 1 
mM, CaCl2 0.1 mM, glucose 0.4% (w/v)] as an acclimatization step. This medium 
composition was used in all in vitro experiments on this chapter. The cell number for 
each strain was then assessed using fluorescent associated flow cytometry. The 
strains were then diluted and mixed together in fresh medium order to have a total of 
106 cells in 200 µl of culture medium, with the mutant either in low, average or high 
frequency. The mix was sampled through flow cytometry and further incubated at 
37ºC with agitation. After 24 hours, the mix was sampled again, propagated into fresh 
media (5 µl suspension in 200 µl fresh medium) and grown again in the same 
conditions. This procedure was repeated every 24 hours until 4 days after mixing, in 
which the propagation was stopped. To determine the ratios of mutant and wild-type 
strains, bacteria numbers were quantified with an LSR Fortessa flow cytometer using 
a 96-well plate autosampler. Samples were always run in the presence of SPHERO 
(AccuCount 2.0-µm blank particles) in order to accurately quantify bacterial numbers 
in the cultures. Briefly, flow cytometry samples consisted of 180 µl of PBS, 10 µl of 
SPHERO beads, and 10 µl of a 100-fold dilution of the bacterial culture in PBS. The 
bacterial concentration was calculated based on the known number of beads added. 
Cyan fluorescent protein (CFP) was excited with a 442-nm laser and measured with 
a 470/20-nm pass filter. Yellow fluorescent protein (YFP) was excited using a 488-
nm laser and measured using a 530/30-nm pass filter. Yellow fluorescent protein 
(YFP) was excited using a 488-nm laser and measured using a 530/30-nm pass filter. 
As in most competitions the dynamics were shifted in the first day compared 
with the following days, we considered the first 24 hours as an additional 
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acclimatization step, namely to the new environment with two strains, and used the 
day 1 to day 4 measurements to calculate the selection coefficients. The selection 
coefficients per day were estimated through the slope of the linear regression of the 
logarithm of the ratio of the mutant to the reference strain. For all mutants, the 
coefficients in high and low frequency were compared through a T test assuming 
homogenous variance. Mutants for which the mean difference was statistically 
significant were considered to be under frequency-dependent selection. In each 
treatment, mutations for which the average fitness effect surpassed 2 times the 
standard error were considered to have an effect. If not considered as frequency 
dependent, mutations that had a fitness effect in only one or two frequency 
treatments were considered as beneficial if all of the individual slopes in all treatments 
were positive, deleterious if all slopes in all treatments were negative, otherwise they 
were considered neutral. A minimum of 3 biological replicates were used to measure 
fitness for each mutant in each treatment. For each biological replicate, the 
experiment was performed separately. Wild-type YFP / CFP competitions did not 
disclose significant differences in fitness between the two fluorescent backgrounds 
[Scfp, low= 0.03 (±0.04 2x standard error), Scfp, avr=0.03 (±0.06) Scfp, high=-0.01(±0.02); 
pcfp, low =0.27, pcfp, avr=0.1, pcfp, high=0.96, One sample T-test]. 
 
Growth curves 
The strains were grown in minimal medium with glucose as an acclimatization 
step. The cell numbers were then assessed using fluorescent associated flow 
cytometry. For each strain, approximately 106 cells were transferred to 200 ul of fresh 
medium, in a honeycomb well plate. The plate was then taken into the Bioscreen, 
and the OD at 600 nm wavelength was measured every 30 minutes, for 24 hours. 
After subtracting the OD value for the blank wells, the data was analyzed using the 
GrowthRates R package (https://cran.r-project.org/ 




lag phase (λ). The carrying capacity (K) was estimated directly by asserting the 
highest OD in each sample. The parameters were each analyzed through a one-way 
ANOVA with Dunnett’s test for multiple comparisons, using the wild-type as a 
reference treatment for comparison. It was not possible to run all the samples in a 
single honeycomb plate. To minimize circumstantial differences between plates, the 
wild-type was grown in each plate, and the statistics were performed using the 
respective wild-type growth. 3 biological replicates per strain were used to estimate 
the growth parameters. 
 
In vivo competition 
Prior to the experiment, we used an antibiotic treatment in order to break the 
colonization resistance 405. Mice were transferred into individual cages and given 
autoclaved drinking water containing streptomycin sulfate (5g/L) for seven days, and 
then were given regular autoclaved drinking water for 2 days. After 4 hours of 
starvation for food and water, the mice were gavaged with 100 µl of a ≈109 cells/ml 
suspension with a 1:7 ratio of the 8 competing strains (each with ≈12.5% frequency). 
To make the suspension, the strains were streaked from stocks in LB agar with 
chloramphenicol (30µg/ml) two days before gavage and incubated for 24 hours, 
followed by an overnight culture of a single colony for each biological replicate in BHI 
(brain heart infusion) medium supplemented with chloramphenicol (30µg/ml). The 
cultures were then diluted 100-fold and grown in BHI medium until an OD600nm ≈ 2. 
The cells were then resuspended in PBS. Following the gavage, mice fecal pellets 
were collected twice per day, starting at 6 and 24 hours after gavage for a week, 
keeping the daily schedule (30 and 48 hours post gavage, and so on). Each time, the 
cells were suspended and homogenized, diluted in PBS and plated in LB agar plates 
supplemented with chloramphenicol (30µg/ml). The plates were incubated overnight 
and the frequencies of CFP and YFP-labeled bacteria were assessed by counting 
the fluorescent colony forming units (CFU) with the help of a fluorescent stereoscope 
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(SteREO Lumar, Carl Zeiss). The samples were also stored in 15% glycerol at -80°C 
for future experiments. For the last time-point (174 hours after gavage), random 
colonies were picked to perform colony PCR against mutant-specific primer pairs 
(Table 3), in order to identify the mutants which were present at the end of the 
competition. 
Table 3 – Primers used in this study. 
Primer name Sequence Primer homology 
LC9 ATGCCTGCTTGCCGAATATCATG KanR end forward 
LC 10 AAGCCACACTGAACAAGATCGC upstream hlyE 
LC11 GTAAGTCAGCGATGAATCAGCAACG upstream gspK 
LC12 AGGTTGTCGTCATCGAACGG downstream entE 
LC14 TGTGGCAGAATAACGGCAGAAG upstream yebF 
LC 16 AGATGCCAGAAGCACACCAC upstream tbpA 
LC17 GATTGTCTGTTGTGCCCAGTCATAG KanR start reverse 
LC 19 CCGTACTTTCTGGCTTGATGTCAG upstream pqqL 
LC 21 TCCTGCAACAGCTTCTTAGCG downstream agp 
 
LC9 amplifies with LC12 in the presence of ΔentE, LC 19 in the presence of 
ΔpqqL and LC21 in the presence of Δagp; LC17 with LC10 in the presence of ΔhlyE, 
LC11 in the presence of ΔgspK, LC14 in the presence of ΔyebF and LC16 in the 
presence of ΔtbpA. These primers can produce non-specific, faint bands in the 
context of a multiplex, so we had to perform regular PCR to identify the mutants.  
A fraction of each colony was suspended in 20 µl of MilliQ water. PCR reactions 
were run with the DreamTaq polymerase, following the standard protocol 
(https://assets.thermofisher.com/TFS-
Assets/LSG/manuals/MAN0012037_DreamTaq DNAPolymerase_5x500U_UG.pdf), 







Secretome deletion polymorphisms show magnitude frequency dependent 
selection 
To enquire how likely it is for frequency dependent selection to arise through a 
single gene polymorphism, we competed E. coli strains carrying single gene 
deletions for different cellular functions against the wild-type strain, in 3 different initial 
frequencies. We performed these competitions in a simple environment with a single 
carbon source, in which phenotypic differences should lead to competitive exclusion 
in the absence of strain interactions. 
We have observed magnitude frequency-dependent selection for 6 out of 28 
mutations (21%) (Figure 1A). For these mutations, the selection coefficient per day 
at low frequency was significantly higher than in high frequency. The mutations Δagp, 
ΔhlyE and ΔgspK conferred a fitness benefit throughout the tested frequencies, while 
the mutant ΔsrlR had a slight fitness benefit in low frequency only. The mutations 
ΔentE and ΔtbpA brought a fitness cost at high frequency. Both seemingly had no 
cost at low frequency. Despite these results, we did not observe a change in the sign 
of the selection coefficient, which would denounce negative frequency-dependent 
selection. It is worth noticing that 5 out of the 6 genes with frequency-dependent 
selection code proteins that are either secreted or involved in secretion, with the 
incidence of frequency-dependent selection being significantly higher in this subset 
of genes than in the remaining genes (p=0.0003, Fisher’s two-sided exact test). 
Furthermore, although the two remaining mutants in the secretome class within our 
selected mutants, ΔyebF and ΔpqqL, did not show a significant fitness difference 
between high and low frequency, their average fitness does decrease with the 
frequency as well (table 2), further suggesting that the leakiness of these functions 
leads to frequency dependence. Although we have observed a deleterious effect due 
to the absence of the peroxidases KatE and KatG, we did not observe a significant 
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difference in the fitness effects of these mutations between the competitions in low 
vs high frequency (pkatE= 0.55; pkatG=0.68, T test for homoscedastic variances). 
Regarding the mutants that do not show frequency dependent selection, 6 out 
of 22 mutations (27%) confer a constant fitness advantage in direct competition with 
the wild-type. 6 (27%) bring a constant cost, while 10 (45%) seem to not affect the 
competitive fitness (Figure 1B-C). The strains are competing in a simple 
environment, which was not expected to provide mutant-specific benefits. Therefore, 
the commonness of beneficial effects of the single gene deletions is unexpected. 
Focusing on the cadaverine cluster, removing the promoter had a beneficial effect on 
fitness, while the removal of the downstream transporter and lysine decarboxylase 

































Figure 1 – Frequency-dependent selection acting on single gene deletion 
polymorphisms. (A) Selection coefficients for the single gene deletions, obtained by pair-
wise competition with wild-type strain at low, average and high frequency. Error bars 
























and high frequencies are highlighted: * p<0.05; **p<0.01; ***p<0.001 (Two tailed T test with 
homoscedasticity). (B) Expectable patterns of selection. (C) Number of mutants with each 
type of selection.  
 
Isolated growth does not fully predict competitive fitness 
We have observed a surprising number of mutations with an effect in minimal 
medium with glucose, inclusively frequency dependent events. These observations 
could be a product of strain interactions between the wild-type and the mutants, or 
just be a reflection of a better or worse ability to grow on minimal medium. In order to 
see to what extent the fitness effects could be predicted by an altered ability to grow, 
we have performed growth curves of the mutants and the wild-type strain, and 
assessed the relative growth dynamics between each mutant compared to the wild-












Table 4 - Average growth curve parameters of the mutant strains relative to the wild-








) for the 




 for the relative carrying capacity. Values below 1 
correspond to a worse performance relative to the wild-type, while values above 1 correspond 
to a better performance. The parameter values that differ significantly from the wild-type’s are 
highlighted in color (p<0.05, ANOVA with Dunnett’s multiple comparison correction). In 
orange are highlighted the parameters for which the mutant performed worse, while in green 



















Genotype µm/µwt 1/(λm/λwt) Km/Kwt
Δagp 1.06 3.85 1.04
ΔcadA 1.28 1.01 1.06
ΔcadB 1.04 1.19 1.02
ΔcadC 1.11 2.33 1.10
ΔcbrA 1.56 1.83 1.19
ΔcitT 0.96 0.73 0.96
ΔdcuB 1.07 2.50 1.01
Δdps 0.99 1.63 1.23
ΔentE 1.07 0.37 0.99
ΔfkpB 1.05 0.50 0.99
ΔgspK 1.09 5.00 1
ΔhepA 1.38 1.04 0.96
ΔhlyE 1.00 11.11 1.1
ΔhtrE 1.08 1.35 1.07
ΔidnD 1.17 1.72 1.18
ΔkatE 0.96 0.79 1.12
ΔkatG 0.6 0.13 0.59
ΔkefC 1.05 1.92 1.07
ΔlamB 1.18 0.74 1.05
ΔompG 1.06 1.59 0.55
ΔpqqL 1.08 5.56 1.06
ΔrpsT 1.09 1.05 1.15
ΔsrlR 1.05 0.96 0.96
ΔtalB 1.10 1.75 1.11
ΔtbpA 1.24 3.57 0.98
ΔtnaA 1.10 1.27 1.05
ΔyebF 0.68 0.40 0.77
ΔyliH 0.97 0.93 1.06
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While comparing the relative growth curve parameters with the observed 
fitness (Table 5 vs Table 4), it becomes clear that the extent by which fitness was 
predictable by isolated growth was dependent on the considered mutant. The length 
of the lag phase was negatively correlated with a better performance in the presence 
of the wild-type strain (R2 =0.71 when compared with fitness at average frequency). 
In fact, the lag phase was more correlated with fitness than the relative growth rate 
and the relative carrying capacity irrespectively of the mutant frequency (Figure 2).  
 
 
Figure 2 – Correlations between selection in pairwise competitions and relative growth 
curve parameters. Shown are the correlations between the growth rate, the lag phase and 
the carrying capacity with the selection coefficient per day of the mutant strains in all tested 
frequencies. A strong negative correlation between lag phase duration and the selection 





Our competitions allowed for a small number of generations per transfer (5-6 
gens), favoring a swift exit from lag phase, and this could help explain this correlation. 
For most mutants (22 out of 28), no significant differences in growth rate and carrying 
capacity were detected. These include three of the most successful mutants in the 
pairwise competitions – Δagp, ΔgspK and ΔhlyE. However, ΔhlyE has a significantly 
shorter lag phase than the wild-type, which could contribute to the observed fitness 
advantage. (Δagp and ΔgspK also have a shorter estimated lag phase, but 
significance was lost after applying multiple comparison correction). 
The mutants Δcbr and Δdps, which also had a fitness advantage over the wild-
type strain, do have a higher relative maximum growth rate and relative carrying 
capacity, respectively. ΔkatG and ΔyebF, two costly mutants, have a significantly 
worse performance than the wild-type in all three growth parameters. For these 
mutants, the outcome of the competitions could be predicted by the isolated growth. 
On the other hand, the mutants ΔhtrE, which had a fitness advantage, and ΔcitT, 
which had a clear fitness disadvantage had close performances relative to the wild-
type when alone, despite their effects in direct competition. 
Regarding the mutants that have a frequency-dependent, negative competitive 
ability in high frequency, ΔentE has a longer lag phase, while showing no other 
growth defects. This phenotype reflects the cost when in high frequency, and might 
derive from an impaired ability to scavenge iron in the absence of the wild-type strain. 
ΔtbpA did not perform worse than the wild-type in any parameter. In fact, it has a 
higher maximum growth rate and a shorter lag phase when growing alone, which 
could support an advantage against the wild-type while in low density. It seems 
however that the presence of the wild-type in high densities imposes a cost on this 






Table 5 – Effects on competitive fitness of single gene deletions. Average 
fitness effects of gene deletions when the mutant is in low, average or high initial 
frequency when competing with the wild type. Within brackets is shown 2 times the 
standard error. Absolute values exceeding it were considered significant. In orange 
are highlighted the treatments for which the mutation was deleterious, while in green 
















    Frequency   
Genotype Low Average High 
Δagp 0.49 (± 0.07) 0.3 (± 0.06) 0.25 (± 0.07) 
ΔcadA 0.2 (± 0.2) 0.2 (± 0.1) 0.18 (± 0.07) 
ΔcadB 0.1 (± 0.2) 0.1 (± 0.1) 0.11 (± 0.05) 
ΔcadC 0.3 (± 0.5) 0.3 (± 0.3) 0.2 (± 0.2) 
ΔcbrA 0.06 (± 0.05) 0.05 (± 0.02) 0.1 (± 0.1) 
ΔcitT -0.9 (± 0.2) -1.0 (± 0.3) -1.1 (± 0.4) 
ΔdcuB 0.2 (± 0.3) 0.2 (± 0.2) 0.22 (± 0.05) 
Δdps -0.2 (± 0.1) -0.3 (± 0.1) -0.4 (± 0.1) 
ΔentE -0.03 (± 0.05) -0.10 (± 0.06) -0.29 (± 0.06) 
ΔfkpB -0.3 (± 0.2) -0.2 (± 0.1) -0.1 (± 0.2) 
ΔgspK 0.8 (± 0.1) 0.5 (± 0.1) 0.41 (± 0.08) 
ΔhepA 0.1 (± 0.2) 0.2 (± 0.2) 0.2 (± 0.2) 
ΔhlyE 0.53 (± 0.03) 0.36 (± 0.04) 0.39 (± 0.08) 
ΔhtrE 0.3 (± 0.2) 0.3 (± 0.1) 0.3 (± 0.2) 
ΔidnD 0.3 (± 0.2) 0.2 (± 0.1) 0.3 (± 0.1) 
ΔkatE -0.2 (± 0.1) -0.20 (± 0.07) -0.18 (± 0.06) 
ΔkatG -1.8 (± 0.2) -1.9 (± 0.6) -2.0 (± 0.8) 
ΔkefC 0.01 (± 0.05) 0.01 (± 0.04) 0 (± 0.2) 
ΔlamB 0.05 (± 0.02) 0.04 (± 0.02) 0.03 (± 0.09) 
ΔompG -0.02 (± 0.06) -0.01 (± 0.08) -0.1 (± 0.1) 
ΔpqqL 0.14 (± 0.08) 0.06 (± 0.01) 0.03 (± 0.09) 
ΔrpsT -0.17 (± 0.06) -0.16 (± 0.04) -0.10 (± 0.08) 
ΔsrlR 0.3 (± 0.1) 0.04 (± 0.08) 0.04 (± 0.09) 
ΔtalB 0.3 (± 0.5) 0.3 (± 0.4) 0.3 (± 0.3) 
ΔtbpA 0 (± 0.07) -0.20 (± 0.03) -0.47 (± 0.06) 
ΔtnaA 0.10 (±0.09) 0.04 (± 0.08) -0.07 (± 0.09) 
ΔyebF 0.77 (± 0.10) -0.9 (± 0.1) -1.0 (± 0.2) 




Surprisingly, ΔompG has a low relative carrying capacity in minimum medium 
while alone, despite the mutation having a neutral effect in the pair-wise competitions 
with the wild-type. It is possible that in higher frequencies than the ones tested here, 
which would impose a starting low density of the wild-type strain, ΔompG would 
actually have a fitness disadvantage and allow the wild-type’s invasion. These 
unexpected disparities between growth parameters and competitive fitness, together 
with the previously observed frequency-dependent fitness effects support a role for 
bacterial interactions in our competitions, despite the simple environment. 
 
Darwinian selection prevails over secretome polymorphism stability in the 
mammalian gut 
We have observed frequency-dependent effects in the course of the pairwise 
competitions, the majority of which involving secretome mutants. While we did not 
observe negative frequency dependent selection, we wondered if in a complex and 
natural environment, these particular frequency dependent effects, which do suggest 
strain interactions, would turn into negative frequency dependent selection and allow 
polymorphism stability, or into Darwinian selection, in which the most fit genotype 
would dominate the intra-specific competition. To assess this, we performed 
competitions involving the wild-type strain and the 7 secretome mutants from the 
previous experiments, altogether in the mouse gut (Figure 3A). We have decided to 
exclude ΔsrlR from these competitions because its nature is different from the other 
mutants, being a metabolic mutation that does not require interactions to obtain a 
fitness advantage. Still, it has previously been shown to be under frequency 
dependent selection in the gut, through resource specialization 395. 
Albeit with a different pace, we have observed the loss of the wild-type strain 
in all mice within the course of a week after colonization (figure 3B). E. coli loads 
were high and constant throughout the competition, supporting the loss of the wild-
type strain as an end result of selection, not drift (Figure 3C). Within a host and while 
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in the presence of other microbes, the wild-type was not the most competitive strain, 
losing to the secretome consortia. To evaluate which mutants were present at the 
end of the competition, we have performed colony PCR with mutant-specific primer 
pairs on the last time-point samples. We found out that the competitions were 
dominated by the ΔgspK mutant, as the sampled colonies (10 per mouse) were 
identified as such (figure 3D). The ΔgspK mutant had previously performed better 
than all the other mutants in the in vitro competitions, even though its fitness in high 
frequency was not superior to the fitness of ΔhlyE and Δagp in low frequency (Table 
4). Our results indicate that Darwinian selection favored ΔgspK, and while we cannot 
exclude the presence of the other strains at low frequency, we found no evidence of 





















Figure 3 – Multi-strain competition in vivo. (A) Design of the multi-strain competition. The 
initial strain frequency was adjusted to have the strains in equal frequency at the beginning 
of the competition. (B) Exclusion of the wild-type strain. Each color and symbol represent the 
wild-type frequency in a singular mouse host. The frequency of the wild-type over the course 
of the competitions is reduced below the limit of detection. (C) Total E. coli loads (CFUs/g 
feces). The bacterial load of the competing strains did not suffer significant variation. (D)  
Colony PCR with specific primers for the gspK deletion, for stool samples from the last time-
point. 3 controls are shown: one with the ΔgspK mutant with the respective primers, one with 
the ΔentE mutant with its specific primers, and one with the ΔentE mutant with ΔgspK primers 
(negative control). The colony PCR for the empty well in mouse 3 was re-run and confirmed 






Frequency dependent fitness effects and secretome mutants 
To assess the existence of frequency dependence in single mutants for a 
variety of genes involved in distinct functions, we have performed competitions with 
the wild-type strain in different frequencies. We have observed situations of 
frequency dependence, in which the performance of the mutants was better in low 
frequency than in high frequency. Our results suggest that magnitude frequency-
dependent selection can occur and should be taken into consideration. However, as 
expected, its presence is likely to be associated with specific classes of genes. Traits 
that concern the outside of the cell, secretome traits, are particularly enriched for 
frequency dependence in our simple environment. 
Here we are considering that a polymorphism is under negative frequency-
dependent selection only when the strains can mutually invade each other, as without 
an advantage in rarity, genetic drift is more likely to eliminate rare mutants and lead 
to a single morph population 162. Under our definition, we do not observe situations 
of negative frequency-dependent selection. We did, however, observe 2 cases of 
frequency-dependent selection in which the mutants, ΔentE and ΔtbpA, have no cost 
when rare and a cost when in high frequency, and 1 in which the mutant ΔsrlR has 
an advantage in low frequency only. These fitness effects allow for the maintenance 
of the mutant and wild-type polymorphism when drift effects are weak, and some 
authors still consider them as negative-frequency dependent selection 512. 
The gene entE codes for a subunit of the enterochelin synthase 513. Looking at 
the growth dynamics, the ΔentE mutant performs worse than the wild-type when 
growing alone, namely through an extended lag phase. Their maximum growth rate 
and carrying capacity however, are similar. Therefore, the presence of the wild-type 
confers a benefit that is not related with the ability to grow fast, but with having 




siderophore in E.coli 514, the extended lag phase is most likely derived from an 
impaired ability to scavenge iron. Our results for the ΔentE mutant were expectable, 
considering that the deletion of another component of the enterochelin synthase, 
entF, has been shown to provide a fitness cost in low iron conditions, but virtually no 
cost when the mutant is within a numerous wild-type population 512. The authors did 
not observe a fitness advantage with mutant/wild-type frequencies as low as 1/1000, 
possibly due to a degree of privatization at low cell density by the wild-type cells. 
Regarding ΔtbpA, it is possible that our range of frequencies throughout the 
competitions did not capture the equilibrium value 515. Therefore, we cannot exclude 
the possibility of this mutant being under negative frequency-dependent selection in 
extremely low frequencies. Alternatively, it is possible that in this simple environment, 
there is not a frequency in which the sign of selection changes for this polymorphism. 
Concerning the individual growth, the mutant does not perform worse than the wild-
type (it actually achieves a slightly superior maximum growth rate), so one would 
think that the presence of the wild-type is detrimental. However, while in competition, 
ΔtbpA performs better when surrounded by wild-type cells.  tbpA encodes the 
periplasmic subunit of an ABC transporter, that is involved in the import of thiamine 
and thiamine pyrophosphate (TPP) into the cell 516,517. Mutants with an impaired 
transporter system have to rely solely in de novo synthesis of thiamine and TPP. 
Alike our observations for the ΔtbpA mutant, Salmonella mutants with impaired 
thiamine transport have no observable growth defects in minimal medium when 
growing alone 516, further supporting that a lower relative fitness of the ΔtbpA mutant 
is due to an interaction with the wild-type strain. While the wild-type can uptake 
thiamine, our minimal medium does not have thiamine in its composition, so the wild-
type would have to access produced thiamine to gain a frequency-dependent 
advantage. Some bacteria release thiamine while growing. E. coli K12 itself releases 
a fraction of the accumulated thiamine when exposed to fresh medium 518. One 
possibility is that the wild-type has access to the leaked thiamine through the thiamine 
transporter, but as its frequency increases, the clonal competition for thiamine 
reduces the benefit. This hypothesis remains to be tested, so for now, the mechanism 
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behind this mutant’s cost in pair-wise competitions and its frequency dependence 
remain undisclosed. 
Polymorphisms in srlR were shown to be under frequency dependent selection 
in the mouse gut 395. Still, our observations of frequency dependent selection acting 
on ΔsrlR, particularly in minimal medium with glucose, are puzzling. srlR codes for a 
repressor, and as such, its deletion leads to an enhanced expression of the sorbitol 
operon 519. In the absence of sorbitol, this represents a waste of resources, and can 
lead to a deleterious effect. However, the sorbitol operon is subjected to catabolite 
repression 520 - high glucose levels typically lead to a lowered cAMP-CRP 
concentration 521, a complex that is essential for the expression of the operon even 
in mutants lacking a functional srlR repressor 519. The operon is, therefore, expected 
to be inactive until late exponential phase and have a neutral effect in the 
competitions, as well as in the individual growth, which in fact, is not significantly 
different from the wild-type’s (table 3). Our observations require ΔsrlR to have an 
advantage during competition, and to either that advantage or a late cost of the srl 
operon activity to be different in high and low frequency. Given that srlR codes a 
metabolic regulator, I would expect the frequency dependence to result from a pure 
density-dependent effect and not from a strain interaction. Further experimentation 
would be required to understand this result. 
 
Absence of dependency and NFDS 
A fairly recent theory, the Black Queen hypothesis states that negative 
frequency dependent selection can arise from the loss of essential genes involved in 
leaky functions 522. The underlying idea is that if a communal function entails a fitness 
cost, there will be a selective pressure towards losing this function, as long as there 
is another strain or species performing it. After gene loss, the fitness of these 
“beneficiary” members will be a balance between the benefit of not producing the 




balancing selection. Evolution through gene loss and dependency has been 
experimentally shown to lead to long lasting, stable polymorphisms 509, further 
corroborating this theory for diversity maintenance. 
We used single gene deletions to generate the mutants in our experiments, 
fully disabling their function. However, our selected genes code non-essential 
functions of E. coli 404. As such, in commonly used media, while frequency 
dependence can occur, metabolic dependencies are not expected. The single 
exception within our sampled genes is the previously mentioned ΔentE mutant. As 
our minimal medium is not supplemented with iron, the inability to scavenge residual 
iron brought a high, frequency-dependent cost. 
A typical case that can result in stabilizing frequency dependent selection is 
detoxification 523,524, and we have chosen to test E. coli peroxidases, KatE and KatG, 
for frequency dependence because the latter has been associated with a Black 
Queen function in a natural 525 and in an experimental 509 system. In both cases 
however, the beneficiary strain was extremely sensitive to hydrogen peroxide, with 
no alternative catalases to degrade it, while in our case, one catalase is still present. 
In our hands, both peroxidase single mutants have shown a clear fitness defect, but 
no frequency dependence. Although the two peroxidases are induced independently 
526 and locate differently in the cell 527, they seem to partially compensate each other 
and buffer putative frequency-dependent effects. Taking these studies into account, 
our results suggest that negative frequency dependent selection through gene loss 
of leaky functions might require essentiality of these functions. 
 
 
Positive directional selection and frequency dependent effects 
We have observed 4 cases of magnitude FDS for genes that confer a fitness 
benefit in low frequency. For the mutants Δagp, ΔgspK and ΔhlyE, selection was 
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positive even in high frequency. While the frequency dependent effects are not 
negligible, the fact that these mutants have an advantage irrespective of their 
frequency suggests that a cost component is always present in the wild-type cell, 
possibly due to the absence of need for these functions in minimal medium with 
glucose. The mutant’s fitness advantage is particularly surprising for ΔgspK and 
ΔhlyE, as these genes were shown to be poorly expressed or not at all by commensal 
E. coli in rich laboratory media 528,529, due to repression by the small chromatin 
associated protein H-NS 530,531. 
The gene hlyE codes for haemolysin E, a pore forming toxin that targets 
mammalian cells 532.  hlyE has been shown not to be induced in laboratory strains 
derived from E. coli K12, when grown in LB medium 528,531. Experiments on E. coli 
K12 BW 3110 as well on other commensal E. coli grown on rich media associate the 
hlyE locus to repression through H-NS binding 531,533, although chromosome immuno-
precipitation experiments failed to detect H-NS binding to this locus on the E. coli K12 
MG1655 strain, isogenic to ours, grown in minimal medium 534.  While it is known that 
gene expression varies with the environment, it is unlikely that the simple conditions 
in which the competitions were performed, lacking host-derived environmental cues, 
would lead to the de-repression or to the activation of hlyE. On the other hand, the 
wild-type genetic background of our strains is still quite close to the BW 3110 strain. 
It is thus unlikely that the hlyE gene is fully derepressed in our strains, although a 
leaky expression scenario is possible. It is known that the secretion of haemolysin E 
involves a transient leakage of periplasmic contents to the extracellular medium 535, 
and as such, it would allow sharing of the wild-type periplasmic contents with the 
mutant cells. While the periplasmic leak could generate a cost, the shared 
compounds could generate a frequency-dependent fitness effect. 
Regarding ΔgspK, the respective gene codes a pseudo pilin of the type II 
secretion system 536. Experiments on E. coli MC4100 have shown a reduced 
expression by the operon’s promoter in LB medium when compared with 
unrepressed, H-NS knock-out mutants 530. As with hlyE, the gspCO operon’s 




culture media than the one used in this study. Once again, it is unlikely, but still 
possible that the expression profile of gspK is different in our wild-type strain under 
our laboratory conditions. Additionally, even if we assume that the differences in the 
environment and genetic background are not having an effect in gspK expression, 
the low level of expression could still generate a phenotype affecting fitness. While 
the full repertoire of proteins that can be transported by E. coli’s type II secretion 
system is not known, putative secretion products could change the surrounding, 
shared environment, and such change would lead to frequency dependent effects. 
Type II secretion systems are widespread among gram-negative proteobacteria and 
feature a broad range of functions 537, inclusively during host infections by pathogenic 
bacteria 538. As our E. coli is commensal, it is possible that the usefulness of having 
gspK, as well as other repressed secretome genes, has been lost due to the absence 
of formerly associated virulence traits. Despite these considerations, the fitness 
benefit and the frequency dependence of these mutations could still be related with 
undisclosed effects of the substitution of these genes by the kanamycin resistance 
cassette. 
As ecological interactions between populations are typically density dependent 
524, it is thought that density dependence underlies most mechanisms of frequency 
dependent selection 502. We performed our competitions in a relatively high cellular 
density, with relatively small bottlenecks (1:40 dilutions), and we did not test for 
frequency dependent selection considering different densities. However, it is likely 
that higher shifts in cell density would change the observed patterns of selection. 
Starting at a lower density would reduce interactions on the beginning of growth and 
change their net benefit or cost. One such example is given by the aforementioned 
work of Scholz and Greenberg 512 on enterochelin, in which the frequency-dependent 
fitness effect of a mutation is the result of a density-dependent interaction. 
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Beneficial effects of whole gene deletions 
As expected, the lack of core genes had a deleterious impact on fitness. The 
exception was the deletion of the transaldolase encoding gene talB. For this mutant, 
the variance in the fitness effect of the mutation between biological samples was high 
(reflected by the high standard error for all treatments, table 4), but still, we have 
observed, on average, a beneficial effect of the mutation. A talB – deficient mutant 
has been previously generated by other authors (by partial deletion and concomitant 
insertion of a kanamycin‐cassette into the talB locus), and its growth in minimal 
medium with glucose was unaffected 539. Transaldolase activity takes part in the 
pentose phosphate pathway non-oxidative branch 540, which in turn is essential for 
the production of NADPH and nucleotide synthesis percursor metabolites 541. 
However, E. coli genome possesses another transaldolase encoding gene, talA, 
which acts on the same pathway. One possibility for the lack of cost of ΔtalB is 
therefore, compensation by talA. Furthermore, talAB knockout mutants have been 
shown to growth at rates comparable to the growth of the wild-type cells in single 
sugar growth, by completing the pentose pathway cycle through recently described, 
alternative reactions 542. The lack of transaldolase can, therefore, be bypassed by E. 
coli, and this could also be the reason why we do not observe a cost. Regarding the 
accessory genes, their deletion had mixed effects. It should be noted however that 
the deletion of the 4 least represented genes (ΔidnD, ΔgspK, ΔhlyE and ΔhtrE) has 
led to a fitness advantage, in accord with the idea that the accessory genome codes 
for functions conferring context-specific fitness benefits and will tend to have a cost 
in the remaining contexts 507. 
We have observed in total 9 deletions with a positive effect on fitness on all 
frequencies (3 with frequency dependent effects) in our simple selective 
environment. The benefits of gene deletions have also been shown in Salmonella 
enterica, where 25% of 55 random deletion mutants conferred a higher growth rate 
when compared with the ancestor strain in at least one of 3 laboratory environments 




decreased energy/mass expenditure on DNA, RNA and protein production. 
Additionally, a study on the distribution of pseudogenes among the sequenced 
strains of Salmonella suggests that the full deletion of a gene confers a higher fitness 
benefit than its function loss by inactivation 544. Having into account that practically 
all sequences in the genome, including pseudogenes and antisense sequences, are 
transcribed in E. coli 545,546, the beneficial effects of our mutations might come from 
the full stop of transcription of genes that are not useful in our experimental setting, 
with the clean, whole gene deletions allowing the avoidance of leaky expression or 
harm to the genome architecture.  
Through comparison of different ways of measuring fitness and the integration 
of frequency-dependence testing, we have observed discrepancies between the 
measurements for some of the mutants, hinting into undescribed bacterial 
interactions. Molecular and ecological studies stemming from these observations are 
necessary, and could elucidate new ecological relationships within bacterial 
populations. Our results stress out that studying the fitness effects of a mutation 
taking into account competitors and the mutant’s frequency in the population can 
reveal otherwise cryptic fitness effects which can have an impact on survival. 
 
Darwinian selection acting on secretome genes 
In order to probe for negative frequency dependent selection in E. coli’s natural 
environment, the mammalian gut, we have competed together a pool of 7 mutants 
plus the wild-type strain in SPF mice. As we observed an enrichment for frequency 
dependence in traits involved with the outside of the cell, we chose to compete single 
mutants for genes encoding these traits. 
We have observed the dominance of a single mutant in all tested mice. Through 
what seemed like a process of Darwinian selection, ΔgspK has risen in frequency, 
while the wild-type has fallen under our limit of detection. Besides having a shorter 
lag phase than the wild-type strain and a beneficial effect with all tested frequencies 
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in in vitro pair-wise competitions, ΔgspK has the highest average fitness value within 
our mutant pool in all frequencies. On the other hand, it is likely that inter-species 
competition, as well as the gut’s structured environment reduce the effect of intra-
strain interactions on fitness. Having this into account, the in vivo dominance of 
ΔgspK might just reflect the superior competitive ability of this mutant relative to the 
other tested strains. 
It seems clear that this single gene deletion confers a fitness advantage in vivo. 
However, as far as I am aware, mutations on gspK were not detected during E. coli 
K12 MG1655 evolution experiments in the mouse gut [66,395,398,411; chapter III]. This 
might have to do with its location in this strain’s genome: the gspCO operon is located 
between core genes, including the rps ribosomal encoding genes and the 
transcription elongation factor tufA (Ecocyc database). An extensive deletion in this 
region could affect the cell’s inner machinery, or even its viability, and consequently, 
mutations of this nature would be highly deleterious. Curiously, the gene is not 
conserved in sequenced E. coli (Table 2), further suggesting that this gene is costly 
to have per se and that the advantages that if confers are context-specific. 
The gut is a complex environment that contains a wide range of potential 
substrates for bacterial growth, derived from host-harvested nutrients, host produced 
substances, their breakdown products and additional substances synthetized by 
microflora itself 488. This multitude of nutrients generates a multitude of niches, with 
different bacteria having distinct niche specializations, which in turn can allow 
prolonged coexistence. Accordingly, a data-supported theoretical model suggests 
that microbiome stability in the gut is achieved through resource competition 489. 
Under this scenario, mutations in metabolic regulators can generate metabolic trade-
offs between the strains, which in turn are predicted to maintain diversity in 
environments with multiple species and resources 451. As mentioned before, srlR was 
shown to be a target for negative frequency-dependent selection in the gut 395, and 
spontaneous mutations in this gene appear, in several E. coli adaptation experiments 
without reaching fixation [395,398,411, chapter III, table 1], an empirical example of a 




Our results and these observations suggest that for E. coli, in a complex 
environment with a multitude of nutritional niches and strong inter-species 
competition like the mammalian gut, resource competition is more likely to lead to 







































































Studying bacteria in their natural environment is crucial to understand their 
ecology and evolution. As in other studies 191,401, the research presented in this thesis 
shows a discrepancy between measuring the fitness effects of mutations in standard 
laboratory medium and within a mouse host. 
We discovered that in the context of the dysbiotic gut, the costs of antibiotic 
resistance mutations are personalized, and identified the gut microbiota as a factor 
contributing decisively to the fate of antibiotic resistance in this system. Hence, our 
results indicate that, besides acting as a reservoir for antibiotic resistance, microbiota 
can promote the subsistence of resistant strains in the gut on its own. Our novel 
results add to an increasing evidence regarding the importance of microbial 
communities. As with our own research, the microbiota has been shown to be a 
source of variation in the expected outcome of various murine-based studies 547, 
including some in which it was not initially thought to be involved 548. For instance, 
two studies have shown that the gender of mice alters autoimmune phenotypes 
partially through the action of microbiota. Through the employment of germ-free 
colonization with defined microbiota 549 and gut microbiota transfer 550, both studies 
show that, while gender influences microbiota composition, microbiota is partially 
responsible for the lower incidence of type I diabetes in male nonobese diabetic mice. 
Another example regards a study on the effect of the mouse microbiota in the gut IgA 
levels551. After observing a binary phenotype of fecal IgA levels between cages, the 
authors perform a series of co-housing and fecal transplantation experiments and 
show that the “low IgA level” phenotype is dominant and transmitted horizontally, 
being driven by bacteria that degrade both IgA and the protective, secretory 
component SIgA. Taking microbiota-driven variation into account, future studies 
involving the gut ecosystem should have a mixed approach, in which an effect of 
microbiota composition is tested through a treatment that allows variation and a 
treatment that tightly controls it. The latter can be obtained through co-housing, as 
performed by us, and also through littermate methods, which are more time-




reproducibility of a phenotype across hosts and to simultaneously control for the 
effects of the microbiome in the phenotype 547. 
We have observed variance in competitive fitness, including situations in which 
a resistant strain had a fitness benefit. While during treatment, selection by an 
antibiotic agent favors directly the resistant strain, our results suggest that microbiota 
imbalances can generate conditions for resistance to be neutral or beneficial after 
the treatment. This state may be temporary, but it will promote the expansion and 
maintenance of the resistant strain. A recent study corroborates this expectation and 
further extends it to a community level, by showing that a short-term cefuroxime 
treatment can increase the general level of resistance in the human gut microbiota 
552. On the other hand, this dysbiotic period is typically a window of opportunity for 
pathogens 553–555. If this lack of cost would happen in a resistant pathogen, its 
elimination would be extremely difficult due to the lack of a method to specifically 
select against it. 
Our experimental system does not allow us to test the fitness effect of antibiotic 
resistance mutations in an unperturbed microbiota. Assuming that the variance in 
fitness costs widens due to the microbiome perturbation and that resistant strains do 
express a cost in equilibrium conditions, an effective way to impair them is to promote 
microbiota recovery. In a study using the streptomycin treated, dysbiotic mouse gut 
as a model, the overproduction of the inter-species quorum sensing molecule, AI-2, 
by a genetically engineered E. coli led to a recovery in Firmicutes abundance after 
the perturbation 406. This type of approach could shorten the window of opportunity 
in which resistant strains and pathogens are able to proliferate. 
For resistance mutations that affect nutritional metabolism, an alternative way 
to address these situations could be through diet manipulation, which has been 
shown to be able to effectively change selective pressure on E. coli polymorphic for 
galactitol consumption 397. Screening and profiling a resistant strain’s nutritional 
preferences and adjusting the host’s diet accordingly could thwart its subsistence in 
the gut ecosystem. However, dietary patterns affect microbiota composition 556,557, 
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and diet manipulation readily causes expansion of specific bacterial groups 557, which 
in turn will affect inter-species competition. Furthermore, inter-species competition 
itself might limit the effectiveness of diet-based manipulation 558. Hence, we cannot 
fully predict the helpful and harmful effects of this approach. 
A study with a simplified model microbiota has shown that the presence of a 
single gut bacterial species can change the outcome of an intra-species competition 
559. Assuming that a such principle is applicable within the gut ecosystem, another 
plausible strategy is to find competitors that will reliably and specifically outcompete 
resistant bacteria, or at least force them to express a cost. Once identified, these 
interfering strains could be administered to the hosts carrying resistant bacteria. 
Furthermore, once present in the community, these competitors could be expanded 
and manipulated through the use of prebiotics 560,561 to prime the treatment. Although 
laborious, studying the fitness effects of resistance mutations in the presence of 
specific gut microbes or defined collections of microbiota members, focusing on the 
“molecular-to-ecological” mechanisms through which fitness is being affected and 
further testing the efficiency of these strains in host models could lead to more 
optimized approaches for selection against resistance. 
The human gut includes an enormous variety of microbes 562. A key study on 
the microbiota of healthy humans, the Human Microbiome Project, has revealed that 
the diversity and the abundance of microbes varies widely among subjects 563. A 
subsequent study performed the tracking of individuals based on the project’s data 
and was able to pinpoint over 80% of the subjects 564. These studies show that even 
when considering healthy individuals, microbiota composition is personal. As the 
microbiota can affect the cost of resistance, it is likely that the subsistence of resistant 
bacteria in humans is also host-specific. Under this scenario, individual microbiomes 
and resistomes should be taken into account when an antibiotic is prescribed. As with 
contemporary health problems that depend on genetics, lifestyle and diet 565,566, the 





Microbiome research is currently thriving 567, and over time we have gained 
access to techniques and technologies that allow us to perform studies in these 
complex communities: The employment of metagenomics 563,568,569, 
metatranscriptomics 570,571 and metabolomics 572 allows for a detailed 
characterization of the environment; The adaptation of classical ecological models to 
the study of microbial communities 573, and the coupling of their predictions with 
empirical experimentation 428,574 can help us determine properties of bacterial 
communities; Reliable and reproducible approaches such the as the colonization of 
germ-free mice with defined culture collections 575 and the use of synthetic microbial 
communities 576 may let us to go over correlative studies and test specific hypothesis 
in experimental systems with intermediate complexity, which nonetheless share 
properties with the natural ones. Coupling these tools with experimental evolution will 
help us learn more about the selective forces that act in microbial communities, how 
they are generated and how they shape the evolution of their members. 
Evolutionary biology has been instrumental to medicine, in understanding the 
origin and devising strategies to fight concerning health problems, such as genetic 
conflicts, aging, cancer, infectious diseases and of course, antibiotic resistance 577,578. 
Through the use of an increasingly integrative approach, evolutionary biology might 
let us learn much more about the ecology and evolution of bacteria (including the 
ones living within us) and hopefully lead to relevant clinical implementations towards 
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